

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 November 2001 (29.11.2001)

PCT

(10) International Publication Number  
WO 01/90156 A2

(51) International Patent Classification<sup>7</sup>: C07K 14/00

(21) International Application Number: PCT/US01/17158

(22) International Filing Date: 24 May 2001 (24.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/579,240 24 May 2000 (24.05.2000) US  
09/686,347 10 October 2000 (10.10.2000) US  
60/275,980 14 March 2001 (14.03.2001) US  
09/864,921 23 May 2001 (23.05.2001) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 09/579,240 (CIP)  
Filed on 24 May 2000 (24.05.2000)  
US Not furnished (CIP)  
Filed on 23 May 2001 (23.05.2001)  
US 09/686,347 (CIP)  
Filed on 10 October 2000 (10.10.2000)  
US 60/275,980 (CIP)  
Filed on 14 March 2001 (14.03.2001)

(71) Applicant (for all designated States except US): **THE BURNHAM INSTITUTE** [US/US]; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **REED, John, C.** [US/US]; 17044 El Camino Real, Rancho Santa Fe, CA 92067 (US). **PIO, Frederick, F.** [FR/CA]; 2142 Venables Street, Vancouver, British Colombia V5L 2J4 (CA). **GODZIK, Adam** [US/US]; 9184 Buckwheat Street, San Diego, CA 92129 (US). **STEHLIK, Christian** [AT/US]; 7535 Charmant Drive, Apt. 304, San Diego,

CA 92122 (US). **DAMIANO, Jason, S.** [US/US]; 329 Bonair Street, La Jolla, CA 92037-5900 (US). **LEE, Sug, Hyung** [KR/US]; 3895 Nobel Drive, Apt. 129, San Diego, CA 92122 (US). **OLIVEIRA, Vasco, A., M.** [PT/US]; 3929 Nobel Drive, Apt. 317, San Diego, CA 92122 (US). **HAYASHI, Hideki** [JP/JP]; 4-2-202 Mihara-cho, Nagasaki City 852-8123 (JP). **PAWLOWSKI, Krzysztof** [PL/US]; 8444 Capricorn Way #67, San Diego, CA 92126 (US).

(74) Agents: **WEBSTER, Melanie, K.** et al.; Campbell & Flores LLP, 7th Floor, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CARD DOMAIN CONTAINING POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE



(57) Abstract: The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.

WO 01/90156 A2

CARD DOMAIN CONTAINING POLYPEPTIDES, ENCODING  
NUCLEIC ACIDS, AND METHODS OF USE

This invention was made in part with U.S.  
Government support under NIH Grant No. GM61694 awarded  
5 by the National Institutes of Health. The U.S.  
Government has certain rights in this invention.

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

This invention relates generally to the  
10 fields of molecular biology and molecular medicine and  
more specifically to the identification of proteins  
involved in programmed cell death, cytokine processing  
and receptor signal transduction, and associations of  
these proteins.

15 BACKGROUND INFORMATION

Programmed cell death is a physiologic  
process that ensures homeostasis is maintained between  
cell production and cell turnover in essentially all  
self-renewing tissues. In many cases, characteristic  
20 morphological changes, termed "apoptosis," occur in a  
dying cell. Since similar changes occur in different  
types of dying cells, cell death appears to proceed  
through a common pathway in different cell types.

In addition to maintaining tissue  
25 homeostasis, apoptosis also occurs in response to a  
variety of external stimuli, including growth factor  
deprivation, alterations in calcium levels, free-  
radicals, cytotoxic lymphokines, infection by some  
viruses, radiation and most chemotherapeutic agents.

Thus, apoptosis is an inducible event that likely is subject to similar mechanisms of regulation as occur, for example, in a metabolic pathway. In this regard, dysregulation of apoptosis also can occur and is  
5 observed, for example, in some types of cancer cells, which survive for a longer time than corresponding normal cells, and in neurodegenerative diseases where neurons die prematurely. In viral infections, induction of apoptosis can figure prominently in the  
10 pathophysiology of the disease process, because immune-based for eradication of viral infections depend on elimination of virus-producing host cells by immune cell attack resulting in apoptosis.

Some of the proteins involved in programmed  
15 cell death have been identified and associations among some of these proteins have been described. However, additional apoptosis regulating proteins remain to be found and the mechanisms by which these proteins mediate their activity remains to be elucidated. The  
20 identification of the proteins involved in cell death and an understanding of the associations between these proteins can provide a means for manipulating the process of apoptosis in a cell and, therefore, selectively regulating the relative lifespan of a cell  
25 or its relative resistance to cell death stimuli.

The principal effectors of apoptosis are a family of intracellular proteases known as Caspases, representing an abbreviation for Cysteine Aspartyl  
Proteases. Caspases are found as inactive zymogens in  
30 essentially all animal cells. During apoptosis, the caspases are activated by proteolytic processing at specific aspartic acid residues, resulting in the production of subunits that assemble into an active protease typically consisting of a heterotetramer

containing two large and two small subunits. The phenomenon of apoptosis is produced directly or indirectly by the activation of caspases in cells, resulting in the proteolytic cleavage of specific substrate proteins. Moreover, in many cases, caspases can cleave and activate themselves and each other, creating cascades of protease activation and mechanisms for "auto"-activation. Thus, knowledge about the proteins that interact with and regulate caspases is important for devising strategies for manipulating cell life and death in therapeutically useful ways. In addition, because caspases can also participate in cytokine activation and other processes, knowledge about the proteins that interact with caspases can be important for manipulating immune responses and other biochemical processes in useful ways.

One of the mechanisms for regulating caspase activation involves protein-protein interactions mediated by a family of protein domains known as caspase recruitment domains (CARDs). The identification of proteins that contain CARD domains and the elucidation of the proteins with which they interact, therefore, can form the basis for strategies designed to alter apoptosis, cytokine production, cytokine receptor signaling, and other cellular processes. Thus, a need exists to identify proteins that contain CARD domains. The present invention satisfies this need and provides additional advantages as well.

30

#### SUMMARY OF THE INVENTION

The invention provides caspase recruitment domain (CARD)-containing polypeptides, and CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom. Also

provided are chimeric polypeptides containing a CARD, NB-ARC, ANGIO-R, LRR or SAM domain of a CARD-containing polypeptide. Methods of producing CARD-containing polypeptides, and compositions containing

5 CARD-containing polypeptides and a pharmaceutically acceptable carrier, are also provided.

The invention further provides nucleic acid molecules encoding CARD-containing polypeptides and CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom.

10 Also provided are antibodies directed against such polypeptides.

The invention also provides methods for identifying a nucleic acid molecule encoding a CARD-containing polypeptide, and methods for detecting

15 the presence of a CARD-containing polypeptide in a sample.

Further provided are methods of identifying a CARD-associated polypeptide (CAP), and methods of identifying an effective agent that alters the

20 association of a CARD-containing polypeptide with a CAP. The invention also provides methods of identifying an effective agent that modulates an activity of a NB-ARC domain of a CARD-containing polypeptide.

25 The invention also provides methods of altering the level of a biochemical process modulated by a CARD-containing polypeptide.

The invention further provides methods of treating a pathology characterized by abnormal cell

30 proliferation, abnormal cell death, or inflammation.

Also provided are methods of diagnosing or predicting clinical prognosis of a pathology characterized by an increased or decreased level of a CARD-containing polypeptide in a subject.

5

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1A shows the genomic organization of the CLAN (CARD 4/5X) gene on chromosome 2 deduced from the BAC 164M19 sequence from the SPG4 candidate region at 2p21-2p22 (Accession No. AL121653) and Homo sapiens chromosome 2 working draft sequence (Accession No. NT\_005194.1). Figure 1B shows mRNA splicing generating CLAN A, B, C and D. Figure 1C shows the deduced domain structure for the splice forms of CARD4/5X (CLAN A, B, C and D).

Figure 2 shows an alignment of the protein sequence of the isoforms of CLAN (designated CLAN A, B, C and D; SEQ ID NOS:97, 99, 103 and 101, respectively). Dark boxes indicate identical amino acids, and white boxes indicate conserved amino acids.

Figure 3 shows the amino acid sequences of the CARD-A, CARD-B and NB-ARC domains of CARD3X (SEQ ID NOS: 170, 172 and 174, respectively).

Figure 4 shows an alignment of COP-1 (SEQ ID NO:86) and caspase-1 (SEQ ID NO:87). The amino acids shaded in black are identical.

Figure 5 shows an alignment of COP-2 (SEQ ID NO:90) and caspase-1 (SEQ ID NO:87), with the consensus sequence (SEQ ID NO:91) shown above the aligned

sequences. The amino acids shaded in black are identical.

Figure 6 shows IL-1 $\beta$  secretion by COS7 cells transfected with the indicated amounts of expression  
5 vectors encoding the indicated proteins.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel polypeptides involved in programmed cell death, or apoptosis. The principal effectors of apoptosis are a  
10 family of intracellular cysteine aspartyl proteases, known as caspases. Caspase activity in the cell is regulated by protein-protein interactions. Similarly, protein-protein interactions influence the activity of other proteins involved in apoptosis. Several protein  
15 interaction domains have been implicated in interactions among some apoptosis-regulating proteins. Among these is the caspase recruitment domain, or CARD-containing polypeptide which are so named for the ability of the CARD-containing polypeptides to bind  
20 caspases. In addition to their ability to bind caspases, numerous CARD-containing polypeptides bind other proteins, particularly, other CARD-containing polypeptides. Further, CARD-containing polypeptides influence a variety of cellular and biochemical  
25 processes beyond apoptosis, including cell adhesion, inflammation and cytokine receptor signaling.

In accordance with the present invention, there are provided isolated CARD-containing polypeptides or functional fragments thereof,  
30 comprising substantially the same amino acid sequence as set forth in any of SEQ ID NOS: 12, 168, 188, 170,

172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90.

The sequence identifiers set forth above correspond to the molecules described herein as set forth in Table 1.

Table 1

<u>Designation</u>	<u>Nucleotide</u> <u>SEQ ID NO:</u>	<u>Polypeptide</u> <u>SEQ ID NO:</u>
CARD2X	11	12
CARD2X CARD Domain	167	168
CARD3X	187	188 and 189
CARD3X CARDA Domain	169	170
CARD3X CARDB Domain	171	172
CARD3X NB-ARC Domain	173	174
CARD3X ANGIO-R Domain	175	176
CLAN A	96	97
CLAN B	98	99
CLAN C	100	101
CLAN D	102	103
CLAN CARD	177	178
CLAN NACHT	179	180
CLAN LRR	181	182
CLAN SAM	183	184
COP1	85	86
COP2	89	90

The terms "CARD-containing protein" or "CARD-containing polypeptide" as used herein refer to a protein or polypeptide containing a CARD domain. As used herein, the term "CARD domain" refers to a Caspase Recruitment Domain. A CARD domain is a well known

protein domain of approximately 80 amino acids with characteristic sequence conservation as described, for example, in Hofmann et al., Trends Biochem. Sci. 22:155-156 (1997). CARD domains have been found in  
5 some members of the Caspase family of cell death proteases. Caspases-1, 2, 4, 5, 9, and 11 contain CARD domains near their NH2-termini. These CARD domains mediate interactions of the zymogen inactive forms of caspases with other proteins which can either activate  
10 or inhibit the activation of these enzymes.

For example, the CARD domain of pro-caspase-9 binds to the CARD domain of a caspase-activating protein called Apaf-1 (Apoptosis Protease Activating Factor-1). Similarly, the CARD domain of pro-caspase-1  
15 permits interactions with another CARD protein known as Cardiac (also referred to as RIP2 and RICK), which results in activation of the caspase-1 protease (Thome et al., Curr. Biol. 16:885-888 (1998)). Additionally, pro-caspase-2 binds to the CARD protein Raidd (also  
20 know as Cradd), which permits recruitment of pro-caspase-2 to Tumor Necrosis Factor (TNF) Receptor complexes and which results in activation of the caspase-2 protease (Ahmad et al., Cancer Res. 57:615-619 (1997)). CARD domains can also participate  
25 in homotypic interactions with themselves, resulting in self-association of polypeptides that contain these protein-interaction domains and producing dimeric or possibly even oligomeric complexes.

CARD domains can be found in association with  
30 other types of functional domains within a single polypeptide, thus providing a mechanism for bringing a functional domain into close proximity or contact with a target protein via CARD:CARD associations involving two CARD-containing polypeptides. For example, the

*Caenorhabditis elegans* cell death gene *ced-4* encodes a protein that contains a CARD domain and a ATP-binding oligomerization domain called an NB-ARC domain (van der Biezen and Jones, Curr. Biol. 8:R226-R227). The CARD domain of the CED-4 protein interacts with the CARD domain of a pro-caspase called CED-3. The NB-ARC domain allows CED-4 to self-associate, thereby forming an oligomeric complex which brings associated pro-CED-3 molecules into close proximity to each other. Because most pro-caspases possess at least a small amount of protease activity even in their unprocessed form, the assembly of a complex that brings the proforms of caspase into juxtaposition can result in trans-processing of zymogens, producing the proteolytically processed and active caspase. Thus, CED-4 employs a CARD domain for binding a pro-caspase and an NB-ARC domain for self-oligomerization, resulting in caspase clustering, proteolytic processing and activation.

In addition to their role in caspase activation, CARD domains have been implicated in other cellular processes. Some CARD-containing polypeptides, for example, induce activation of the transcription factor NF-kB. NF-kB activation is induced by many cytokines and plays an important role in cytokine receptor signal transduction mechanisms (DiDonato et al., Nature 388:548-554 (1997)). Moreover, CARD domains are found in some proteins that inhibit rather than activate caspases, such as the IAP (Inhibitor of Apoptosis Protein) family members, cIAP1 and cIAP2 (Rothe et al., Cell 83:1243-1252 (1995)) and oncogenic mutants of the Bcl-10 protein (Willis et al., Cell 96:35-45 (1999)). Also, though caspase activation resulting from CARD domain interactions is often involved in inducing apoptosis, other caspases are

primarily involved in proteolytic processing and activation of inflammatory cytokines (such as pro-IL-1b and pro-IL-18). Thus, CARD-containing polypeptides can also be involved in cytokine receptor signaling and  
5 cytokine production, and, therefore, can be involved in regulation of immune and inflammatory responses.

In view of the function of the CARD domain within the invention CARD-containing polypeptides or functional fragments thereof, polypeptides of the  
10 invention are contemplated herein for use in methods to alter biochemical processes such as apoptosis, NF-kB induction, cytokine processing, cytokine receptor signaling, caspase-mediated proteolysis, thus having modulating effects on cell life and death (i.e.,  
15 apoptosis), inflammation, cell adhesion, and other cellular and biochemical processes.

Invention CARD-containing polypeptides or functional fragments thereof (including CARD domains) are also contemplated in methods to identify CARD-  
20 binding agents and CARD-associated polypeptides (CAPs) that alter apoptosis, NF-kB induction, cytokine processing, cytokine receptor signaling, caspase-mediated proteolysis, thus having modulating effects on cell life and death (i.e., apoptosis), inflammation,  
25 cell adhesion, and other cellular and biochemical processes.

It is also contemplated herein that invention CARD-containing polypeptides can associate with other CARD-containing polypeptides to form invention hetero-  
30 oligomers or homo-oligomers, such as heterodimers or homodimers. In particular, the association of the CARD domain of invention polypeptides with other CARD-

containing polypeptides, such as Apaf-1, CED-4, caspases-1, 2, 9, 11, cIAPs-1 and 2, CARDIAK, Raidd, Dark, CLAN, other invention CARD-containing polypeptides, and the like, including homo-  
5 oligomerization, is sufficiently specific such that the bound complex can form *in vivo* in a cell or *in vitro* under suitable conditions. Similarly therefore, an invention CARD-containing polypeptide can associate with another CARD-containing polypeptide by CARD:CARD  
10 form invention hetero-oligomers or homo-oligomers, such as heterodimers or homodimers.

In accordance with the present invention, sequences for novel CARD-containing polypeptides have been determined. Thus, the present invention provides  
15 novel CARD-containing polypeptides, including the newly identified CARD-containing polypeptides designated CARD2X, CARD3X, CLAN A, CLAN B, CLAN C, CLAN D, COP-1 and COP-2 (set forth in SEQ ID NOS: 12, 188, 97, 99, 101, 103, 86 and 90).

20 In addition to CARD domains, invention polypeptides can contain one or more additional domains. The locations within the reference sequence of the domains described herein are set forth in Table 2.

Table 2

	<u>Domain</u>	<u>Corresponding amino acids</u>	<u>SEQ ID NO:</u>
	CARD2X CARD Domain	4-78 of SEQ ID NO:12	167 (nt) 168 (aa)
5	CARD3X CARDA Domain	2-78 of SEQ ID NO:107	169 (nt) 170 (aa)
	CARD3X CARDB Domain	105-185 of SEQ ID NO:107	171 (nt) 172 (aa)
10	CARD3X NB-ARC Domain	265-560 of SEQ ID NO:107	173 (nt) 174 (aa)
	CARD3X ANGIO-R Domain	437-839 of SEQ ID NO:107	175 (nt) 176 (aa)
	CLAN CARD Domain	1-87 of SEQ ID NO:97	177 (nt) 178 (aa)
15	CLAN NACHT Domain	161-457 of SEQ ID NO:97	179 (nt) 180 (aa)
	CLAN LRR Domain	760-965 of SEQ ID NO:97	181 (nt) 182 (aa)
20	CLAN SAM Domain	642-696 of SEQ ID NO:97	183 (nt) 184 (aa)

CARD3X (SEQ ID NO:88) contains at least four distinct domains: two CARD domains, designated CARD-A and CARD-B, an NB-ARC domain and an angio-R domain. A second in-frame, open reading frame that begins after a stop codon encodes a domain with several leucine rich repeats (LRR) (SEQ ID NO:189) (see Example). An invention CARD3X polypeptide can thus contain the amino acid sequence designated SEQ ID NO:188 and the amino acid sequence designated SEQ ID NO:189; contain SEQ ID NO:188 but not SEQ ID NO:189; or contain SEQ ID NO:189 but not SEQ ID NO:188. A murine CARD3X polypeptide can contain the amino acid sequence designated SEQ ID

NO:193, which is homologous to a portion of the human CARD3X ANGIO-R domain, with or without one or more additional CARD3X domains.

CLAN exists in four isoforms (see Example),  
5 each of which contains a CARD domain. The longest isoform, CLAN-A, also contains an NB-ARC (NACHT) domain, a LRR domain and a SAM domain. CLAN represents a new member of the CED-4 related protein family. Numerous CED-4-related proteins have recently been  
10 identified. These proteins belong to the CED-4 family of proteins, and include CED-4 (Yuan and Horvitz, Development 116:309-320 (1992)), Apaf-1, (Zou et al., Cell 90:405-413 (1997)), Dark (Rodriguez et al., Nature Cell Biol. 1:272-279 (1999)), and CARD4/Nod1 (Bertin et al., J. Biol. Chem. 274:12955-12958 (1999) and Inohara et al., J. Biol. Chem. 274:14560-14567 (1999)). As  
15 used herein, a "CED-4 family" member or "CED-4 protein family" member, also referred to herein as a "NAC" polypeptide, is a polypeptide that comprises a NB-ARC  
20 domain and a CARD domain.

The CED-4 homolog in humans and rodents, referred to as Apaf-1, contains a (i) CARD domain, (ii) NB-ARC domain, and (iii) multiple copies of a WD-repeat domain. In contrast to CED-4 which can spontaneously  
25 oligomerize, the mammalian Apaf-1 protein is an inactive monomer until induced to oligomerize by binding of a co-factor protein, cytochrome c (Li et al., Cell 91:479-489 (1997)). In Apaf-1, the WD repeat domains prevent oligomerization of the Apaf-1 protein,  
30 until coming into contact with cytochrome c. Thus, the WD-repeats function as a negative-regulatory domain that maintains Apaf-1 in a latent state until cytochrome c release from damaged mitochondria triggers the assembly of an oligomeric Apaf-1 complex (Saleh, J.

Biol. Chem. 274:17941-17945 (1999)). By binding pro-caspase-9 through its CARD domain, Apaf-1 oligomeric complexes are thought to bring the zymogen forms of caspase-9 into close proximity, permitting  
5 them to cleave each other and produce the proteolytic processed and active caspase-9 protease (Zou et al., J. Biol. Chem. 274:11549-11556 (1999)).

Another characteristic of the invention CARD-containing polypeptides is that they can associate  
10 with pro-caspases, caspases or with caspase-associated proteins, thereby altering caspase proteolytic activity. Caspase proteolytic activity is associated with apoptosis of cells, and additionally with cytokine production. Therefore, an invention CARD-containing  
15 polypeptide can alter apoptosis or cytokine production by altering caspase proteolytic activity. As used herein a "caspase" is any member of the cysteine aspartyl proteases. Typically, a caspase can associate with a CARD-containing polypeptide of the  
20 invention such as a NAC polypeptide. Similarly, a "pro-caspase" is an inactive or less-active precursor form of a caspase, which is typically converted to the more active caspase form by a proteolytic event, and often a proteolytic event preceded by a protein:protein  
25 interaction such as a CARD: CARD interaction, and the like.

As described in the Example, COP-1 interacts with the prodomain of pro-caspase-1 and also with RIP2, a protein previously demonstrated to bind the prodomain  
30 of pro-caspase-1. COP-1 competes with RIP2 for binding to pro-caspase-1, thereby inhibiting RIP2-mediated caspase-1 oligomerization. Consequently, COP-1 interferes with the ability of RIP2 to enhance caspase-1-induced secretion of mature IL- 1 $\beta$ .

Therefore, COP-1 is likely to play a role in controlling IL-1 $\beta$  generation and thereby opposing IL-1 $\beta$ -induced inflammation. IL-1 $\beta$  plays a critical role in septic shock, which currently represents the most common cause of lethality in patients treated in the intensive care setting. Accordingly, COP-1 likely plays a role in IL-1 $\beta$  homeostasis to prevent systemic inflammatory reactions when challenged with gram-negative bacteria or other inflammatory insults.

As also described in the Example, because of their interactions with diverse other CARD proteins, the isoforms of CLAN (A, B, C and D) likely influence apoptosis, cytokine processing, or NF-kB activity. Interactions of CLAN with pro-caspase-1 likely indicates a role for CLAN as a IL-1 $\beta$  regulator. In this regard, different isoforms of CLAN likely have opposing effects on pro-caspase-1 activation. The longest isoform, CLAN-A, for example, can trigger pro-caspase-1 activation by the "induced proximity" mechanism as a result of oligomerization mediated by its NB-ARC (NACHT) domain. In contrast, the shorter isoforms of CLAN lacking this self-oligomerization can operate as competitive antagonists of pro-caspase-1 activation, analogous to ICEBERG, a CARD-containing protein that competes with CARDIAK (RIP2/RICK) for binding to pro-caspase-1. Interactions of CLAN with NAC also suggest this protein can have an influence on apoptosis mediated by Apaf-1, in as much as NAC binds Apaf-1 and enhances its ability to activate caspase-9 in response to cytochrome c. Finally, CLAN associations with NF-kB regulators such as Bcl-10 and Nod2 strongly suggest that at least some of the CLAN isoforms can influence the activity of this transcription factor.

In addition to the ability to bind caspases, invention CARD-containing polypeptides can contain a protease domain, such as a protease domain found in caspase, and the like. A caspase protease domain  
5 hydrolyzes amide bonds, particularly the amide bond of a peptide or polypeptide backbone. Typically, a caspase protease domain contains a P20/P10 domain in the active site region of the caspase protease domain. Thus, a caspase protease domain has proteolytic  
10 activity.

CARD-containing polypeptides are also known to induce activation of the transcription factor NF-kB. Thus, an invention CARD-containing polypeptide can also alter transcription by, for example, modulation of  
15 NF-kB activity, and the like.

The NB-ARC (NACHT) domain of invention NAC polypeptides such as CLAN and CARD3X (see Example) associates with other polypeptides, particularly with polypeptides comprising NB-ARC domains. Thus, a  
20 functional NB-ARC domain associates with NB-ARC domain-containing polypeptides by way of NB-ARC:NACHT association. As used herein, the term "associate" or "association" means that CARD-containing polypeptide such as a NAC polypeptide can bind to a polypeptide  
25 relatively specifically and, therefore, can form a bound complex. For example, the association of a CARD domain of an invention CARD-containing polypeptide with another CARD-containing polypeptide or the association of a NB-ARC domain of NAC with another NB-ARC  
30 domain-containing polypeptides is sufficiently specific such that the bound complex can form *in vivo* in a cell or *in vitro* under suitable conditions.

Further, a NB-ARC domain demonstrates both nucleotide-binding (e.g., ATP-binding) and hydrolysis activities, which is typically required for its ability to associate with NB-ARC domain-containing polypeptides. Thus, an NB-ARC domain of the invention NAC comprises one or more nucleotide binding sites. As used herein, a nucleotide binding site is a portion of a polypeptide that specifically binds a nucleotide such as, e.g., ADP, ATP, and the like. Typically, the nucleotide binding site of NB-ARC will comprise a P-loop, a kinase 2 motif, or a kinase 3a motif of the invention NAC (these motifs are defined, for example, in van der Biezen and Jones, supra). Preferably, the nucleotide binding site of NB-ARC comprises a P-loop of the invention NAC. The NB-ARC domain of the an invention CARD-containing polypeptide, therefore, is capable of associating with other NB-ARC domains in homo- or hetero-oligomerization. Additionally, the NB-ARC domain is characterized by nucleotide hydrolysis activity, which can influence the ability of an NB-ARC domain to associate with another NB-ARC domain.

An invention NAC, therefore, is capable of CARD:CARD association and/or NB-ARC:NB-ARC association, resulting in a multifunctional polypeptide capable of one or more specific associations with other polypeptides. An invention NAC can alter cell processes such as apoptosis, cytokine production, and the like. For example, it is contemplated herein that an invention NAC polypeptide can increase the level of apoptosis in a cell. It is also contemplated herein that an invention NAC can decrease the level of apoptosis in a cell. For example, a NAC which does not induce apoptosis may form hetero-oligomers with a NAC which is apoptotic, thus interfering with the apoptosis-inducing activity of NAC.

In another embodiment of the invention, a CARD-containing polypeptide of the invention, such as CLAN (SEQ ID NOS:96, 98, 100 and 102) and an isoform of CARD3X (containing SEQ ID NO:189) also contains

5 Leucine-Rich Repeats (LRR) domain. LRR domains are well known in the art and, in one embodiment, the LRR domain of an invention CARD-containing polypeptide has substantially the same sequence as a LRR described in another CARD-containing polypeptide known as Nod1

10 (Inohara et al., J. Biol. Chem. 274:14560-14567 (1999)). The function of the LRR domain is to mediate specific interactions with other polypeptides.

In another embodiment of the invention, there are provided CARD-containing polypeptides that contain

15 an NB-ARC domain and a CARD domain. NAC polypeptide sequences disclosed herein, for example, CARD4/5X (CLAN), modulate a variety of biochemical processes such as apoptosis. NAC polypeptides can also have other domains that modulate biochemical processes such

20 as an LRR domain or a WD domain.

Those of skill in the art will recognize that numerous residues of the above-described sequences can be substituted with other, chemically, sterically and/or electronically similar residues without

25 substantially altering the biological activity of the resulting CARD-containing polypeptide species. In addition, larger polypeptide sequences comprising substantially the same sequence as amino acids set forth in SEQ ID NOS:12, 168, 188, 170, 172, 174, 176,

30 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90, therein are contemplated within the scope of the invention.

As employed herein, the term "substantially the same amino acid sequence" refers to amino acid sequences having at least about 70% or 75% identity with respect to the reference amino acid sequence, and  
5 retaining comparable functional and biological activity characteristic of the polypeptide defined by the reference amino acid sequence. Preferably, polypeptides having "substantially the same amino acid sequence" will have at least about 80%, 82%, 84%, 86%  
10 or 88%, more preferably 90%, 91%, 92%, 93% or 94% amino acid identity with respect to the reference amino acid sequence; with greater than about 95%, 96%, 97%, 98% or 99% amino acid sequence identity being especially preferred. It is recognized, however, that  
15 polypeptides or nucleic acids containing less than the described levels of sequence identity arising as splice variants or that are modified by conservative amino acid substitutions, or by substitution of degenerate codons are also encompassed within the scope of the  
20 present invention.

In accordance with the invention, specifically included within the definition of substantially the same amino acid sequence is the predominant amino acid sequence of a particular  
25 invention CARD-containing polypeptide or domain disclosed herein. The predominant amino acid sequence refers to the most commonly expressed naturally occurring amino acid sequence in a species population. A predominant polypeptide with multiple isoforms will  
30 have the most commonly expressed amino acid sequence for each isoform. A predominant CARD-containing polypeptide of the invention refers to an amino acid sequence having sequence identity to an amino acid sequence disclosed herein that is greater than that of

any other naturally occurring protein of a particular species (e.g., human).

Given the teachings herein of the location and nucleic acid or amino acid sequences corresponding to the invention CARD-containing polypeptides, one of skill in the art can readily confirm and, if necessary, revise the nucleic acid or amino acid sequences associated with the CARD-containing polypeptides of the invention. For example, the sequences can be confirmed by probing a cDNA library with a nucleic acid probe corresponding to a nucleic acid of the invention using PCR or other known methods. Further, an appropriate bacterial artificial chromosome containing the region of the genome encoding an invention CARD-containing polypeptide can be commercially obtained and probed using PCR, restriction mapping, sequencing, and other known methods.

The term "biologically active" or "functional", when used herein as a modifier of invention CARD-containing polypeptides, or polypeptide fragments thereof, refers to a polypeptide that exhibits functional characteristics similar to a CARD-containing polypeptide of the invention. Biological activities of a CARD-containing polypeptide include, for example, the ability to bind, preferably *in vivo*, to a nucleotide, to a CARD-associated polypeptide, to a NB-ARC-containing polypeptide, or to homo-oligomerize, or to alter protease activation, particularly caspase activation, or to catalyze reactions such as proteolysis or nucleotide hydrolysis, or to alter NF-kB activity, or to alter apoptosis, cytokine processing, cytokine receptor signaling, inflammation, immune response, and other biological activities described herein.

The ability of a CARD-containing polypeptide to bind another polypeptide such as a CARD-associated polypeptide can be assayed, for example, using the methods well known in the art such as yeast two-hybrid assays, co-immunoprecipitation, GST fusion co-purification, and other methods provided in standard technique manuals such as Sambrook, supra, and Ausubel et al., supra. Another biological activity of a CARD-containing polypeptide is the ability to act as an immunogen for the production of polyclonal and monoclonal antibodies that bind specifically to an invention CARD-containing polypeptide. Thus, an invention nucleic acid encoding a CARD-containing polypeptide can encode a polypeptide specifically recognized by an antibody that also specifically recognizes a CARD-containing polypeptide (preferably human) including the amino acid set forth in SEQ ID NOS: 12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90. Such immunologic activity may be assayed by any method known to those of skill in the art. For example, a test-polypeptide can be used to produce antibodies, which are then assayed for their ability to bind to an invention polypeptide. If the antibody binds to the test-polypeptide and to the reference polypeptide with substantially the same affinity, then the polypeptide possesses the requisite immunologic biological activity.

As used herein, the term "substantially purified" means a polypeptide that is in a form that is relatively free from contaminating lipids, polypeptides, nucleic acids or other cellular material normally associated with a polypeptide in a cell. A substantially purified CARD-containing polypeptide can be obtained by a variety of methods well-known in the art, e.g., recombinant expression systems described

herein, chemical synthesis or purification from native sources. Purification methods can include, for example, precipitation, gel filtration, ion-exchange, reverse-phase and affinity chromatography, and the like. Other well-known methods are described in Deutscher et al., "Guide to Protein Purification" Methods in Enzymology Vol. 182, (Academic Press, (1990)). Alternatively, the isolated polypeptides of the present invention can be obtained using well-known recombinant methods as described, for example, in Sambrook et al., supra, (1989) and Ausubel et al., supra (2000). The methods and conditions for biochemical purification of a polypeptide of the invention can be chosen by those skilled in the art, and purification monitored, for example, by an immunological assay, binding assay, or a functional assay.

In addition to the ability of invention CARD-containing polypeptides, or functional fragments thereof, to interact with other, heterologous proteins (e.g., CARD-containing polypeptides), invention CARD-containing polypeptides have the ability to self-associate to form invention homo-oligomers such as homodimers. This self-association is possible through interactions between CARD domains, and also through interactions between NB-ARC domains. Further, self-association can take place as a result of interactions between LRR domains.

In accordance with the invention, there are also provided mutations and fragments of CARD-containing polypeptides which have activity different than a predominant naturally occurring CARD-containing polypeptide activity. As used herein, a "mutation" can be any deletion, insertion, or change of one or more

amino acids in the predominant naturally occurring protein sequence (e.g., wild-type), and a "fragment" is any truncated form, either carboxy-terminal, amino-terminal, or both, of the predominant naturally occurring protein. Preferably, the different activity of the mutation or fragment is a result of the mutant polypeptide or fragment maintaining some but not all of the activities of the respective predominant naturally occurring CARD-containing polypeptide.

For example, a functional fragment of an invention polypeptide can contain or consist of one or more of the following: a CARD domain, a NB-ARC domain, a LRR domain, a SAM domain, or an angio-R domain. In a specific example, a fragment of a CARD-containing polypeptide such as CLAN can contain a CARD domain and LRR domain, but lack a functional NB-ARC domain. Such a fragment will maintain a portion of the predominant naturally occurring CLAN activity (e.g., CARD domain functionality), but not all such activities (e.g., lacking an active NB-ARC domain). The resultant fragment will therefore have an activity different than the predominant naturally occurring CLAN activity. In another example, the CLAN polypeptide might have only the NB-ARC domain, allowing it to interact with other NB-ARC domain proteins in forming homo-oligomers or hetero-oligomers. In one embodiment, the activity of the fragment will be "dominant-negative." A dominant-negative activity will allow the fragment to reduce or inactivate the activity of one or more isoforms of a predominant naturally occurring CARD-containing polypeptide. Another functional fragment can include an angio-R domain (see Example), or any of the domains disclosed herein (see, for example, Table 2).

Isoforms of the CARD-containing polypeptides are also provided which arise from alternative mRNA splicing and may alter or modify the interactions of the CARD-containing polypeptide with other

5 polypeptides. For example, four isoforms of CLAN and three isoforms of CARD3X are disclosed herein. Additional isoforms of the CARD-containing polypeptides designated SEQ ID NOS: 12, 188, 97, 99, 101, 103, 86 and 90, are contemplated herein and therefore, are

10 encompassed within the scope of the invention CARD-containing polypeptides.

Methods to identify polypeptides containing a functional fragment of a CARD-containing polypeptide of the invention are well known in the art and are

15 disclosed herein. For example, genomic or cDNA libraries, including universal cDNA libraries can be probed according to methods disclosed herein or other methods known in the art. Full-length polypeptide encoding nucleic acids such as full-length cDNAs can be

20 obtained by a variety of methods well-known in the art. For example, 5' and 3' RACE, methodology is well known in the art and described in Ausubel et al., supra, and the like.

In another embodiment of the invention,

25 chimeric polypeptides are provided comprising a CARD-containing polypeptide, or a functional fragment thereof, fused with another protein or functional fragment thereof. Functional fragments of a CARD-containing polypeptide include, for example, NB-ARC

30 (NACHT), CARD, LRR, and ANGIO-R domains or other fragments that retain a biological activity of an invention CARD-containing polypeptide. Polypeptides with which the CARD-containing polypeptide or functional fragment thereof are fused will include, for

example, glutathione-S-transferase, an antibody, or other proteins or functional fragments thereof which facilitate recovery of the chimera. Further, polypeptides with which a CARD-containing polypeptide or functional fragment thereof are fused will include, for example, luciferase, green fluorescent protein, an antibody, or other proteins or functional fragments thereof which facilitate identification of the chimera. Still further polypeptides with which a CARD-containing polypeptide or functional fragment thereof are fused will include, for example, the LexA DNA binding domain, ricin, a-sarcin, an antibody or fragment thereof, or other polypeptides which have therapeutic properties or other biological activity.

Further invention chimeric polypeptides contemplated herein are chimeric polypeptides wherein a functional fragment of a CARD-containing polypeptide is fused with a catalytic domain or a protein interaction domain from a heterologous polypeptide. For example, the NB-ARC domain of CLAN, as disclosed herein, can be replaced by the NB-ARC domain of other CARD polypeptides, such as CARD3X, and the like. Another example of such a chimera is a polypeptide wherein the CARD domain of CLAN is replaced by the CARD domain from CARD2X or CARD3X, and the like. In a further example, an NB-ARC domain can be fused with a caspase catalytic P20 domain to form a novel chimera with caspase activity. One of skill in the art will appreciate that a large number of chimeric polypeptides are readily available by combining domains of two or more CARD-containing polypeptides of the invention. Further, chimeric polypeptides can contain a functional fragment of a CARD-containing polypeptide of the invention fused with a domain of a protein known in the art, such as CED-4, Apaf-1, caspase-1, and the like.

In another embodiment of the invention, polypeptides are provided comprising 10 or more contiguous amino acids selected from the group consisting of SEQ ID NOS:12, 188, 97, 99, 101, 103, 86  
5 and 90.

As used herein, the term "polypeptide" when used in reference to a CARD-containing polypeptide or fragment is intended to refer to a peptide or polypeptide of two or more amino acids. The term  
10 "polypeptide analog" includes any polypeptide having an amino acid residue sequence substantially the same as a sequence specifically described herein in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the  
15 ability to functionally mimic a CARD-containing polypeptide as described herein. A "modification" of an invention polypeptide also encompasses conservative substitutions of an invention polypeptide amino acid sequence. Conservative substitutions of encoded amino  
20 acids include, for example, amino acids that belong within the following groups: (1) non-polar amino acids (Gly, Ala, Val, Leu, and Ile); (2) polar neutral amino acids (Cys, Met, Ser, Thr, Asn, and Gln); (3) polar acidic amino acids (Asp and Glu); (4) polar basic amino  
25 acids (Lys, Arg and His); and (5) aromatic amino acids (Phe, Trp, Tyr, and His). Other groupings of amino acids can be found, for example in Taylor, J. Theor. Biol. 119:205-218 (1986), which is incorporated herein by reference. Other minor modifications are included  
30 within invention polypeptides so long as the polypeptide retains some or all of its function as described herein.

The amino acid length of functional fragments or polypeptide analogs of the present invention can

range from about 5 amino acids up to the full-length protein sequence of an invention CARD-containing polypeptide. In certain embodiments, the amino acid lengths include, for example, at least about 10 amino acids, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 125, at least about 150, at least about 175, at least about 200, at least about 250 or more amino acids in length up to the full-length CARD-containing polypeptide sequence. The functional fragments can be contiguous amino acid sequences of an invention polypeptide, including contiguous amino acid sequences of SEQ ID NOS: 12, 188, 97, 99, 101, 103, 86 and 90. A peptide of at least about 10 amino acids can be used, for example, as an immungen to raise antibodies specific for an invention CARD-containing polypeptide.

A modification of a polypeptide can also include derivatives, analogues and functional mimetics thereof, provided that such polypeptide displays a CARD-containing polypeptide biological activity. For example, derivatives can include chemical modifications of the polypeptide such as alkylation, acylation, carbamylation, iodination, or any modification that derivatizes the polypeptide. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and

ethyl esters or other types of esters or hydrazides. Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine can be derivatized to form

5 N-im-benzylhistidine. Also included as derivatives or analogues are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids, for example,

10 4-hydroxyproline, 5-hydroxylysine, 3-methylhistidine, homoserine, ornithine or carboxyglutamate, and can include amino acids that are not linked by peptide bonds. Polypeptides of the present invention also include any polypeptide having one or more additions and/or deletions of residues, relative to the sequence

15 of a polypeptide whose sequence is shown herein, so long as CARD-containing polypeptide activity is maintained.

A modification of an invention polypeptide includes functional mimetics thereof. Mimetics

20 encompass chemicals containing chemical moieties that mimic the function of the polypeptide. For example, if a polypeptide contains two charged chemical moieties having functional activity, a mimetic places two charged chemical moieties in a spatial orientation and

25 constrained structure so that the charged chemical function is maintained in three-dimensional space. Thus, a mimetic, which orients functional groups that provide a function of a CARD-containing polypeptide, are included within the meaning of a CARD-containing

30 polypeptide derivative. All of these modifications are included within the term "polypeptide" so long as the invention polypeptide or functional fragment retains its function. Exemplary mimetics are peptidomimetics, peptoids, or other peptide-like polymers such as

35 poly(b-amino acids), and also non-polymeric compounds

upon which functional groups that mimic a peptide are positioned.

Another embodiment of the invention provides a CARD-containing polypeptide, or a functional fragment thereof, fused with a moiety to form a conjugate. As used herein, a "moiety" can be a physical, chemical or biological entity which contributes functionality to a CARD-containing polypeptide or a functional fragment thereof. Functionalities contributed by a moiety include therapeutic or other biological activity, or the ability to facilitate identification or recovery of a CARD-containing polypeptide. Therefore, a moiety will include molecules known in the art to be useful for detection of the conjugate by, for example, by fluorescence, magnetic imaging, detection of radioactive emission. A moiety may also be useful for recovery of the conjugate, for example a His tag or other known tags used for protein isolation and/or purification, or a physical substance such as a bead. A moiety can be a therapeutic compound, for example, a cytotoxic drug which can be useful to effect a biological change in cells to which the conjugate localizes.

An example of the means for preparing the invention polypeptide(s) is to express nucleic acids encoding a CARD-containing polypeptide in a suitable host cell, such as a bacterial cell, a yeast cell, an amphibian cell such as an oocyte, or a mammalian cell, using methods well known in the art, and recovering the expressed polypeptide, again using well-known purification methods. Invention polypeptides can be isolated directly from cells that have been transformed with expression vectors as known in the art. Recombinantly expressed polypeptides of the invention

can also be expressed as fusion proteins with appropriate affinity tags, such as glutathione S transferase (GST) or poly His, and affinity purified. The invention polypeptide, biologically functional  
5 fragments, and functional equivalents thereof can also be produced by *in vitro* transcription/translation methods known in the art, such as using reticulocyte lysates, as used for example, in the TNT system (Promega). The invention polypeptide, biologically  
10 functional fragments, and functional equivalents thereof can also be produced by chemical synthesis. For example, synthetic polypeptides can be produced using Applied Biosystems, Inc. Model 430A or 431A automatic peptide synthesizer (Foster City, CA)  
15 employing the chemistry provided by the manufacturer.

In accordance with another embodiment of the invention, there are provided isolated nucleic acids encoding a CARD-containing polypeptide or functional fragment thereof. The isolated nucleic acids can be  
20 selected from:

- (a) DNA encoding a polypeptide containing the amino acid sequence set forth in SEQ ID NOS: 12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86  
25 and 90, or
- (b) DNA that hybridizes to the DNA of (a) under moderately stringent conditions, where the DNA encodes biologically active CARD-containing polypeptide, or
- 30 (c) DNA degenerate with respect to (b), where the DNA encodes biologically active CARD-containing polypeptide.

The nucleic acid molecules described herein are useful for producing invention polypeptides, when

such nucleic acids are incorporated into a variety of protein expression systems known to those of skill in the art. In addition, such nucleic acid molecules or fragments thereof can be labeled with a readily  
5 detectable substituent and used as hybridization probes for assaying for the presence and/or amount of an invention CARD-encoding gene or mRNA transcript in a given sample. The nucleic acid molecules described herein, and fragments thereof, are also useful as  
10 primers and/or templates in a PCR reaction for amplifying genes encoding invention polypeptides described herein.

The term "nucleic acid" (also referred to as polynucleotides) encompasses ribonucleic acid (RNA) or  
15 deoxyribonucleic acid (DNA), probes, oligonucleotides, and primers and can be single stranded or double stranded. DNA can be either complementary DNA (cDNA) or genomic DNA, e.g. a CARD-encoding gene, and can represent the sense strand, the anti-sense strand, or  
20 both. Examples of nucleic acids are RNA, cDNA, or isolated genomic DNA encoding a CARD-containing polypeptide. One means of isolating a CARD-encoding nucleic acid is to probe a mammalian genomic or cDNA library with a natural or artificially designed DNA  
25 probe using methods well known in the art. DNA probes derived from the CARD-encoding gene are particularly useful for this purpose. DNA and cDNA molecules that encode CARD-containing polypeptides can be used to obtain complementary genomic DNA, cDNA or RNA from  
30 mammalian (e.g., human, mouse, rat, rabbit, pig, and the like), or other animal sources, or to isolate related cDNA or genomic clones by screening cDNA or genomic libraries, using methods described in more detail below. Such nucleic acids include, but are not  
35 limited to, nucleic acids comprising substantially the

same nucleotide sequence as set forth in SEQ ID NOS:  
11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102,  
177, 179, 181, 183, 85 and 89. In general, a genomic  
sequence of the invention includes regulatory regions  
5 such as promoters, enhancers, and introns that are  
outside of the exons encoding a CARD-containing  
polypeptide but does not include proximal genes that do  
not encode a CARD-containing polypeptide.

Thus a CARD-encoding nucleic acid as used  
10 herein refers to a nucleic acid encoding a CARD-  
containing polypeptide of the invention, or a  
functional fragment thereof.

Use of the terms "isolated" and/or "purified"  
and/or "substantially purified" in the present  
15 specification and claims as a modifier of DNA, RNA,  
polypeptides or proteins means that the DNA, RNA,  
polypeptides or proteins so designated have been  
produced in such form by the hand of man, and thus are  
separated from their native in vivo cellular  
20 environment, and are substantially free of any other  
species of nucleic acid or protein. As a result of  
this human intervention, the recombinant DNAs, RNAs,  
polypeptides and proteins of the invention are useful  
in ways described herein that the DNAs, RNAs,  
25 polypeptides or proteins as they naturally occur are  
not.

Invention nucleic acids encoding CARD-  
containing polypeptides and invention CARD-containing  
polypeptides can be obtained from any species of  
30 organism, such as prokaryotes, eukaryotes, plants,  
fungi, vertebrates, invertebrates, and the like. A  
particular species can be mammalian, As used herein,  
"mammalian" refers to a subset of species from which an

invention CARD-encoding nucleic acid is derived, e.g., human, rat, mouse, rabbit, monkey, baboon, bovine, porcine, ovine, canine, feline, and the like. A preferred CARD-encoding nucleic acid herein, is human  
5 CARD-encoding nucleic acid.

In one embodiment of the present invention, cDNAs encoding the invention CARD-containing polypeptides disclosed herein comprise substantially the same nucleotide sequence as the coding region set  
10 forth in any of SEQ ID NOS: 11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89.

As employed herein, the term "substantially the same nucleotide sequence" refers to a nucleic acid  
15 molecule (DNA or RNA) having sufficient identity to the reference polynucleotide, such that it will hybridize to the reference nucleotide under moderately or highly stringent hybridization conditions. In one embodiment, a nucleic acid molecule having substantially the same  
20 nucleotide sequence as the reference nucleotide sequence encodes substantially the same amino acid sequence as that set forth in any of SEQ ID NOS: 12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90. In another embodiment, a  
25 nucleic acid molecule having "substantially the same nucleotide sequence" as the reference nucleotide sequence has at least 60%, or at least 65% identity with respect to the reference nucleotide sequence, such as at least 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%,  
30 86%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the reference nucleotide sequence.

In accordance with the invention, specifically included within the definition of substantially the same nucleotide sequence is the predominant nucleotide sequence of a particular invention CARD-containing polypeptide described herein. The predominant nucleotide sequence refers to the most commonly present naturally occurring nucleotide sequence in a species population. A predominant CARD-encoding nucleic acid of the invention refers to a nucleotide sequence having sequence identity to a nucleotide sequence disclosed herein that is greater than that of any other naturally occurring nucleotide sequence of a particular species (e.g., human).

In one embodiment, a nucleic acid molecule that has substantially the same nucleotide sequence as a reference sequence is a modification of the reference sequence. As used herein, a "modification" of a nucleic acid can include one or several nucleotide additions, deletions, or substitutions with respect to a reference sequence. A modification of a nucleic acid can include substitutions that do not change the encoded amino acid sequence due to the degeneracy of the genetic code. Such modifications can correspond to variations that are made deliberately, or which occur as mutations during nucleic acid replication.

Exemplary modifications of the recited nucleotide sequences include sequences that correspond to homologs of other species, including mammalian species such as mouse, primates, including monkey and baboon, rat, rabbit, bovine, porcine, ovine, canine, feline, or other animal species. The corresponding nucleotide sequences of non-human species can be determined by methods known in the art, such as by PCR or by screening genomic, cDNA or expression libraries.

Another exemplary modification of the invention CARD-encoding nucleic acid or CARD-containing polypeptide can correspond to splice variant forms of the CARD-encoding nucleotide sequence. Additionally, a  
5 modification of a nucleotide sequence can include one or more non-native nucleotides, having, for example, modifications to the base, the sugar, or the phosphate portion, or having a modified phosphodiester linkage. Such modifications can be advantageous in increasing  
10 the stability of the nucleic acid molecule.

Furthermore, a modification of a nucleotide sequence can include, for example, a detectable moiety, such as a radiolabel, a fluorochrome, a ferromagnetic substance, a luminescent tag or a detectable binding  
15 agent such as biotin. Such modifications can be advantageous in applications where detection of a CARD-encoding nucleic acid molecule is desired.

In another embodiment, a nucleic acid molecule that has substantially the same nucleotide  
20 sequence as a reference sequence is a functionally equivalent nucleic acid, which indicates that it is phenotypically similar to the reference nucleic acid. As used herein, the phrase "functionally equivalent nucleic acids" encompasses nucleic acids characterized  
25 by slight and non-consequential sequence variations that will function in substantially the same manner to produce the same polypeptide product(s) as the nucleic acids disclosed herein. In particular, functionally equivalent nucleic acids encode polypeptides that are  
30 the same as those encoded by the nucleic acids disclosed herein or that have conservative amino acid variations, as described above. These variations include those recognized by skilled artisans as those

that do not substantially alter the tertiary structure of the protein.

Further provided are nucleic acids encoding CARD-containing polypeptides that, by virtue of the degeneracy of the genetic code, do not necessarily hybridize to the invention nucleic acids under specified hybridization conditions. Preferred nucleic acids encoding the invention CARD-containing polypeptides are comprised of nucleotides that encode substantially the same amino acid sequence as set forth in SEQ ID NOS:12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90.

Hybridization refers to the binding of complementary strands of nucleic acid (i.e., sense:antisense strands or probe:target-DNA) to each other through hydrogen bonds, similar to the bonds that naturally occur in chromosomal DNA. Stringency levels used to hybridize a given probe with target-DNA can be readily varied by those of skill in the art.

The phrase "stringent hybridization" is used herein to refer to conditions under which polynucleic acid hybrids are stable. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature ( $T_m$ ) of the hybrids. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of lower stringency, followed by washes of varying, but higher, stringency. Reference to hybridization stringency relates to such washing conditions.

As used herein, the phrase "moderately stringent hybridization" refers to conditions that

permit target-nucleic acid to bind a complementary nucleic acid. The hybridized nucleic acids will generally have at least about 60% identity, at least about 75% identity, such as at least about 85% identity; or at least about 90% identity. Moderately stringent conditions are conditions equivalent to hybridization in 50% formamide, 5X Denhart's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.2X SSPE, 0.2% SDS, at 42°C.

10           The phrase "high stringency hybridization" refers to conditions that permit hybridization of only those nucleic acid sequences that form stable hybrids in 0.018M NaCl at 65°C, for example, if a hybrid is not stable in 0.018M NaCl at 65°C, it will not be stable under high stringency conditions, as contemplated herein. High stringency conditions can be provided, for example, by hybridization in 50% formamide, 5X Denhart's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.1X SSPE, and 0.1% SDS at 65°C.

20           The phrase "low stringency hybridization" refers to conditions equivalent to hybridization in 10% formamide, 5X Denhart's solution, 6X SSPE, 0.2% SDS at 22°C, followed by washing in 1X SSPE, 0.2% SDS, at 37°C. Denhart's solution contains 1% Ficoll, 1% polyvinylpyrrolidone, and 1% bovine serum albumin (BSA). 20X SSPE (sodium chloride, sodium phosphate, ethylene diamide tetraacetic acid (EDTA)) contains 3M sodium chloride, 0.2M sodium phosphate, and 0.025 M (EDTA). Other suitable moderate stringency and high stringency hybridization buffers and conditions are well known to those of skill in the art and are described, for example, in Sambrook et al., supra (1989); and Ausubel et al., supra, 2000). Nucleic acids encoding polypeptides hybridize under moderately stringent or

high stringency conditions to substantially the entire sequence, or substantial portions, for example, typically at least 15-30 nucleotides of the nucleic acid sequence set forth in SEQ ID NOS:11, 167, 187,  
5 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89.

As used herein, the term "degenerate" refers to codons that differ in at least one nucleotide from a reference nucleic acid, e.g., SEQ ID NOS:11, 167, 187,  
10 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89, but encode the same amino acids as the reference nucleic acid. For example, codons specified by the triplets "UCU", "UCC", "UCA", and "UCG" are degenerate with respect to each other since all four of  
15 these codons encode the amino acid serine.

The invention also provides a modification of a nucleotide sequence that hybridizes to a CARD-encoding nucleic acid molecule, for example, a nucleic acid molecule referenced as any of SEQ ID NOS:11, 167,  
20 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89 under moderately stringent conditions. Modifications of nucleotide sequences, where the modification has at least 60% identity to a CARD-encoding nucleotide sequence, are also provided.  
25 The invention also provides modification of a CARD-encoding nucleotide sequence having at least 65% identity, at least 70% identity, at least 72% identity, at least 74% identity, at least 76% identity, at least 78% identity, at least 80% identity, at least 82%  
30 identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity,

at least 96% identity, at least 97% identity, at least 98% identity or at least 99% identity.

Identity of any two nucleic acid or amino acid sequences can be determined by those skilled in the art based, for example, on a BLAST 2.0 computer alignment, using default parameters. BLAST 2.0 searching is known in the art and is publicly available, for example, at <http://www.ncbi.nlm.nih.gov/BLAST/>, as described by Tatiana et al., FEMS Microbiol Lett. 174:247-250 (1999); Altschul et al., Nucleic Acids Res., 25:3389-3402 (1997).

One means of isolating a nucleic acid encoding a CARD-containing polypeptide is to probe a cDNA library or genomic library with a natural or artificially designed nucleic acid probe using methods well known in the art. Nucleic acid probes derived from a CARD-encoding gene are particularly useful for this purpose. DNA and cDNA molecules that encode CARD-containing polypeptides can be used to obtain complementary genomic DNA, cDNA or RNA from mammals, for example, human, mouse, rat, rabbit, pig, and the like, or other animal sources, or to isolate related cDNA or genomic clones by the screening of cDNA or genomic libraries, by methods well known in the art (see, for example, the Examples set forth hereinafter; and Sambrook et al., supra, 1989; Ausubel et al., supra, 2000).

Another useful method for producing a CARD-encoding nucleic acid molecule of the invention involves amplification of the nucleic acid molecule using PCR and invention oligonucleotides and, optionally, purification of the resulting product by

gel electrophoresis. Either PCR or RT-PCR can be used to produce a CARD-encoding nucleic acid molecule having any desired nucleotide boundaries as described in the Examples. Desired modifications to the nucleic acid sequence can also be introduced by choosing an appropriate oligonucleotide primer with one or more additions, deletions or substitutions. Such nucleic acid molecules can be amplified exponentially starting from as little as a single gene or mRNA copy, from any cell, tissue or species of interest.

The invention additionally provides a nucleic acid that hybridizes under high stringency conditions to the CARD coding portion of any of SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89, such as to any of SEQ ID NOS: 168, 170, 172 and 178. The invention also provides a nucleic acid having a nucleotide sequence substantially the same as set forth in any of SEQ ID 11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89.

The invention also provides a method for identifying nucleic acids encoding a mammalian CARD-containing polypeptide by contacting a sample containing nucleic acids with one or more invention nucleic acid molecules or oligonucleotides, wherein the contacting is effected under high stringency hybridization conditions, and identifying a nucleic acid that hybridizes to the oligonucleotide. The invention additionally provides a method of detecting a CARD-encoding nucleic acid molecule in a sample by contacting the sample with two or more invention oligonucleotides, amplifying a nucleic acid molecule, and detecting the amplification. The amplification can be performed, for example, using PCR. The invention further provides oligonucleotides that function as

single stranded nucleic acid primers for amplification of a CARD-encoding nucleic acid, wherein the primers comprise a nucleic acid sequence derived from the nucleic acid sequences set forth as SEQ ID NOS:11, 187,  
5 96, 98, 100, 102, 85 and 89.

In accordance with a further embodiment of the present invention, optionally labeled CARD-encoding cDNAs, or fragments thereof, can be employed to probe library(ies) such as cDNA, genomic, BAC, and the like  
10 for predominant nucleic acid sequences or additional nucleic acid sequences encoding novel CARD-containing polypeptides. Construction and screening of suitable mammalian cDNA libraries, including human cDNA libraries, is well-known in the art, as demonstrated,  
15 for example, in Ausubel et al., supra. Screening of such a cDNA library is initially carried out under low-stringency conditions, which comprise a temperature of less than about 42°C, a formamide concentration of less than about 50%, and a moderate to low salt  
20 concentration.

Probe-based screening conditions can comprise a temperature of about 37°C, a formamide concentration of about 20%, and a salt concentration of about 5X standard saline citrate (SSC; 20X SSC contains 3M  
25 sodium chloride, 0.3M sodium citrate, pH 7.0). Such conditions will allow the identification of sequences which have a substantial degree of similarity with the probe sequence, without requiring perfect homology. The phrase "substantial similarity" refers to sequences  
30 which share at least 50% homology. Hybridization conditions are selected which allow the identification of sequences having at least 70% homology with the probe, while discriminating against sequences which have a lower degree of homology with the probe. As a

result, nucleic acids having substantially the same nucleotide sequence as any of SEQ ID NOS:11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89 are obtained.

5           As used herein, a nucleic acid "probe" is single-stranded nucleic acid, or analog thereof, that has a sequence of nucleotides that includes at least 15, at least 20, at least 50, at least 100, at least 200, at least 300, at least 400, or at least 500  
10 contiguous bases that are substantially the same as, or the complement of, any contiguous bases set forth in any of SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89. In addition, the entire cDNA encoding region of an invention CARD-containing polypeptide, or an entire  
15 sequence substantially the same as SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89 can be used as a probe. Probes can be labeled by methods well-known in the art, as described hereinafter, and used in various diagnostic kits.

20           The invention additionally provides an oligonucleotide comprising between 15 and 300 contiguous nucleotides of any of SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89 or the anti-sense strand thereof. As used herein, the term "oligonucleotide"  
25 refers to a nucleic acid molecule that includes at least 15 contiguous nucleotides from a reference nucleotide sequence, can include at least 16, 17, 18, 19, 20 or at least 25 contiguous nucleotides, and often includes at least 30, 40, 50, 60, 70, 80, 90, 100, 125,  
30 150, 175, 200, 225, 250, 275, 300, 325, up to 350 contiguous nucleotides from the reference nucleotide sequence. The reference nucleotide sequence can be the sense strand or the anti-sense strand.

The oligonucleotides of the invention that contain at least 15 contiguous nucleotides of a reference CARD-encoding nucleotide sequence are able to hybridize to CARD-encoding nucleotide sequences under  
5 moderately stringent hybridization conditions and thus can be advantageously used, for example, as probes to detect CARD-encoding DNA or RNA in a sample, and to detect splice variants thereof; as sequencing or PCR  
primers; as antisense reagents to block transcription  
10 of CARD-encoding RNA in cells; or in other applications known to those skilled in the art in which hybridization to a CARD-encoding nucleic acid molecule is desirable.

In accordance with another embodiment of the  
15 invention, a method is provided for identifying nucleic acids encoding a CARD-containing polypeptide. The method comprises contacting a sample containing nucleic acids with an invention probe or an invention  
oligonucleotide, wherein said contacting is effected  
20 under high stringency hybridization conditions, and identifying nucleic acids which hybridize thereto. Methods for identification of nucleic acids encoding a CARD-containing polypeptide are disclosed herein and exemplified in the Examples.

25 Also provided in accordance with present invention is a method for identifying a CARD-encoding nucleotide sequence comprising the steps of using a CARD-encoding nucleotide sequence selected from SEQ ID  
NOS:11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102,  
30 177, 179, 181, 183, 85 and 89 to identify a candidate CARD-encoding nucleotide sequence and verifying the candidate CARD-encoding nucleotide sequence by aligning the candidate sequence with known CARD-encoding nucleotide sequences, where a conserved CARD domain

sequence or a predicted three dimensional polypeptide structure similar to a known CARD domain three dimensional structure confirms the candidate sequence as a CARD-encoding sequence. Methods for identifying  
5 CARD-encoding sequences are provided herein (See Examples).

It is understood that a CARD-encoding nucleic acid molecule of the invention, as used herein, specifically excludes previously known nucleic acid  
10 molecules consisting of nucleotide sequences having identity with the CARD-encoding nucleotide sequence (SEQ ID NOS:11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89), such as Expressed Sequence Tags (ESTs), Sequence Tagged Sites  
15 (STSs) and genomic fragments, deposited in public databases such as the nr, dbest, dbsts, gss and htgs databases, which are available for searching at <http://www.ncbi.nlm.nih.gov/blast/>.

In particular, an invention CARD-encoding  
20 nucleic acid molecule excludes the exact, specific and complete nucleic acid molecule sequence corresponding to any of the nucleotide sequences having the Genbank (gb), EMBL (emb) or DDBJ (dbj) accession numbers described below. Accession numbers specifically  
25 excluded include GI:6165147 (Phase-1), AC007728 (Phase-1), NT-002476 (Phase-1), AC010968 (Phase-1), AP001153, AC022468 (Phase-1), GI:6253000 (Phase-1), AC0097959 (Phase-1), GI:6497652 (Phase-1) (contig:23086:40635), GI:6497652 (Phase-1) (contig:41136:57024), AC023068  
30 (Phase-1), W58453, AA257158, AA046000, AW085161, AI189838, AA418021, AA046105, W58488, AA418193, AA257066, AI217611, AW295205, AI023795, AL389934, AA070591, AA070591, AC027011, AP002787, AQ889169, AV719179, AI263294, AV656315, AW337918, BF207840,

AW418826, BK903662, AI023795, H25984, AL121653 and NT\_005194.1. The human contig referenced as GenBank accession No. AC007608 is also specifically excluded from a CARD encoding nucleic acid molecule. The  
5 genomic contigs referenced as GenBank accession numbers GI 5001450, GI 8575872 and GI 9795562 are also specifically excluded from invention nucleic acid molecules. Since one of skill in the art will realize that the above-recited excluded sequences may be  
10 revised at a later date, the skilled artisan will recognize that the above-recited sequences are excluded as they stand on the priority date of this application.

The isolated nucleic acid molecules of the invention can be used in a variety of diagnostic and  
15 therapeutic applications. For example, the isolated nucleic acid molecules of the invention can be used as probes, as described above; as templates for the recombinant expression of CARD-containing polypeptides; or in screening assays such as two-hybrid assays to  
20 identify cellular molecules that bind CARD-containing polypeptides.

The invention thus provides methods for detecting a CARD-encoding nucleic acid in a sample. The methods of detecting a CARD-encoding nucleic acid  
25 in a sample can be either qualitative or quantitative, as desired. For example, the presence, abundance, integrity or structure of a CARD-encoding nucleic acid can be determined, as desired, depending on the assay format and the probe used for hybridization or primer  
30 pair chosen for application.

Useful assays for detecting a CARD-containing nucleic acid based on specific hybridization with an isolated invention oligonucleotide are well known in

the art and include, for example, *in situ* hybridization, which can be used to detect altered chromosomal location of the nucleic acid molecule, altered gene copy number, and RNA abundance, depending  
5 on the assay format used. Other hybridization assays include, for example, Northern blots and RNase protection assays, which can be used to determine the abundance and integrity of different RNA splice variants, and Southern blots, which can be used to  
10 determine the copy number and integrity of DNA. A hybridization probe can be labeled with any suitable detectable moiety, such as a radioisotope, fluorochrome, chemiluminescent marker, biotin, or other detectable moiety known in the art that is detectable  
15 by analytical methods.

As used herein, the terms "label" and "indicating means" in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a  
20 detectable signal. Any label or indicating means can be linked to invention nucleic acid probes, expressed proteins, polypeptide fragments, or antibody molecules. These atoms or molecules can be used alone or in conjunction with additional reagents. Such labels are  
25 themselves well-known in clinical diagnostic chemistry.

Useful assays for detecting a CARD-encoding nucleic acid in a sample based on amplifying a CARD-encoding nucleic acid with two or more invention oligonucleotides are also well known in the art, and  
30 include, for example, qualitative or quantitative polymerase chain reaction (PCR); reverse-transcription PCR (RT-PCR); single strand conformational polymorphism (SSCP) analysis, which can readily identify a single point mutation in DNA based on differences in the

secondary structure of single-strand DNA that produce an altered electrophoretic mobility upon non-denaturing gel electrophoresis; and coupled PCR, transcription and translation assays, such as a protein truncation test, 5 in which a mutation in DNA is determined by an altered protein product on an electrophoresis gel. Additionally, the amplified CARD-encoding nucleic acid can be sequenced to detect mutations and mutational hot-spots, and specific assays for large-scale 10 screening of samples to identify such mutations can be developed.

Also provided are antisense-nucleic acids having a sequence capable of binding specifically with full-length or any portion of an mRNA that encodes 15 CARD-containing polypeptides so as to prevent translation of the mRNA. The antisense-nucleic acid can have a sequence capable of binding specifically with any portion of the sequence of the cDNA encoding CARD-containing polypeptides. As used herein, the 20 phrase "binding specifically" encompasses the ability of a nucleic acid sequence to recognize a complementary nucleic acid sequence and to form double-helical segments therewith via the formation of hydrogen bonds between the complementary base pairs. An example of an 25 antisense-nucleic acid is an antisense-nucleic acid comprising chemical analogs of nucleotides.

The present invention provides means to alter levels of expression of CARD-containing polypeptides by recombinantly expressing CARD-containing anti-sense 30 nucleic acids or employing synthetic anti-sense nucleic acid compositions (hereinafter SANC) that inhibit translation of mRNA encoding these polypeptides. Synthetic oligonucleotides, or other antisense-nucleic

acid chemical structures designed to recognize and selectively bind to mRNA are constructed to be complementary to full-length or portions of a CARD-encoding strand, including nucleotide sequences

5 substantially the same as SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89.

The SANC is designed to be stable in the blood stream for administration to a subject by injection, or in laboratory cell culture conditions.

10 The SANC is designed to be capable of passing through the cell membrane in order to enter the cytoplasm of the cell by virtue of physical and chemical properties of the SANC, which render it capable of passing through cell membranes, for example, by designing small,

15 hydrophobic SANC chemical structures, or by virtue of specific transport systems in the cell which recognize and transport the SANC into the cell. In addition, the SANC can be designed for administration only to certain selected cell populations by targeting the SANC to be

20 recognized by specific cellular uptake mechanisms which bind and take up the SANC only within select cell populations. In a particular embodiment the SANC is an antisense oligonucleotide.

For example, the SANC may be designed to bind

25 to a receptor found only in a certain cell type, as discussed above. The SANC is also designed to recognize and selectively bind to target mRNA sequence, which can correspond to a sequence contained within the sequences shown in SEQ ID NOS:11, 187, 96, 98, 100,

30 102, 85 and 89. The SANC is designed to inactivate target mRNA sequence by either binding thereto and inducing degradation of the mRNA by, for example, RNase I digestion, or inhibiting translation of mRNA target sequence by interfering with the binding of

translation-regulating factors or ribosomes, or inclusion of other chemical structures, such as ribozyme sequences or reactive chemical groups which either degrade or chemically modify the target mRNA.

- 5 SANCs have been shown to be capable of such properties when directed against mRNA targets (see Cohen et al., TIPS, 10:435 (1989) and Weintraub, Sci. American, January (1990), pp.40).

The invention further provides a method of  
10 altering the level of a biochemical process modulated by a CARD-containing polypeptide by introducing an antisense nucleotide sequence into the cell, wherein the antisense nucleotide sequence specifically hybridizes to a CARD-encoding nucleic acid molecule,  
15 wherein the hybridization reduces or inhibits the expression of the CARD-containing polypeptide in the cell. The use of anti-sense nucleic acids, including recombinant anti-sense nucleic acids or SANCs, can be advantageously used to inhibit cell death.

20 Compositions comprising an amount of the antisense-nucleic acid of the invention, effective to reduce expression of CARD-containing polypeptides by entering a cell and binding specifically to CARD-encoding mRNA so as to prevent translation and an  
25 acceptable hydrophobic carrier capable of passing through a cell membrane are also provided herein. Suitable hydrophobic carriers are described, for example, in U.S. Patent Nos. 5,334,761; 4,889,953; 4,897,355, and the like. The acceptable hydrophobic  
30 carrier capable of passing through cell membranes may also comprise a structure which binds to a receptor specific for a selected cell type and is thereby taken up by cells of the selected cell type. For example,

the structure can be part of a protein known to bind to a cell-type specific receptor such as a tumor.

Antisense-nucleic acid compositions are useful to inhibit translation of mRNA encoding invention polypeptides. Synthetic oligonucleotides, or other antisense chemical structures are designed to bind to CARD-encoding mRNA and inhibit translation of mRNA and are useful as compositions to inhibit expression of CARD-encoding genes or CARD-associated polypeptide genes in a tissue sample or in a subject.

The invention also provides vectors containing the CARD-encoding nucleic acids of the invention. Suitable expression vectors are well-known in the art and include vectors capable of expressing nucleic acid operatively linked to a regulatory sequence or element such as a promoter region or enhancer region that is capable of regulating expression of such nucleic acid. Appropriate expression vectors include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

Promoters or enhancers, depending upon the nature of the regulation, can be constitutive or regulated. The regulatory sequences or regulatory elements are operatively linked to a nucleic acid of the invention such that the physical and functional relationship between the nucleic acid and the regulatory sequence allows transcription of the nucleic acid.

Suitable vectors for expression in prokaryotic or eukaryotic cells are well known to those

skilled in the art (see, for example, Ausubel et al., supra, 2000). Vectors useful for expression in eukaryotic cells can include, for example, regulatory elements including the SV40 early promoter, the  
5 cytomegalovirus (CMV) promoter, the mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, and the like. The vectors of the invention are useful for subcloning and amplifying a CARD-encoding nucleic acid molecule  
10 and for recombinantly expressing a CARD-containing polypeptide. A vector of the invention can include, for example, viral vectors such as a bacteriophage, a baculovirus or a retrovirus; cosmids or plasmids; and, particularly for cloning large nucleic acid molecules,  
15 bacterial artificial chromosome vectors (BACs) and yeast artificial chromosome vectors (YACs). Such vectors are commercially available, and their uses are well known in the art. One skilled in the art will know or can readily determine an appropriate promoter  
20 for expression in a particular host cell.

The invention additionally provides recombinant cells containing CARD-encoding nucleic acids of the invention. The recombinant cells are generated by introducing into a host cell a vector  
25 containing a CARD-encoding nucleic acid molecule. The recombinant cells are transduced, transfected or otherwise genetically modified. Exemplary host cells that can be used to express recombinant CARD molecules include mammalian primary cells; established mammalian  
30 cell lines, such as COS, CHO, HeLa, NIH3T3, HEK 293 and PC12 cells; amphibian cells, such as *Xenopus* embryos and oocytes and other vertebrate cells. Exemplary host cells also include insect cells such as *Drosophila*, yeast cells such as *Saccharomyces cerevisiae*,  
35 *Saccharomyces pombe*, or *Pichia pastoris*, and

prokaryotic cells such as *Escherichia coli*. Additional host cells can be obtained, for example, from ATCC (Manassas, VA).

In one embodiment, CARD-encoding nucleic acids can be delivered into mammalian cells, either *in vivo* or *in vitro* using suitable vectors well-known in the art. Suitable vectors for delivering a CARD-containing polypeptide, or a functional fragment thereof to a mammalian cell, include viral vectors such as retroviral vectors, adenovirus, adeno-associated virus, lentivirus, herpesvirus, as well as non-viral vectors such as plasmid vectors. Such vectors are useful for providing therapeutic amounts of a CARD-containing polypeptide (see, for example, U.S. Patent No. 5,399,346, issued March 21, 1995). Delivery of CARD polypeptides or nucleic acids therapeutically can be particularly useful when targeted to a tumor cell, thereby inducing apoptosis in tumor cells. In addition, where it is desirable to limit or reduce the *in vivo* expression of a CARD-containing polypeptide, the introduction of the antisense strand of the invention nucleic acid is contemplated.

Viral based systems provide the advantage of being able to introduce relatively high levels of the heterologous nucleic acid into a variety of cells. Suitable viral vectors for introducing an invention CARD-encoding nucleic acid into mammalian cells are well known in the art. These viral vectors include, for example, Herpes simplex virus vectors (Geller et al., Science, 241:1667-1669 (1988)); vaccinia virus vectors (Piccini et al., Meth. Enzymology, 153:545-563 (1987)); cytomegalovirus vectors (Mocarski et al., in Viral Vectors, Y. Gluzman and S.H. Hughes, Eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.,

1988, pp. 78-84)); Moloney murine leukemia virus vectors (Danos et al., Proc. Natl. Acad. Sci. USA, 85:6460-6464 (1988); Blaese et al., Science, 270:475-479 (1995); Onodera et al., J. Virol., 72:1769-1774 (1998)); adenovirus vectors (Berkner, Biotechniques, 6:616-626 (1988); Cotten et al., Proc. Natl. Acad. Sci. USA, 89:6094-6098 (1992); Graham et al., Meth. Mol. Biol., 7:109-127 (1991); Li et al., Human Gene Therapy, 4:403-409 (1993); Zabner et al., Nature Genetics, 6:75-83 (1994)); adeno-associated virus vectors (Goldman et al., Human Gene Therapy, 10:2261-2268 (1997); Greelish et al., Nature Med., 5:439-443 (1999); Wang et al., Proc. Natl. Acad. Sci. USA, 96:3906-3910 (1999); Snyder et al., Nature Med., 5:64-70 (1999); Herzog et al., Nature Med., 5:56-63 (1999)); retrovirus vectors (Donahue et al., Nature Med., 4:181-186 (1998); Shackelford et al., Proc. Natl. Acad. Sci. USA, 85:9655-9659 (1988); U.S. Patent Nos. 4,405,712, 4,650,764 and 5,252,479, and WIPO publications WO 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO 92/14829; and lentivirus vectors (Kafri et al., Nature Genetics, 17:314-317 (1997))).

For example, in one embodiment of the present invention, adenovirus-transferrin/polylysine-DNA (TfAdpl-DNA) vector complexes (Wagner et al., Proc. Natl. Acad. Sci., USA, 89:6099-6103 (1992); Curiel et al., Hum. Gene Ther., 3:147-154 (1992); Gao et al., Hum. Gene Ther., 4:14-24 (1993)) are employed to transduce mammalian cells with heterologous CARD-encoding nucleic acid. Any of the plasmid expression vectors described herein may be employed in a TfAdpl-DNA complex.

Vectors useful for therapeutic administration of a CARD-encoding nucleic acid can contain a

regulatory element that provides tissue specific or inducible expression of an operatively linked nucleic acid. One skilled in the art can readily determine an appropriate tissue-specific promoter or enhancer that  
5 allows expression of a CARD polypeptide or nucleic acid in a desired tissue. Any of a variety of inducible promoters or enhancers can also be included in the vector for regulatable expression of a CARD polypeptide or nucleic acid. Such inducible systems, include, for  
10 example, tetracycline inducible system (Gossen & Bizard, Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992); Gossen et al., Science, 268:1766-1769 (1995); Clontech, Palo Alto, CA); metallothionein promoter induced by heavy metals; insect steroid hormone  
15 responsive to ecdysone or related steroids such as muristerone (No et al., Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996); Yao et al., Nature, 366:476-479 (1993); Invitrogen, Carlsbad, CA); mouse mammary tumor virus (MMTV) induced by steroids such as glucocorticoid  
20 and estrogen (Lee et al., Nature, 294:228-232 (1981); and heat shock promoters inducible by temperature changes.

An inducible system particularly useful for therapeutic administration utilizes an inducible  
25 promoter that can be regulated to deliver a level of therapeutic product in response to a given level of drug administered to an individual and to have little or no expression of the therapeutic product in the absence of the drug. One such system utilizes a Gal4  
30 fusion that is inducible by an antiprogesterone such as mifepristone in a modified adenovirus vector (Burien et al., Proc. Natl. Acad. Sci. USA, 96:355-360 (1999)). Another such inducible system utilizes the drug rapamycin to induce reconstitution of a transcriptional  
35 activator containing rapamycin binding domains of

FKBP12 and FRAP in an adeno-associated virus vector (Ye et al., Science, 283:88-91 (1999)). It is understood that any combination of an inducible system can be combined in any suitable vector, including those  
5 disclosed herein. Such a regulatable inducible system is advantageous because the level of expression of the therapeutic product can be controlled by the amount of drug administered to the individual or, if desired, expression of the therapeutic product can be terminated  
10 by stopping administration of the drug.

The invention also provides a method for expression of a CARD-containing polypeptide by culturing cells containing a CARD-encoding nucleic acid under conditions suitable for expression of a CARD-  
15 containing polypeptide. Thus, there is provided a method for the recombinant production of a CARD-containing polypeptide of the invention by expressing the CARD-encoding nucleic acid sequences in suitable host cells. Recombinant DNA expression systems that  
20 are suitable to produce a CARD-containing polypeptide described herein are well-known in the art (see, for example, Ausubel et al., supra, 2000). For example, the above-described nucleotide sequences can be incorporated into vectors for further manipulation. As  
25 used herein, vector refers to a recombinant DNA or RNA plasmid or virus containing discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof.

The invention additionally provides an  
30 isolated anti-CARD antibody having specific reactivity with a invention CARD-containing polypeptide. The anti-CARD antibody can be a monoclonal antibody or a polyclonal antibody. The invention further provides cell lines producing monoclonal antibodies having

specific reactivity with an invention CARD-containing protein.

The invention thus provides antibodies that specifically bind a CARD-containing polypeptide. As used herein, the term "antibody" is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as antigen binding fragments of such antibodies. With regard to an anti-CARD antibody of the invention, the term "antigen" means a native or synthesized CARD-containing polypeptide or fragment thereof. An anti-CARD antibody, or antigen binding fragment of such an antibody, is characterized by having specific binding activity for a CARD polypeptide or a peptide portion thereof of at least about  $1 \times 10^5 \text{ M}^{-1}$ . Thus, Fab,  $F(ab')_2$ , Fd and Fv fragments of an anti-CARD antibody, which retain specific binding activity for a CARD-containing polypeptide, are included within the definition of an antibody. Specific binding activity of a CARD-containing polypeptide can be readily determined by one skilled in the art, for example, by comparing the binding activity of an anti-CARD antibody to a CARD-containing polypeptide versus a reference polypeptide that is not a CARD-containing polypeptide. Methods of preparing polyclonal or monoclonal antibodies are well known to those skilled in the art (see, for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1988)).

In addition, the term "antibody" as used herein includes naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, single chain antibodies, chimeric, bifunctional and humanized antibodies, as well as antigen-binding fragments thereof. Such non-naturally

occurring antibodies can be constructed using solid phase peptide synthesis, can be produced recombinantly or can be obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and variable light chains as described by Huse  
5 et al., Science 246:1275-1281 (1989)). These and other methods of making, for example, chimeric, humanized, CDR-grafted, single chain, and bifunctional antibodies are well known to those skilled in the art (Winter and  
10 Harris, Immunol. Today 14:243-246 (1993); Ward et al., Nature 341:544-546 (1989) ; Harlow and Lane, supra, 1988); Hilyard et al., Protein Engineering: A practical approach (IRL Press 1992); Borrabeck, Antibody Engineering, 2d ed. (Oxford University Press  
15 1995)).

Anti-CARD antibodies can be raised using a CARD immunogen such as an isolated CARD-containing polypeptide having substantially the same amino acid sequence as SEQ ID NOS:12, 188, 97, 99, 101, 103, 86  
20 and 90, or a fragment thereof, which can be prepared from natural sources or produced recombinantly, or a peptide portion of the CARD-containing polypeptide. Such peptide portions of a CARD-containing polypeptide are functional antigenic fragments if the antigenic  
25 peptides can be used to generate a CARD-specific antibody. A non-immunogenic or weakly immunogenic CARD-containing polypeptide or portion thereof can be made immunogenic by coupling the hapten to a carrier molecule such as bovine serum albumin (BSA) or keyhole  
30 limpet hemocyanin (KLH). Various other carrier molecules and methods for coupling a hapten to a carrier molecule are well known in the art (see, for example, Harlow and Lane, supra, 1988). An immunogenic CARD-containing polypeptide fragment can also be  
35 generated by expressing the peptide as a fusion

protein, for example, to glutathione S transferase (GST), polyHis or the like. Methods for expressing peptide fusions are well known to those skilled in the art (Ausubel et al., supra, (2000)).

5           The invention further provides a method for detecting the presence of a human CARD-containing polypeptide in a sample by contacting a sample with a CARD-specific antibody, and detecting the presence of specific binding of the antibody to the sample, thereby  
10 detecting the presence of a human CARD-containing polypeptide in the sample. CARD-specific antibodies can be used in diagnostic methods and systems to detect the level of CARD-containing polypeptide present in a sample. As used herein, the term "sample" is intended  
15 to mean any biological fluid, cell, tissue, organ or portion thereof, that includes or potentially includes CARD nucleic acids or polypeptides. The term includes samples present in an individual as well as samples obtained or derived from the individual. For example,  
20 a sample can be a histologic section of a specimen obtained by biopsy, or cells that are placed in or adapted to tissue culture. A sample further can be a subcellular fraction or extract, or a crude or substantially pure nucleic acid or polypeptide  
25 preparation.

CARD-specific antibodies can also be used for the immunoaffinity or affinity chromatography purification of an invention CARD-containing polypeptide. In addition, methods are contemplated  
30 herein for detecting the presence of an invention CARD-containing polypeptide in a cell, comprising contacting the cell with an antibody that specifically binds to CARD-containing polypeptides under conditions permitting binding of the antibody to the CARD-

containing polypeptides, detecting the presence of the antibody bound to the CARD-containing polypeptide, and thereby detecting the presence of invention polypeptides in a cell. With respect to the detection  
5 of such polypeptides, the antibodies can be used for *in vitro* diagnostic or *in vivo* imaging methods.

Immunological procedures useful for *in vitro* detection of target CARD-containing polypeptides in a sample include immunoassays that employ a detectable  
10 antibody. Such immunoassays include, for example, immunohistochemistry, immunofluorescence, ELISA assays, radioimmunoassay, FACS analysis, immunoprecipitation, immunoblot analysis, Pandex microfluorimetric assay, agglutination assays, flow cytometry and serum  
15 diagnostic assays, which are well known in the art (Harlow and Lane, *supra*, 1988; Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1999)).

An antibody can be made detectable by various  
20 means well known in the art. For example, a detectable marker can be directly attached to the antibody or indirectly attached using, for example, a secondary agent that recognizes the CARD specific antibody. Useful markers include, for example, radionucleotides,  
25 enzymes, binding proteins such as biotin, fluorogens, chromogens and chemiluminescent labels.

An antibody can also be detectable by, for example, a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturation to  
30 form a fluorochrome (dye) that is a useful immunofluorescent tracer. A description of immunofluorescent analytic techniques is found in DeLuca, "Immunofluorescence Analysis", in Antibody As a

Tool, Marchalonis et al., eds., John Wiley & Sons, Ltd., pp. 189-231 (1982), which is incorporated herein by reference.

In one embodiment, the indicating group is an  
5 enzyme, such as horseradish peroxidase (HRP), glucose oxidase, and the like. In another embodiment, radioactive elements are employed labeling agents. The linking of a label to a substrate, i.e., labeling of  
nucleic acid probes, antibodies, polypeptides, and  
10 proteins, is well known in the art. For instance, an invention antibody can be labeled by metabolic incorporation of radiolabeled amino acids provided in the culture medium. See, for example, Galfre et al.,  
Meth. Enzymol., 73:3-46 (1981). Conventional means of  
15 protein conjugation or coupling by activated functional groups are particularly applicable. See, for example, Aurameas et al., Scand. J. Immunol., Vol. 8, Suppl. 7:7-23 (1978), Rodwell et al., Biotech., 3:889-894 (1984), and U.S. Patent No. 4,493,795.

20 In addition to detecting the presence of a CARD-containing polypeptide, invention anti-CARD antibodies are contemplated for use herein to alter the activity of the CARD-containing polypeptide in living animals, in humans, or in biological tissues or fluids  
25 isolated therefrom. The term "alter" refers to the ability of a compound such as a CARD-containing polypeptide, a CARD-encoding nucleic acid, an agent or other compound to increase or decrease biological activity which is modulated by the compound, by  
30 functioning as an agonist or antagonist of the compound. Accordingly, compositions comprising a carrier and an amount of an antibody having specificity for CARD-containing polypeptides effective to block

naturally occurring ligands or other CARD-associated polypeptides from binding to invention CARD-containing polypeptides are contemplated herein. For example, a monoclonal antibody directed to an epitope of an invention CARD-containing polypeptide, including an amino acid sequence substantially the same as SEQ ID 12, 188, 97, 99, 101, 103, 86 and 90, can be useful for this purpose.

The present invention further provides transgenic non-human mammals that are capable of expressing exogenous nucleic acids encoding CARD-containing polypeptides. As employed herein, the phrase "exogenous nucleic acid" refers to nucleic acid sequence which is not native to the host, or which is present in the host in other than its native environment, for example, as part of a genetically engineered DNA construct. In addition to naturally occurring CARD-containing polypeptide levels, a CARD-containing polypeptide of the invention can either be overexpressed or underexpressed in transgenic mammals, for example, underexpressed in a knock-out animal.

Also provided are transgenic non-human mammals capable of expressing CARD-encoding nucleic acids so mutated as to be incapable of normal activity. Therefore, the transgenic non-human mammals do not express native CARD-containing polypeptide or have reduced expression of native CARD-containing polypeptide. The present invention also provides transgenic non-human mammals having a genome comprising antisense nucleic acids complementary to CARD-encoding nucleic acids, placed so as to be transcribed into antisense mRNA complementary to CARD-encoding mRNA, which hybridizes to the mRNA and, thereby, reduces the

translation thereof. The nucleic acid can additionally comprise an inducible promoter and/or tissue specific regulatory elements, so that expression can be induced, or restricted to specific cell types.

5           Animal model systems useful for elucidating the physiological and behavioral roles of CARD-containing polypeptides are also provided, and are produced by creating transgenic animals in which the expression of the CARD-containing polypeptide is  
10 altered using a variety of techniques. Examples of such techniques include the insertion of normal or mutant versions of nucleic acids encoding a CARD-containing polypeptide by microinjection, retroviral infection or other means well known to those skilled in  
15 the art, into appropriate fertilized embryos to produce a transgenic animal, see, for example, Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual (Cold Spring Harbor Laboratory, (1986)). Transgenic animal model systems are useful for *in vivo* screening  
20 of compounds for identification of specific ligands, such as agonists or antagonists, which activate or inhibit a biological activity.

          Also contemplated herein, is the use of homologous recombination of mutant or normal versions  
25 of CARD-encoding genes with the native gene locus in transgenic animals, to alter the regulation of expression or the structure of CARD-containing polypeptides by replacing the endogeneous gene with a recombinant or mutated CARD-encoding gene. Methods for  
30 producing a transgenic non-human mammal including a gene knock-out non-human mammal, are well known to those skilled in the art (see, Capecchi et al., Science 244:1288 (1989); Zimmer et al., Nature 338:150 (1989);

Shastri, Experientia, 51:1028-1039 (1995); Shastri, Mol. Cell. Biochem., 181:163-179 (1998); and U.S. Patent No. 5,616,491, issued April 1, 1997, No. 5,750,826, issued May 12, 1998, and No. 5,981,830, issued November 9, 5 1999).

In addition to homologous recombination, additional methods such as microinjection can be used which add genes to the host genome without removing host genes. Microinjection can produce a transgenic 10 animal that is capable of expressing both endogenous and exogenous CARD-containing polypeptides. Inducible promoters can be linked to the coding region of nucleic acids to provide a means to regulate expression of the transgene. Tissue specific regulatory elements can be 15 linked to the coding region to permit tissue-specific expression of the transgene. Transgenic animal model systems are useful for *in vivo* screening of compounds for identification of specific ligands, i.e., agonists and antagonists, which activate or inhibit CARD- 20 containing polypeptide responses.

In accordance with another embodiment of the invention, a method is provided for identifying a CARD-associated polypeptide (CAP). The method is carried out by contacting an invention CARD-containing 25 polypeptide with a candidate CAP and detecting association of the CARD-containing polypeptide with the CAP.

As used herein, the term "CARD-associated polypeptide" or "CAP" means a polypeptide that can 30 specifically bind to the CARD-containing polypeptides of the invention, or to any functional fragment of a CARD-containing polypeptide of the invention. Because

CARD-containing polypeptides of the invention contain domains which can self-associate, CARD-containing polypeptides are encompassed by the term CAP. An exemplary CAP is a protein or a polypeptide portion of  
5 a protein that can bind an NB-ARC (NACHT), CARD, LRR or ANGIO-R domain of an invention CARD-containing polypeptide. A CAP can be identified, for example, using *in vitro* protein binding assays similar to those described in, for example, Ausubel et al., supra, 2000,  
10 and by *in vivo* methods including methods such as yeast two-hybrid assays, or other protein-interaction assays and methods known in the art.

Normal association of CARD-containing polypeptide and a CAP polypeptide in a cell can be  
15 altered due, for example, to the expression in the cell of a variant CAP or CARD-containing polypeptide, respectively, either of which can compete with the normal binding function of a CARD-containing polypeptide and, therefore, can decrease the  
20 association of CAP and CARD-containing polypeptides in a cell. The term "variant" is used generally herein to mean a polypeptide that is different from the CAP or CARD-containing polypeptide that normally is found in a particular cell type. Thus, a variant can include a  
25 mutated protein or a naturally occurring protein, such as an isoform, that is not normally found in a particular cell type.

CARD-containing polypeptides and CARD-associated polypeptides of the invention can be  
30 characterized, for example, using *in vitro* binding assays or the yeast two hybrid system. An *in vivo* transcription activation assay such as the yeast two hybrid system is particularly useful for identifying

and manipulating the association of proteins. In addition, the results observed in such an assay likely mirror the events that naturally occur in a cell.

Thus, the results obtained in such an *in vivo* assay can  
5 be predictive of results that can occur in a cell in a subject such as a human subject.

A transcription activation assay such as the yeast two hybrid system is based on the modular nature of transcription factors, which consist of functionally  
10 separable DNA-binding and trans-activation domains. When expressed as separate proteins, these two domains fail to mediate gene transcription. However, transcription activation activity can be restored if the DNA-binding domain and the trans-activation domain  
15 are bridged together due, for example, to the association of two proteins. The DNA-binding domain and trans-activation domain can be bridged, for example, by expressing the DNA-binding domain and trans-activation domain as fusion proteins (hybrids),  
20 provided that the proteins that are fused to the domains can associate with each other. The non-covalent bridging of the two hybrids brings the DNA-binding and trans-activation domains together and creates a transcriptionally competent complex. The  
25 association of the proteins is determined by observing transcriptional activation of a reporter gene.

The yeast two hybrid systems exemplified herein use various strains of *S. cerevisiae* as host cells for vectors that express the hybrid proteins. A  
30 transcription activation assay also can be performed using, for example, mammalian cells. However, the yeast two hybrid system is particularly useful due to the ease of working with yeast and the speed with which

the assay can be performed. For example, yeast host cells containing a lacZ reporter gene linked to a LexA operator sequence can be used to demonstrate that a CARD domain of an invention CARD-containing polypeptide can interact with itself or other CARD-containing polypeptides. For example, the DNA-binding domain can consist of the LexA DNA-binding domain, which binds the LexA promoter, fused to the CARD domain of a CARD-containing polypeptide of the invention and the trans-activation domain can consist of the B42 acidic region separately fused to several cDNA sequences which encode known CARD-containing polypeptides. When the LexA domain is non-covalently bridged to a trans-activation domain fused to a CARD-containing polypeptide, the association can activate transcription of the reporter gene.

A CAP, for example, a CARD-containing polypeptide, an NB-ARC-containing polypeptide or a LRR-containing polypeptide, also can be identified using well known *in vitro* assays, for example, an assay utilizing a glutathione-S-transferase (GST) fusion protein. Such an *in vitro* assay provides a simple, rapid and inexpensive method for identifying and isolating a CAP. Such an *in vitro* assay is particularly useful in confirming results obtained *in vivo* and can be used to characterize specific binding domains of a CAP. For example, a GST can be fused to a CARD-containing polypeptide of the invention, and expressed and purified by binding to an affinity matrix containing immobilized glutathione. If desired, a sample that can contain a CAP or active fragments of a CAP can be passed over an affinity column containing bound GST/CARD and a CAP that binds to a CARD-containing polypeptide can be obtained. In addition,

GST/CARD can be used to screen a cDNA expression library, wherein binding of the GST/CARD fusion protein to a clone indicates that the clone contains a cDNA encoding a CAP.

5                   Thus, one of skill in the art will recognize that using the CARD-containing polypeptides described herein, a variety of methods, such as protein purification, protein interaction cloning, or protein mass-spectrometry, can be used to identify a CAP.

10                   Although the term "CAP" is used generally, it should be recognized that a CAP that is identified using the novel polypeptides described herein can be a fragment of a protein. Thus, as used herein, a CAP also includes a polypeptide that specifically  
15 associates to a portion of an invention CARD-containing polypeptide that does not include a CARD domain. For example, a CAP can associate with the NB-ARC domain of CLAN or CARD3X. As used herein, a "candidate CAP" refers to a polypeptide containing a polypeptide  
20 sequence known or suspected of binding one or more CARD-containing polypeptides of the invention. Thus, a CAP can represent a full-length protein or a CARD-associating fragment thereof. Since a CAP polypeptide can be a full-length protein or a CARD-associating  
25 fragment thereof, one of skill in the art will recognize that a CAP-encoding nucleic acid, such as the genomic sequence, an mRNA sequence or a cDNA sequence need not encode the full-length protein. Thus, a cDNA can encode a polypeptide that is a fragment of a full-  
30 length CAP which, nevertheless, binds one or more invention CARD-containing polypeptides. It is also within the scope of the invention that a full-length CAP can assume a conformation that does not, absent

some post-translational modification, bind a CARD-containing polypeptide of the invention, due, for example, to steric blocking of the binding site. Thus, a CAP can be a protein or a polypeptide portion of a  
5 protein that can bind one of the CARD-containing polypeptides of the invention. Also, it should be recognized that a CAP can be identified by using a minimal polypeptide derived from the sequences of the CARD-containing polypeptides of the invention, and does  
10 not necessarily require that the full-length molecules be employed for identifying such CAPs.

Since CARD-containing polypeptides can be involved in apoptosis, the association of a CAP with a CARD-containing polypeptide can affect the sensitivity  
15 or resistance of a cell to apoptosis or can induce or block apoptosis induced by external or internal stimuli. The identification of various CAPs by use of known methods can be used to determine the function of these CAPs in cell death or signal transduction  
20 pathways controlled by CARD-containing polypeptides, allowing for the development of assays that are useful for identifying agents that effectively alter the association of a CAP with a CARD-containing polypeptide. Such agents can be useful for providing  
25 effective therapy for conditions caused, at least in part, by insufficient apoptosis, such as a cancer, autoimmune disease or certain viral infections. Such agents can also be useful for providing an effective therapy for diseases where excessive apoptosis is known  
30 to occur, such as stroke, heart failure, or AIDS.

Assays of the invention can be used for identification of agents that alter the self-association of the CARD-containing polypeptides of the

invention. Thus, the methods of the invention can be used to identify agents that alter the self-association of CARD2X, CARD3X, CLAN A, CLAN B, CLAN C, CLAN D, COP-1 and COP-2 (set forth in SEQ ID NOS: 12, 188, 97, 99, 5 101, 103, 86 and 90) via their CARD domains, NB-ARC domains, LRR domains, or other domains within these polypeptides.

The ATP-binding and hydrolysis of the NB-ARC domains can be critical for function of a NAC 10 polypeptide, for example, by altering the oligomerization of the NAC. Thus, agents that interfere with or enhance ATP or nucleotide binding and/or hydrolysis by the NB-ARC domain of a NAC polypeptide of the invention, such as CLAN (SEQ ID 15 NOS:97, 99, 101 or 103) can also be useful for altering the activity of these polypeptides in cells.

A further embodiment of the invention provides a method to identify agents that can effectively alter CARD-containing polypeptide activity, 20 for example the ability of CARD-containing polypeptides to associate with one or more heterologous proteins. Thus, the present invention provides a screening assay useful for identifying an effective agent, which can alter the association of a CARD-containing polypeptide 25 with a CARD-associated polypeptide (CAP), such as a heterologous CARD-containing polypeptide. Since CARD-containing polypeptides are involved in biochemical processes such as apoptosis, the identification of such effective agents can be useful for altering the level 30 of a biochemical process such as apoptosis in a cell, for example in a cell of a subject having a pathology characterized by an increased or decreased level of apoptosis.

Further, effective agents can be useful for alteration of other biochemical process modulated by a CARD-containing polypeptide of the invention.

Additional biochemical processes modulated by CARD-  
5 containing polypeptide include, for example, NF-kB induction, cytokine processing, cytokine receptor signaling, cJUN N-terminal kinase induction, and caspase-mediated proteolysis activation/inhibition, transcription, inflammation and cell adhesion.

10 As used herein, the term "agent" means a chemical or biological molecule such as a simple or complex organic molecule, a peptide, a peptido-mimetic, a polypeptide, a protein or an oligonucleotide that has the potential for altering the association of a CARD-  
15 containing polypeptide with a heterologous protein or altering the ability of a CARD-containing polypeptide to self-associate or altering the ligand binding or catalytic activity of a CARD-containing polypeptide. An exemplary ligand binding activity is nucleotide  
20 binding activity, such as ADP or ATP binding activity; and exemplary catalytic activities are nucleotide hydrolytic activity and proteolytic activity. In addition, the term "effective agent" is used herein to mean an agent that is confirmed as capable of altering  
25 the association of a CARD-containing polypeptide with a heterologous protein or altering the ability of a CARD-containing polypeptide to self-associate or altering the ligand binding or catalytic activity of a CARD-containing polypeptide. For example, an effective  
30 agent may be an anti-CARD antibody, a CARD-associated polypeptide, a caspase inhibitor, and the like.

As used herein, the term "alter the association" means that the association between two

specifically interacting polypeptides either is increased or decreased due to the presence of an effective agent. As a result of an altered association of CARD-containing polypeptide with another polypeptide  
5 in a cell, the activity of the CARD-containing polypeptide or the CAP can be increased or decreased, thereby altering a biochemical process, for example, the level of apoptosis in the cell. As used herein, the term "alter the activity" means that the agent can  
10 increase or decrease the activity of a CARD-containing polypeptide in a cell, thereby modulating a biochemical process in a cell, for example, the level of apoptosis in the cell. Similarly, the term "alter the level" of a biological process modulated by a CARD-containing  
15 polypeptide refers to an increase or decrease a biochemical process which occurs upon altering the activity of a CARD-containing polypeptide. For example, an effective agent can increase or decrease the CARD: CARD-associating activity of a CARD-containing  
20 polypeptide, which can result in decreased apoptosis. In another example, alteration of the ATP hydrolysis activity can modulate the ability of the NB-ARC domain of a CARD-containing polypeptide to associate with other NB-ARC-containing polypeptides, such as Apaf-1,  
25 thereby altering any process effected by such association between a CARD-containing polypeptide and an NB-ARC-containing polypeptide.

An effective agent can act by interfering with the ability of a CARD-containing polypeptide to  
30 associate with another polypeptide, or can act by causing the dissociation of a CARD-containing polypeptide from a complex with a CARD-associated polypeptide, wherein the ratio of bound CARD-containing polypeptide to free CARD-containing polypeptide is

related to the level of a biochemical process, such as, apoptosis, in a cell. For example, binding of a ligand to a CAP can allow the CAP, in turn, to bind a specific CARD-containing polypeptide such that all of the  
5 specific CARD-containing polypeptide is bound to a CAP, and can result in decreased apoptosis. The association, for example, of a CARD-containing polypeptide and a CARD-containing polypeptide can result in activation or inhibition of the NB-ARC:NB-  
10 ARC-associating activity of a CARD-containing polypeptide. In the presence of an effective agent, the association of a CARD-containing polypeptide and a CAP can be altered, which can, for example, alter the activation of caspases in the cell. As a result of the  
15 altered caspase activation, the level of apoptosis in a cell can be increased or decreased. Thus, the identification of an effective agent that alters the association of a CARD-containing polypeptide with another polypeptide can allow for the use of the  
20 effective agent to increase or decrease the level of a biological process such as apoptosis.

An effective agent can be useful, for example, to increase the level of apoptosis in a cell such as a cancer cell, which is characterized by having  
25 a decreased level of apoptosis as compared to its normal cell counterpart. An effective agent also can be useful, for example, to decrease the level of apoptosis in a cell such as a T lymphocyte in a subject having a viral disease such as acquired  
30 immunodeficiency syndrome, which is characterized by an increased level of apoptosis in an infected T cell as compared to a normal T cell. Thus, an effective agent can be useful as a medicament for altering the level of apoptosis in a subject having a pathology characterized

by increased or decreased apoptosis. In addition, an effective agent can be used, for example, to decrease the level of apoptosis and, therefore, increase the survival time of a cell such as a hybridoma cell in culture. The use of an effective agent to prolong the survival of a cell *in vitro* can significantly improve bioproduction yields in industrial tissue culture applications.

A CARD-containing polypeptide that lacks the ability to bind the NB-ARC domain or LRR domain of another polypeptide but retains the ability to self-associate via its CARD domain or to bind to other CARD-containing polypeptides is an example of an effective agent, since the expression of a non-NB-ARC-associating or non-catalytically active CARD-containing polypeptide in a cell can alter the association of a the endogenous CARD-containing polypeptide with itself or with CAPs.

Thus, it should be recognized that a mutation of a CARD-containing polypeptide can be an effective agent, depending, for example, on the normal levels of CARD-containing polypeptide and CARD-associated polypeptide that occur in a particular cell type. In addition, an active fragment of a CARD-containing polypeptide can be an effective agent, provided the active fragment can alter the association of a CARD-containing polypeptide and another polypeptide in a cell. Such active fragments, which can be peptides as small as about five amino acids, can be identified, for example, by screening a peptide library (see, for example, Ladner et al., U.S. Patent No: 5,223,409) to identify peptides that can bind a CARD-associated polypeptide.

Similarly, a fragment of a CARD-associated polypeptide also can be an effective agent. A fragment of CARD-associated polypeptide can be useful, for example, for decreasing the association of a CARD-  
5 containing polypeptide with a CAP in a cell by competing for binding to the CARD-containing polypeptide. A non-naturally occurring peptido-mimetic also can be useful as an effective agent. Such a peptido-mimetic can include, for example, a peptoid,  
10 which is peptide-like sequence containing N-substituted glycines, or an oligocarbamate. A peptido-mimetic can be particularly useful as an effective agent due, for example, to having an increased stability to enzymatic degradation *in vivo*.

15 In accordance with another embodiment of the present invention, there is provided a method of identifying an effective agent that alters the association of an invention CARD-containing polypeptide with a CARD-associated polypeptide (CAP), by the steps  
20 of:

(a) contacting a CARD-containing polypeptide and a CAP polypeptide, under conditions that allow the CARD-containing polypeptide and CAP polypeptide to associate,  
25 with an agent suspected of being able to alter the association of the CARD-containing polypeptide and CAP polypeptides; and

(b) detecting the altered association of the CARD-containing polypeptide and CAP polypeptide, where the altered association  
30 identifies an effective agent.

Methods well-known in the art for detecting the altered association of the CARD-containing polypeptide and CAP polypeptides, for example, measuring protein:protein binding, protein degradation  
5 or apoptotic activity can be employed in bioassays described herein to identify agents as agonists or antagonists of CARD-containing polypeptides. As described herein, CARD-containing polypeptides have the ability to self-associate. Thus, methods for  
10 identifying effective agents that alter the association of a CARD-containing polypeptide with a CAP are useful for identifying effective agents that alter the ability of a CARD-containing polypeptide to self-associate.

As used herein, "conditions that allow said  
15 CARD-containing polypeptide and CAP polypeptide to associate" refers to environmental conditions in which a CARD-containing polypeptide and CAP specifically associate. Such conditions will typically be aqueous conditions, with a pH between 3.0 and 11.0, and  
20 temperature below 100°C. Preferably, the conditions will be aqueous conditions with salt concentrations below the equivalent of 1 M NaCl, and pH between 5.0 and 9.0, and temperatures between 0°C and 50°C. Most preferably, the conditions will range from  
25 physiological conditions of normal yeast or mammalian cells, or conditions favorable for carrying out *in vitro* assays such as immunoprecipitation and GST protein:protein association assays, and the like.

In another embodiment of the invention, a method is provided for identifying agents that modulate a ligand binding or catalytic activity of an invention CARD-containing polypeptide. The method contains the

5 steps of contacting an invention CARD-containing polypeptide with an agent suspected of modulating a ligand binding or catalytic activity of the CARD-containing polypeptide and measuring a ligand binding or catalytic activity of the CARD-containing

10 polypeptide, where modulated ligand binding or catalytic activity identifies the agent as an agent that alters the ligand binding or catalytic activity of a CARD-containing polypeptide.

As used herein in regard to ligand binding or

15 catalytic activity, "modulate" refers to an increase or decrease in ligand binding or catalytic activity. Thus, modulation encompasses inhibition of ligand binding or catalytic activity as well as activation or enhancement of ligand binding or catalytic activity.

20 Exemplary ligand binding activities include nucleotide binding activity. Exemplary catalytic binding activities include nucleotide hydrolysis and proteolysis activities.

Methods for measuring ligand binding or

25 catalytic activities are well known in the art, as disclosed herein. For example, an agent known or suspected of modulating ligand binding or catalytic activity can be contacted with an invention CARD-containing polypeptide in vivo or in vitro, and the

30 ligand binding or catalytic activity can be measured using known methods. For example, enzymatic activity can be measured using a cleavable reporter, where the

cleavable reporter generates or alters a measurable signal such as absorption, fluorescence or radioactive decay. Exemplary agents that can modulate ligand binding or catalytic activity include peptides,  
5   peptidomimetics and other peptide analogs, non-peptide organic molecules such as naturally occurring protease inhibitors and derivatives thereof, nucleotides and nucleotide analogs, and the like. Such inhibitors can be either reversible or irreversible, as is well known  
10   in the art.

Agents that modulate the ligand binding or catalytic activity of a CARD-containing polypeptide identified using the invention methods can be used to modulate the activity of a CARD-containing polypeptide.  
15   For example, an agent can modulate the nucleotide binding or nucleotide hydrolytic activity of an NB-ARC domain of a CARD-containing polypeptide. In another example, an agent can modulate the catalytic activity of a protease domain such as a caspase domain. Methods  
20   of modulating the ligand binding or catalytic activities of invention CARD-containing proteins can be used in methods of altering biochemical processes modulated by CARD-containing proteins, such as the biochemical processes disclosed herein.

25               In yet another embodiment of the present invention, there are provided methods for altering ligand binding or catalytic activity of a CARD-containing polypeptide of the invention, the method comprising:

30               contacting an CARD-containing polypeptide with an effective amount of an agent identified by the herein-described bioassays.

The present invention also provides *in vitro* screening assays. Such screening assays are particularly useful in that they can be automated, which allows for high through-put screening, for  
5 example, of randomly or rationally designed agents such as drugs, peptidomimetics or peptides in order to identify those agents that effectively alter the association of a CARD-containing polypeptide and a CAP or the catalytic or ligand binding activity of a CARD-  
10 containing polypeptide and, thereby, alter a biochemical process modulated by a CARD-containing polypeptide such as apoptosis. An *in vitro* screening assay can utilize, for example, a CARD-containing polypeptide including a CARD-containing fusion protein  
15 such as a CARD-glutathione-S-transferase fusion protein. For use in the *in vitro* screening assay, the CARD-containing polypeptide should have an affinity for a solid substrate as well as the ability to associate with a CARD-associated polypeptide. For example, when  
20 a CARD-containing polypeptide is used in the assay, the solid substrate can contain a covalently attached anti-CARD antibody. Alternatively, a GST/CARD fusion protein can be used in the assay and the solid substrate can contain covalently attached glutathione,  
25 which is bound by the GST component of the GST/CARD fusion protein. Similarly, a CARD-associated polypeptide, or GST/NB-ARC-containing polypeptide fusion protein can be used in any of a variety of *in vitro* enzymatic or *in vitro* binding assays known in the  
30 art and described in texts such as Ausubel et al., supra, 2000.

An *in vitro* screening assay can be performed by allowing a CARD-containing polypeptide, for example, to bind to the solid support, then adding a CARD-associated polypeptide and an agent to be tested.

5 Reference reactions, which do not contain an agent, can be performed in parallel. Following incubation under suitable conditions, which include, for example, an appropriate buffer concentration and pH and time and temperature that permit binding of the particular CARD-  
10 containing polypeptide and CARD-associated polypeptide, the amount of protein that has associated in the absence of an agent and in the presence of an agent can be determined. The association of a CARD-associated polypeptide with a CARD-containing polypeptide can be  
15 detected, for example, by attaching a detectable moiety such as a radionuclide or a fluorescent label to a CARD-associated polypeptide and measuring the amount of label that is associated with the solid support, wherein the amount of label detected indicates the  
20 amount of association of the CARD-associated polypeptide with a CARD-containing polypeptide. An effective agent is determined by comparing the amount of specific binding in the presence of an agent as compared to a reference level of binding, wherein an  
25 effective agent alters the association of CARD-containing polypeptide with the CARD-associated polypeptide. Such an assay is particularly useful for screening a panel of agents such as a peptide library in order to detect an effective agent.

30 Various binding assays to identify cellular proteins that interact with protein binding domains are known in the art and include, for example, yeast two-hybrid screening assays (see, for example, U.S.

Patent Nos. 5,283,173, 5,468,614 and 5,667,973; Ausubel et al., supra, 2000; Luban et al., Curr. Opin. Biotechnol. 6:59-64 (1995)) and affinity column chromatography methods using cellular extracts. By  
5 synthesizing or expressing polypeptide fragments containing various CARD-associating sequences or deletions, the CARD binding interface can be readily identified.

Another assay for screening of agents that  
10 alter the activity of a CARD-containing polypeptide is based on altering the phenotype of yeast by expressing a CARD-containing polypeptide. In one embodiment, expression of a CARD-containing polypeptide can be inducible (Tao et al., J. Biol. Chem. 273:23704-23708  
15 (1998), and the compounds can be screened when CARD-containing polypeptide expression is induced. CARD-containing polypeptides of the invention can also be co-expressed in yeast with CAP polypeptides used to screen for compounds that antagonize the activity of  
20 the CARD-containing polypeptide.

Also provided with the present invention are assays to identify agents that alter CARD-containing polypeptide expression. Methods to determine CARD-containing polypeptide expression can involve detecting  
25 a change in CARD-containing polypeptide abundance in response to contacting the cell with an agent that modulates CARD-containing polypeptide expression. Assays for detecting changes in polypeptide expression include, for example, immunoassays with CARD-specific  
30 antibodies, such as immunoblotting, immunofluorescence, immunohistochemistry and immunoprecipitation assays, as described herein.

As understood by those of skill in the art, assay methods for identifying agents that alter CARD-containing polypeptide activity generally require comparison to a reference. One type of a "reference" is a cell or culture that is treated substantially the same as the test cell or test culture exposed to the agent, with the distinction that the "reference" cell or culture is not exposed to the agent. Another type of "reference" cell or culture can be a cell or culture that is identical to the test cells, with the exception that the "reference" cells or culture do not express a CARD-containing polypeptide. Accordingly, the response of the transfected cell to an agent is compared to the response, or lack thereof, of the "reference" cell or culture to the same agent under the same reaction conditions.

Methods for producing pluralities of agents to use in screening for compounds that alter the activity of a CARD-containing polypeptide, including chemical or biological molecules such as simple or complex organic molecules, metal-containing compounds, carbohydrates, peptides, proteins, peptidomimetics, glycoproteins, lipoproteins, nucleic acids, antibodies, and the like, are well known in the art and are described, for example, in Huse, U.S. Patent No. 5,264,563; Francis et al., Curr. Opin. Chem. Biol. 2:422-428 (1998); Tietze et al., Curr. Biol., 2:363-371 (1998); Sofia, Mol. Divers. 3:75-94 (1998); Eichler et al., Med. Res. Rev. 15:481-496 (1995); and the like. Libraries containing large numbers of natural and synthetic agents also can be obtained from commercial sources. Combinatorial libraries of molecules can be prepared using well known combinatorial chemistry methods (Gordon et al., J. Med. Chem. 37: 1233-1251

(1994); Gordon et al., J. Med. Chem. 37: 1385-1401  
(1994); Gordon et al., Acc. Chem. Res. 29:144-154  
(1996); Wilson and Czarnik, eds., Combinatorial  
Chemistry: Synthesis and Application, John Wiley &  
5 Sons, New York (1997)).

The invention further provides a method of  
diagnosing or predicting clinical prognosis of a  
pathology characterized by an increased or decreased  
level of a CARD-containing polypeptide in a subject.  
10 The method includes the steps of (a) obtaining a test  
sample from the subject; (b) contacting the sample with  
an agent that can bind a CARD-containing polypeptide of  
the invention under suitable conditions, wherein the  
conditions allow specific binding of the agent to the  
15 CARD-containing polypeptide; and (c) comparing the  
amount of the specific binding in the test sample with  
the amount of specific binding in a reference sample,  
wherein an increased or decreased amount of the  
specific binding in the test sample as compared to the  
20 reference sample is diagnostic of, or predictive of the  
clinical prognosis of, a pathology. The agent can be,  
for example, an anti-CARD antibody, a CARD-associated-  
polypeptide (CAP), or a CARD-encoding nucleic acid.

Exemplary pathologies for diagnosis or the  
25 prediction of clinical prognosis include any of the  
pathologies described herein, such as neoplastic  
pathologies (e.g. cancer), autoimmune diseases, and  
other pathologies related to abnormal cell  
proliferation or abnormal cell death (e.g. apoptosis),  
30 as disclosed herein.

The invention also provides a method of  
diagnosing cancer or monitoring cancer therapy by

contacting a test sample from a patient with a CARD-specific antibody. The invention additionally provides a method of assessing prognosis (e.g., predicting the clinical prognosis) of patients with cancer comprising  
5 contacting a test sample from a patient with a CARD-specific antibody.

The invention additionally provides a method of diagnosing cancer or monitoring cancer therapy by contacting a test sample from a patient with a  
10 oligonucleotide that selectively hybridizes to a CARD-encoding nucleic acid molecule. The invention further provides a method of assessing prognosis (e.g., predicting the clinical prognosis) of patients with cancer by contacting a test sample from a patient with  
15 a oligonucleotide that selectively hybridizes to a CARD-encoding nucleic acid molecule.

The methods of the invention for diagnosing cancer or monitoring cancer therapy using a CARD-specific antibody or oligonucleotide or nucleic acid  
20 that selectively hybridizes to a CARD-encoding nucleic acid molecule can be used, for example, to segregate patients into a high risk group or a low risk group for diagnosing cancer or predicting risk of metastasis or risk of failure to respond to therapy. Therefore, the  
25 methods of the invention can be advantageously used to determine, for example, the risk of metastasis in a cancer patient, or the risk of an autoimmune disease of a patient, or as a prognostic indicator of survival or disease progression in a cancer patient or patient with  
30 an autoimmune disease. One of ordinary skill in the art would appreciate that the prognostic indicators of survival for cancer patients suffering from stage I cancer can be different from those for cancer patients

suffering from stage IV cancer. For example, prognosis for stage I cancer patients can be oriented toward the likelihood of continued growth and/or metastasis of the cancer, whereas prognosis for stage IV cancer patients can be oriented toward the likely effectiveness of therapeutic methods for treating the cancer. Accordingly, the methods of the invention directed to measuring the level of or determining the presence of a CARD-containing polypeptide or CARD-encoding nucleic acid can be used advantageously as a prognostic indicator for the presence or progression of a cancer or response to therapy.

The invention further provides methods for introducing a CARD-encoding nucleic acid into a cell in a subject, for example, for gene therapy. Viruses are specialized infectious agents that can elude host defense mechanisms and can infect and propagate in specific cell types. Viral based systems provide the advantage of being able to introduce relatively high levels of the heterologous nucleic acid into a variety of cells. Suitable viral vectors for introducing an invention CARD-encoding nucleic acid into mammalian cells (e.g., vascular tissue segments) are well known in the art. These viral vectors include, for example, Herpes simplex virus vectors (e.g., Geller et al., Science, 241:1667-1669 (1988)), Vaccinia virus vectors (e.g., Piccini et al., Meth. in Enzymology, 153:545-563 (1987); Cytomegalovirus vectors (Mocarski et al., in Viral Vectors, Y. Gluzman and S.H. Hughes, Eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988, pp. 78-84), Moloney murine leukemia virus vectors (Danos et al., Proc. Natl. Acad. Sci., USA, 85:6469 (1980)), adenovirus vectors (e.g., Logan et al., Proc. Natl. Acad. Sci., USA, 81:3655-3659 (1984);

Jones et al., Cell, 17:683-689 (1979); Berkner, Biotechniques, 6:616-626 (1988); Cotten et al., Proc. Natl. Acad. Sci., USA, 89:6094-6098 (1992); Graham et al., Meth. Mol. Biol., 7:109-127 (1991)),  
5 adeno-associated virus vectors, retrovirus vectors (see, e.g., U.S. Patent 4,405,712 and 4,650,764), and the like. Especially preferred viral vectors are the adenovirus and retroviral vectors.

Suitable retroviral vectors for use herein  
10 are described, for example, in U.S. Patent 5,252,479, and in WIPO publications WO 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO 92/14829, incorporated herein by reference, which provide a description of methods for efficiently introducing nucleic acids into  
15 human cells using such retroviral vectors. Other retroviral vectors include, for example, the mouse mammary tumor virus vectors (e.g., Shackleford et al., Proc. Natl. Acad. Sci. USA, 85:9655-9659 (1988)), and the like.

20 In particular, the specificity of viral vectors for particular cell types can be utilized to target predetermined cell types. Thus, the selection of a viral vector will depend, in part, on the cell type to be targeted. For example, if a  
25 neurodegenerative disease is to be treated by increasing the level of a CARD-containing polypeptide in neuronal cells affected by the disease, then a viral vector that targets neuronal cells can be used. A vector derived from a herpes simplex virus is an  
30 example of a viral vector that targets neuronal cells (Battleman et al., J. Neurosci. 13:941-951 (1993), which is incorporated herein by reference). Similarly, if a disease or pathological condition of the

hematopoietic system is to be treated, then a viral vector that is specific for a particular blood cell or its precursor cell can be used. A vector based on a human immunodeficiency virus is an example of such a viral vector (Carroll et al., J. Cell. Biochem. 17E:241 (1993), which is incorporated herein by reference). In addition, a viral vector or other vector can be constructed to express a CARD-encoding nucleic acid in a tissue specific manner by incorporating a tissue-specific promoter or enhancer into the vector (Dai et al., Proc. Natl. Acad. Sci. USA 89:10892-10895 (1992), which is incorporated herein by reference).

For gene therapy, a vector containing a CARD-encoding nucleic acid or an antisense nucleotide sequence can be administered to a subject by various methods. For example, if viral vectors are used, administration can take advantage of the target specificity of the vectors. In such cases, there is no need to administer the vector locally at the diseased site. However, local administration can be a particularly effective method of administering a CARD-encoding nucleic acid. In addition, administration can be via intravenous or subcutaneous injection into the subject. Following injection, the viral vectors will circulate until they recognize host cells with the appropriate target specificity for infection. Injection of viral vectors into the spinal fluid also can be an effective mode of administration, for example, in treating a neurodegenerative disease.

Receptor-mediated DNA delivery approaches also can be used to deliver a CARD-encoding nucleic acid molecule into cells in a tissue-specific manner using a tissue-specific ligand or an antibody that is

non-covalently complexed with the nucleic acid molecule via a bridging molecule (Curiel et al., Hum. Gene Ther. 3:147-154 (1992); Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987), each of which is incorporated  
5 herein by reference). Direct injection of a naked or a nucleic acid molecule encapsulated, for example, in cationic liposomes also can be used for stable gene transfer into non-dividing or dividing cells *in vivo* (Ulmer et al., Science 259:1745-1748 (1993), which is  
10 incorporated herein by reference). In addition, a CARD-encoding nucleic acid molecule can be transferred into a variety of tissues using the particle bombardment method (Williams et al., Proc. Natl. Acad. Sci. USA 88:2726-2730 (1991), which is incorporated  
15 herein by reference). Such nucleic acid molecules can be linked to the appropriate nucleotide sequences required for transcription and translation.

A particularly useful mode of administration of a CARD-encoding nucleic acid is by direct  
20 inoculation locally at the site of the disease or pathological condition. Local administration can be advantageous because there is no dilution effect and, therefore, the likelihood that a majority of the targeted cells will be contacted with the nucleic acid  
25 molecule is increased. Thus, local inoculation can alleviate the targeting requirement necessary with other forms of administration and, if desired, a vector that infects all cell types in the inoculated area can be used. If expression is desired in only a specific  
30 subset of cells within the inoculated area, then a promoter, an enhancer or other expression element specific for the desired subset of cells can be linked to the nucleic acid molecule. Vectors containing such nucleic acid molecules and regulatory elements can be

viral vectors, viral genomes, plasmids, phagemids and the like. Transfection vehicles such as liposomes also can be used to introduce a non-viral vector into recipient cells. Such vehicles are well known in the art.

The present invention also provides therapeutic compositions useful for practicing the therapeutic methods described herein. Therapeutic compositions of the present invention, such as pharmaceutical compositions, contain a physiologically compatible carrier together with an invention CARD-containing polypeptide (or functional fragment thereof), an invention CARD-encoding nucleic acid, an agent that alters CARD activity or expression identified by the methods described herein, or an anti-CARD antibody, as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic composition is not immunogenic when administered to a mammal or human patient for therapeutic purposes.

As used herein, the terms "pharmaceutically acceptable", "physiologically compatible" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to a mammal without the production of undesirable physiological effects.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well known in the art. Typically such compositions are prepared as injectibles either as liquid solutions or suspensions; however,

solid forms suitable for solution, or suspension, in liquid prior to use can also be prepared. The preparation can also be emulsified.

The active ingredient can be mixed with  
5 excipients which are pharmaceutically acceptable and compatible with the active ingredient in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, as  
10 well as combinations of any two or more thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and the like, which enhance the effectiveness of the active  
15 ingredient.

The therapeutic composition of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable nontoxic salts include the acid addition salts (formed  
20 with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid,  
25 lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid, and the like.

Salts formed with the free carboxyl groups  
30 can also be derived from inorganic bases such as, for example, sodium hydroxide, ammonium hydroxide, potassium hydroxide, and the like; and organic bases

such as mono-, di-, and tri-alkyl and -aryl amines  
(e.g., triethylamine, diisopropyl amine, methyl amine,  
dimethyl amine, and the like) and optionally  
substituted ethanolamines (e.g., ethanolamine,  
5 diethanolamine, and the like).

Physiologically tolerable carriers are well  
known in the art. Exemplary liquid carriers are  
sterile aqueous solutions that contain no materials in  
addition to the active ingredients and water, or  
10 contain a buffer such as sodium phosphate at  
physiological pH, physiological saline or both, such as  
phosphate-buffered saline. Still further, aqueous  
carriers can contain more than one buffer salt, as well  
as salts such as sodium and potassium chlorides,  
15 dextrose, polyethylene glycol and other solutes.

Liquid compositions can also contain liquid  
phases in addition to and to the exclusion of water.  
Exemplary additional liquid phases include glycerin,  
vegetable oils such as cottonseed oil, and water-oil  
20 emulsions.

As described herein, an "effective amount" is  
a predetermined amount calculated to achieve the  
desired therapeutic effect, i.e., to alter the protein  
binding activity of a CARD-containing polypeptide or  
25 the catalytic activity of a CARD-containing  
polypeptide, resulting in altered biochemical process  
modulated by a CARD-containing polypeptide. The  
required dosage will vary with the particular treatment  
and with the duration of desired treatment; however, it  
30 is anticipated that dosages between about 10 micrograms  
and about 1 milligram per kilogram of body weight per  
day will be used for therapeutic treatment. It may be

particularly advantageous to administer such agents in depot or long-lasting form as discussed herein. A therapeutically effective amount is typically an amount of an agent identified herein that, when administered  
5 in a physiologically acceptable composition, is sufficient to achieve a plasma concentration of from about 0.1 µg/ml to about 100 µg/ml, preferably from about 1.0 µg/ml to about 50 µg/ml, more preferably at least about 2 µg/ml and usually 5 to 10 µg/ml.

10 Therapeutic invention anti-CARD antibodies can be administered in proportionately appropriate amounts in accordance with known practices in this art.

Also provided herein are methods of treating pathologies characterized by abnormal cell  
15 proliferation, abnormal cell death, or inflammation said method comprising administering an effective amount of an invention therapeutic composition. Such compositions are typically administered in a physiologically compatible composition.

20 Exemplary abnormal cell proliferation diseases associated with CARD-containing polypeptides contemplated herein for treatment according to the present invention include cancer pathologies, keratinocyte hyperplasia, neoplasia, keloid, benign  
25 prostatic hypertrophy, inflammatory hyperplasia, fibrosis, smooth muscle cell proliferation in arteries following balloon angioplasty (restenosis), and the like. Exemplary cancer pathologies contemplated herein for treatment include, gliomas, carcinomas,  
30 adenocarcinomas, sarcomas, melanomas, hamartomas, leukemias, lymphomas, and the like. Further diseases associated with CARD-containing polypeptides contemplated herein for treatment according to the

present invention include inflammatory diseases and diseases of cell loss. Such diseases include allergies, inflammatory diseases including arthritis, lupus, Schrogen's syndrome, Crohn's disease, ulcerative colitis, as well as allograft rejection, such as graft-versus-host disease, and the like. CARD-containing polypeptides can also be useful in design of strategies for preventing diseases related to abnormal cell death in conditions such as stroke, myocardial infarction, heart failure, neurodegenerative diseases such as Parkinson's and Alzheimer's diseases, and for immunodeficiency associated diseases such as HIV infection, HIV-related disease, and the like.

Methods of treating pathologies can include methods of modulating the activity of one or more oncogenic proteins, wherein the oncogenic proteins specifically interact with a CARD-containing polypeptide of the invention. Methods of modulating the activity of such oncogenic proteins will include contacting the oncogenic protein with a substantially pure CARD-containing polypeptide or an active fragment (i.e., oncogenic protein-binding fragment) thereof. This contacting will alter the activity of the oncogenic protein, thereby providing a method of treating a pathology caused by the oncogenic protein. Further methods of modulating the activity of oncogenic proteins will include contacting the oncogenic protein with an agent, wherein the agent alters interaction between a CARD-containing polypeptide and an oncogenic protein.

Also contemplated herein, are therapeutic methods using invention pharmaceutical compositions for the treatment of pathological disorders in which there

is too little cell division, such as, for example, bone marrow aplasias, immunodeficiencies due to a decreased number of lymphocytes, and the like. Methods of treating a variety of inflammatory diseases with invention therapeutic compositions are also contemplated herein, such as treatment of sepsis, fibrosis (e.g., scarring), arthritis, graft versus host disease, and the like.

The present invention also provides methods for diagnosing a pathology that is characterized by an increased or decreased level of a biochemical process to determine whether the increased or decreased level of the biochemical process is due, for example, to increased or decreased expression of a CARD-containing polypeptide or to expression of a variant CARD-containing polypeptide. As disclosed herein, such biochemical processes include apoptosis, NF-kB induction, cytokine processing, caspase-mediated proteolysis, transcription, inflammation, cell adhesion, and the like. The identification of such a pathology, which can be due to altered association of a CARD-containing polypeptide with a CARD-associated polypeptide in a cell, or altered ligand binding or catalytic activity of a CARD-containing polypeptide, can allow for intervention therapy using an effective agent or a nucleic acid molecule or an antisense nucleotide sequence as described herein. In general, a test sample can be obtained from a subject having a pathology characterized by having or suspected of having increased or decreased apoptosis and can be compared to a reference sample from a normal subject to determine whether a cell in the test sample has, for example, increased or decreased expression of a CARD-encoding gene. The level of a CARD-containing

polypeptide in a cell can be determined by contacting a sample with a reagent such as an anti-CARD antibody or a CARD-associated polypeptide, either of which can specifically bind a CARD-containing polypeptide. For example, the level of a CARD-containing polypeptide in a cell can be determined by well known immunoassay or immunohistochemical methods using an anti-CARD antibody (see, for example, Reed et al., Anal. Biochem. 205:70-76 (1992); see, also, Harlow and Lane, supra, (1988)).

As used herein, the term "reagent" means a chemical or biological molecule that can specifically bind to a CARD-containing polypeptide or to a bound CARD/CARD-associated polypeptide complex. For example, either an anti-CARD antibody or a CARD-associated polypeptide can be a reagent for a CARD-containing polypeptide, whereas either an anti-CARD antibody or an anti-CARD-associated polypeptide antibody can be a reagent for a CARD/CARD-associated polypeptide complex.

As used herein, the term "test sample" means a cell or tissue specimen that is obtained from a subject and is to be examined for expression of a CARD-encoding gene in a cell in the sample. A test sample can be obtained, for example, during surgery or by needle biopsy and can be examined using the methods described herein to diagnose a pathology characterized by increased or decreased apoptosis. Increased or decreased expression of a CARD-encoding gene in a cell in a test sample can be determined, for example, by comparison to an expected normal level of CARD-containing polypeptide or CARD-encoding mRNA in a particular cell type. A normal range of CARD-containing polypeptide or CARD-encoding mRNA levels in various cell types can be determined by sampling a statistically significant number of normal subjects.

In addition, a reference sample can be evaluated in parallel with a test sample in order to determine whether a pathology characterized by increased or decreased apoptosis is due to increased or decreased expression of a CARD-encoding gene. The test sample can be examined using, for example, immunohistochemical methods as described above or the sample can be further processed and examined. For example, an extract of a test sample can be prepared and examined to determine whether a CARD-containing polypeptide in the sample can associate with a CARD-associated polypeptide in the same manner as a CARD-containing polypeptide from a reference cell or whether, instead, a variant CARD-containing polypeptide is expressed in the cell.

In accordance with another embodiment of the present invention, there are provided diagnostic systems, preferably in kit form, comprising at least one invention CARD-encoding nucleic acid, CARD-containing polypeptide, and/or anti-CARD antibody described herein, in a suitable packaging material. In one embodiment, for example, the diagnostic nucleic acids are derived from any of SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89. Invention diagnostic systems are useful for assaying for the presence or absence of CARD-encoding nucleic acid in either genomic DNA or in transcribed CARD-encoding nucleic acid, such as mRNA or cDNA.

A suitable diagnostic system includes at least one invention CARD-encoding nucleic acid, CARD-containing polypeptide, and/or anti-CARD antibody, preferably two or more invention nucleic acids, proteins and/or antibodies, as a separately packaged chemical reagent(s) in an amount sufficient for at

least one assay. Instructions for use of the packaged reagent are also typically included. Those of skill in the art can readily incorporate invention nucleic acid probes and/or primers into kit form in combination with  
5 appropriate buffers and solutions for the practice of the invention methods as described herein.

As employed herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit, such as  
10 invention nucleic acid probes or primers, and the like. The packaging material is constructed by well known methods, preferably to provide a sterile, contaminant-free environment. The packaging material has a label which indicates that the invention nucleic  
15 acids can be used for detecting a particular CARD-encoding sequence including the nucleotide sequences set forth in SEQ ID NOS:11, 187, 96, 98, 100, 102, 85 and 89 or mutations or deletions therein, thereby diagnosing the presence of, or a predisposition for a  
20 pathology such as cancer or an autoimmune disease. In addition, the packaging material contains instructions indicating how the materials within the kit are employed both to detect a particular sequence and diagnose the presence of, or a predisposition for a  
25 pathology such as cancer or an autoimmune disease.

The packaging materials employed herein in relation to diagnostic systems are those customarily utilized in nucleic acid-based diagnostic systems. As used herein, the term "package" refers to a solid  
30 matrix or material such as glass, plastic, paper, foil, and the like, capable of holding within fixed limits an isolated nucleic acid, oligonucleotide, or primer of the present invention. Thus, for example, a package

can be a glass vial used to contain milligram quantities of a contemplated nucleic acid, oligonucleotide or primer, or it can be a microtiter plate well to which microgram quantities of a  
5 contemplated nucleic acid probe have been operatively affixed.

"Instructions for use" typically include a tangible expression describing the reagent concentration or at least one assay method parameter,  
10 such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions, and the like.

A diagnostic assay should include a simple  
15 method for detecting the amount of a CARD-containing polypeptide or CARD-encoding nucleic acid in a sample that is bound to the reagent. Detection can be performed by labeling the reagent and detecting the presence of the label using well known methods (see,  
20 for example, Harlow and Lane, supra, 1988; chap. 9, for labeling an antibody). A reagent can be labeled with various detectable moieties including a radiolabel, an enzyme, biotin or a fluorochrome. Materials for labeling the reagent can be included in the diagnostic  
25 kit or can be purchased separately from a commercial source. Following contact of a labeled reagent with a test sample and, if desired, a control sample, specifically bound reagent can be identified by detecting the particular moiety.

30 A labeled antibody that can specifically bind the reagent also can be used to identify specific binding of an unlabeled reagent. For example, if the

reagent is an anti-CARD antibody, a second antibody can be used to detect specific binding of the anti-CARD antibody. A second antibody generally will be specific for the particular class of the first antibody. For  
5 example, if an anti-CARD antibody is of the IgG class, a second antibody will be an anti-IgG antibody. Such second antibodies are readily available from commercial sources. The second antibody can be labeled using a detectable moiety as described above. When a sample is  
10 labeled using a second antibody, the sample is first contacted with a first antibody, then the sample is contacted with the labeled second antibody, which specifically binds to the first antibody and results in a labeled sample.

15 In accordance with another embodiment of the invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. For example, it is contemplated herein that abnormal levels of CARD-  
20 containing polypeptides (either higher or lower) in primary tumor tissue show a high correlation with either increased or decreased tumor recurrence or spread, and therefore indicates the likelihood of disease free or overall survival. Thus, the present  
25 invention advantageously provides a significant advancement in cancer management because early identification of patients at risk for tumor recurrence or spread will permit aggressive early treatment with significantly enhanced potential for survival. Also  
30 provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor; methods for screening a cancer patient to determine the risk of tumor metastasis; and methods for determining the proper course of treatment for a

patient suffering from cancer. These methods are carried out by collecting a sample from a patient and comparing the level of CARD-encoding gene expression in the patient to the level of expression in a control or  
5 to a reference level of CARD-encoding gene expression as defined by patient population sampling, tissue culture analysis, or any other method known for determining reference levels for determination of disease prognosis. The level of CARD-encoding gene  
10 expression in the patient is then classified as higher than the reference level or lower than the reference level, wherein the prognosis of survival or tumor recurrence is different for patients with higher levels than the prognosis for patients with lower levels.

15 All U.S. patents and all publications mentioned herein are incorporated in their entirety by reference thereto. The invention will now be described in greater detail by reference to the following non-limiting examples.

20 EXAMPLES

1.0 Identification of CARD-containing polypeptides.

The process of gene identification and assembling include the following steps:

A) Identification of new candidate CARD containing  
25 polypeptides. A database search was performed using the TBLASTN program with the CARD domain of caspase-1 and caspase-12 as the query in the following NCBI databases: high throughput genome sequence (HTGS), genomic survey sequence (GSS) and expressed sequence  
30 tag (EST) databases.

B) Verification that the new candidate CARD containing polypeptide is novel. Using PSI-BLAST, each new candidate CARD gene was queried in the annotated non-redundant (NR) database at NCBI. When the new  
5 candidate gene showed significant but not identical homology with other known CARD containing polypeptides during this search, the CARD containing polypeptide candidate was kept for further analysis.

C) 3-D-Model Building of new candidate CARD  
10 polypeptide: When the sequence homology was low (<25% identity), three-dimensional criteria was added to characterization of new CARD-containing polypeptides. The candidate CARD fragment was analyzed by a profile-profile sequence comparison method which aligns the  
15 candidate CARD domain with a database of sequences of known three-dimensional structure. From this analysis, a sequence alignment was produced and a three-dimensional model was built according to the known structure of CARD domain of IAP-1. In most cases, the  
20 best score was produced using CARD domain sequences having known three-dimensional structures. The quality of the three-dimensional model obtained from the alignments confirmed that novel CARD-domain containing polypeptides had been identified.

25

D) Identification of additional domains in the full length protein. Full length protein sequences were obtained using the closest full-length caspase homolog of the new CARD identified in step B as query. TBLASTN  
30 searches of the sequences containing the newly identified CARD domains were performed. Longer aligned fragments or multiple aligned fragments in the accession number corresponding to the newly identified

CARD containing polypeptides indicated a longer protein.

E) These additional domains were assembled using the following gene building procedure:

5                    Genomic DNA fragments were identified by  
T-BLAST-N analysis using mouse caspase-12 and human  
caspase-1 full length protein as query and scanning  
HTGS database from NCBI of incomplete DNA genomics  
sequences. New fragments homologous to caspase-12 and  
10 caspase-1 were further confirmed by psi-blast analysis  
using the TBLASTN genomic DNA homolog fragment as query  
and scanning NR database. The boundary of each  
fragment was identified according to the following  
criteria:

15                    Disruption of sequence similarity between the  
protein alignment of the target fragment and the query.

Extension of the protein sequence alignment  
between query and target using ORF finder.

Protein sequence overlap between two  
20 contiguous fragments in sequence relative to the query.

Conservation of exon-intron junction between  
DNA sequence of the target and query.

Orientation of the ORF of the different  
genomic DNA fragment.

25                    Presence of contiguous fragments, based on  
sequence alignment with the query, on the same contig.

Finally, the reconstituted sequences were aligned by CLUSTALW with the query and exon-intron junctions further refined by repeating the above process.

- 5    2.0            Identification of CARD2X, CARD3X and CLAN.  
Nucleic acids encoding CARD containing proteins CARD2X, CARD3X and CLAN were identified from different CARD queries using tblastn and systematically scanning gss, htgs, and all EST databases at NCBI. Further analysis  
10    using translated genomic fragment containing CARD domains larger than the CARD domain itself as query were performed to identify additional domains. Genomic DNA were translated in all reading frames and examined for additional domains using psi-blast and nr database.
- 15    3.0            *Cloning and sequencing of large cDNA.* For cDNA larger than 1500 bp, cloning is accomplished by amplification of multiple fragments of the cDNA. Jurkat total RNA is reverse-transcribed to complementary DNAs using MMLV reverse transcriptase  
20    (Stratagene) and random hexanucleotide primers. Overlapping cDNA fragments of a CARD-containing polypeptide are amplified from the Jurkat complementary DNAs with Turbo Pfu DNA polymerase (Stratagene) using an oligonucleotide primer set for every 1500 bp of  
25    cDNA, where the amplified cDNA fragment contains a unique restriction site near the end that is to be ligated with an adjacent amplified cDNA fragment.

The resultant cDNA fragments are ligated into mammalian expression vector pcDNA-myc (Invitrogen,  
30    modified as described in Roy et al., EMBO J. 16:6914-6925 (1997)) and assembled to full-length cDNA by consecutively ligating adjacent fragments at the unique

endonuclease sites form the full-length cDNA. Sequencing analysis of the assembled full-length cDNA is carried out, and splice isoforms of CARD-containing polypeptides can be identified.

5    4.0            *Plasmid Constructions.* Complementary DNA encoding a CARD-containing polypeptide, or a functional fragment thereof is amplified from Jurkat cDNAs with Turbo Pfu DNA polymerase (Stratagene) and desired primers, such as those described above. The resultant  
10 PCR fragments are digested with restriction enzymes such as *EcoRI* and *Xho I* and ligated into pGEX-4T1 (Pharmacia) and pcDNA-myc vectors.

5.0            *In vitro Protein Binding Assays.* CARD-containing or fragments thereof encoded in pGEX-4T1 are  
15 expressed in XL-1 blue *E. coli* cells (Stratagene), and affinity-purified using glutathione (GSH)-sepharose according to known methods, such as those in Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley and Sons (1999). For GST pull-down assays,  
20 purified CARD-GST fusion proteins and GST alone (0.1-0.5 µg immobilized on 10-15 µl GSH-sepharose beads) are incubated with 1 mg/ml of BSA in 100 µl Co-IP buffer (142.4 mM KCl, 5mM MgCl<sub>2</sub>, 10 mM HEPES (pH 7.4), 0.5 mM EGTA, 0.2% NP-40, 1 mM DTT, and 1 mM PMSF)  
25 for 30 min. at room temperature. The beads are then incubated with 1 µl of rat reticulocyte lysates (TnT-lysate; Promega, Inc.) containing <sup>35</sup>S-labeled, in vitro translated CARD-containing or control protein Skp-1 in 100 µl Co-IP buffer supplemented with 0.5  
30 mg/ml BSA for overnight at 4°C. The beads are washed four times in 500 µl Co-IP buffer, followed by boiling in 20 µl Laemmli-SDS sample buffer. The eluted

proteins are analyzed by SDS-PAGE. The bands of SDS-PAGE gels are detected by fluorography.

The resultant oligomerization pattern will reveal that CARD:CARD and other protein:protein  
5 interactions occur with CARD-containing polypeptides or fragments thereof.

*In vitro* translated candidate CARD-associated polypeptides such as Apaf-1 (lacking its WD domain), CED4, and control Skp-1 are subjected to GST pull-down  
10 assay using GSH-sepharose beads conjugated with GST and GST-CARD-containing polypeptides as described above. Lanes containing GST-CARD yield significant signals when incubated with a CARD-associated polypeptide whereas, the controls GST alone and Skp-1 yield  
15 negligible signals.

6.0        *Protein Interaction Studies in Yeast.* EGY48 yeast cells (*Saccharomyces cerevisiae*: MAT $\alpha$ , trp1, ura3, his, leu2::plexApo6-leu2) are transformed with pGilda-CARD plasmids (his marker) encoding the LexA DNA  
20 binding domain fused to: CARD-containing polypeptides, fragments thereof, or CARD-associated polypeptides. EGY48 are also transformed with a LexA-LacZ reporter plasmid pSH1840 (ura3 marker), as previously described (Durfee et al., 1993; Sato et al., 1995). Sources for  
25 cells and plasmids are described previously in U.S. Patent 5,632,994, and in Zervous et al., Cell 72:223-232 (1993); Gyuris et al., Cell 75:791-803 (1993); Golemis et al., In Current Protocols in Molecular Biology (ed. Ausubel et al.; Green Publ.; NY 1994),  
30 each of which is incorporated herein by reference. Transformants are replica-plated on Burkholder's minimal medium (BMM) plates supplemented with leucine

and 2% glucose as previously described (Sato et al.,  
Gene 140:291-292 (1994)). Protein-protein interactions  
are scored by growth of transformants on leucine  
deficient BMM plates containing 2% galactose and 1%  
5 raffinose.

Protein-protein interactions are also  
evaluated using  $\beta$ -galactosidase activity assays.  
Colonies grown on BMM/Leu/Glucose plates are  
filter-lifted onto nitrocellulose membranes, and  
10 incubated over-night on BMM/Leu/galactose plates.  
Yeast cells are lysed by soaking filters in liquid  
nitrogen and thawing at room temperature.  
 $\beta$ -galactosidase activity is measured by incubating the  
filter in 3.2 ml Z buffer (60 mM,  $\text{Na}_2\text{HPO}_4$ , 40 mM  
15  $\text{Na}_2\text{HPO}_4$ , 10 mM KCl, 1 mM  $\text{MgSO}_4$ ) supplemented with 50 $\mu$ l  
X-gal solution (20 mg/ml). Levels of  $\beta$ -galactosidase  
activity are scaled according to the intensity of blue  
color generated for each transformant.

The results of this experiment will show  
20 colonies on leucine deficient plates for yeast  
containing CARD/LexA fusions together with CARD-  
associated polypeptide/B42. In addition, the  
CARD/LexA:CARD-associated polypeptide/B42 cells will  
have significant amounts of LacZ activity.

25 7.0 *Self-Association of NB-ARC domain of CARD-*  
*containing polypeptides.* In vitro translated,  
 $^{35}\text{S}$ -labeled rat reticulocyte lysates (1  $\mu$ l) containing  
NB-ARC or Skp-1 (used as a control) are incubated with  
GSH-sepharose beads conjugated with purified GST-NB-ARC  
30 or GST alone for GST pull-down assay, resolved on  
SDS-PAGE and visualized by fluorography as described

above. One tenth of input is loaded for NB-ARC or Skp-1 as controls.

8.0           *Protein-Protein Interactions of CARD-containing polypeptides.* Transient transfection of 293T, a human embryonic kidney fibroblast cell line, are conducted using SuperFect reagents (Qiagen) according to manufacturer's instructions. The cDNA fragments encoding full-length CED4 and the truncated form of Apaf-1 (Apaf-1 $\Delta$ WD) comprising amino acids 1-420 of the human Apaf-1 protein are amplified by PCR and subcloned into pcDNA3HA at EcoRI and Xho I sites. Expression plasmids encoding catalytically inactive forms of caspases such as pro-Casp8 (pro-Casp8 (C/A)) are prepared by replacing Cys 377 with an Ala using site-directed mutagenesis and pro-Casp9 (pro-Casp9 (C/A)) has been described previously, Cardone et al., Science 282:1318-1321 (1998)). 293T cells are transiently transfected with an expression plasmid (2  $\mu$ g) encoding HA-tagged human Apaf-1 $\Delta$ WD, CED4, pro-Casp8 (C/A) or C-Terminal Flag-tagged pro-Casp9 (C/A) in the presence or absence of a plasmid (2  $\mu$ g) encoding myc-tagged CARD-containing polypeptide. After 24 hr growth in culture, transfected cells are collected and lysed in Co-IP buffer (142.4 mM KCl, 5 mM MgCl<sub>2</sub>, 10 mM HEPES (pH 7.4), 0.5 mM EGTA, 0.1 % NP-40, and 1 mM DTT) supplemented with 12.5 mM  $\beta$ -glycerolphosphate, 2 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM PMSF, and 1X protease inhibitor mix (Boehringer Mannheim). Cell lysates are clarified by microcentrifugation and subjected to immunoprecipitation using either a mouse monoclonal antibody to myc (Santa Cruz Biotechnologies, Inc) or a control mouse IgG. Proteins from the immune complexes are resolved by SDS-PAGE, transferred to nitrocellulose membranes, and subjected to immunoblot analysis using

anti-HA antibodies followed by anti-myc antibodies using a standard Western blotting procedure and ECL reagents from Amersham-Pharmacia Biotechnologies, Inc. (Krajewski et al., Proc. Natl. Acad. Sci. USA 96:5752-5 5757 (1999)).

9.0 *Cloning and characterization of CARD2X.* CARD2X-encoding cDNA was obtained by PCR using primers CGGAATTCATGGCTACCGAGAGTACTCC (SEQ ID NO:76) and GTAAAACGACGGCCAGT (SEQ ID NO:77) to amplify a 0.9 kb 10 cDNA molecule from a human skeletal muscle cDNA library (Clontech). The PCR products was then purified by agarose gel electrophoresis and the purified products subcloned into pBluescript II SK vector (Stratagene). Using the forward primers, the PCR fragments were 15 directly sequenced using the ABI PRISM Big Dye Terminal Cycle sequencing kit, according to manufacturer's instructions (Perkin Elmer). Based on the sequence obtained, a third CARD2X-specific primer was generated having the sequence GCAGAAGCCACTGTGGAAGAGGAGGTT (SEQ ID 20 NO:78). In identifying the 3'end of the CARD2X-encoding cDNA, this third CARD2X-specific primer was used in conjunction with a phage-specific primer having the sequence ATACGACTCACTATAGGGCGAATTGGCC (SEQ ID NO:79) to amplify a 0.3 kb cDNA molecule using methods 25 described above. The 0.3 kb cDNA molecule was cloned and sequenced as described above, and the sequences of the 0.3 and 0.9 kb cDNA molecules were merged to produce a 1.0 kb cDNA sequence.

The sequence of CARD2X was confirmed. 30 Additional 5' untranslated sequence was identified (nucleotide sequence of CARD2X including 5' untranslated sequence, SEQ ID NO:84). The CARD domain extends from amino acids 4 to 78 of SEQ ID NO:12.

The association between CARD2X and other CARD-containing proteins was determined. HEK 293T cells in 6-well plates were transfected using SuperFect (Qiagen) with pairwise combinations of Myc-tagged or  
5 FLAG-tagged CARD2X, CARDIAK or NOD1 (total DNA 2µg). After 24 hours, cells were collected in 400 µl of lysis buffer (20mM Tris, pH 7.4, 150mM NaCl, 1% NP-40, and 1mM EDTA supplemented with 1x protease inhibitors mix (Roche/Boehringer Mannheim)). Cell lysates were  
10 clarified by centrifugation and subjected to immunoprecipitation using Agarose-beads conjugated with anti-FLAG M2 antibody (Sigma). Immune-complexes were washed three times with wash buffer (20mM Tris, pH 7.4, 100mM NaCl, 0.05% NP-40, and 1mM EDTA), and resolved on  
15 SDS-PAGE gels. Proteins in the gels were transferred to nitrocellulose membranes, immunoblotted with anti-Myc antibodies, and detected with ECL (Amersham-Pharmacia Biotech). Epitope-specific antibodies for myc, FLAG, or HA tag were obtained from  
20 Santa Cruz Biotech, Roche/Boehringer Mannheim, and Sigma. The results of these co-immunoprecipitation assays demonstrated that CARD2X specifically associates with both NOD1 and with CARDIAK.

The effect of CARDIAK on CARD2X  
25 phosphorylation was next determined. HEK 293T cells transiently expressing FLAG-CARDIAK were lysed and immunoprecipitated with Agarose-beads conjugated with anti-FLAG M2 antibody. In vitro phosphorylation was performed in the immune complex with or without  
30 purified Myc-CARD-2X as a substrate. The kinase reaction was initiated by adding 1µM of [ $\gamma$ -<sup>32</sup>P]ATP in 10µl of kinase buffer (50mM Tris, pH7.4, 100mM NaCl, 6mM MgCl<sub>2</sub>, 1mM MnCl, and 1mM EDTA). After 20min at 37°C, the reaction was stopped by adding 10µl of 2x SDS

sample buffer, and subjected to SDS-PAGE and autoradiography. The results of these assays indicated that CARD2X is not phosphorylated directly by CARDIAK.

Phosphatase assays were also performed to  
5 examine phosphorylation of CARD2X. HEK 293 cells were transfected with plasmids encoding Myc-CARD-2X with or without FLAG-CARDIAK or FLAG-CARDIAK(K47M), which is a kinase deficient mutant of CARDIAK. The cleared  
10 lysates were diluted 1:20 with 20 $\mu$ l of reaction buffer (25mM Tris, pH8.0, 50mM NaCl, 5mM MgCl<sub>2</sub>), and optionally treated with 2 units of calf intestine alkaline phosphatase (Gibco BRL) for 30min at 37°C. The reaction was terminated by adding 7 $\mu$ l 4x SDS sample  
15 buffer, and subjected to SDS-PAGE and immunoblot. The phosphorylated form of CARD2X migrates more slowly than CARD2X, and is not observed after phosphatase treatment. The results of these assays indicated that CARD2X is phosphorylated *in vivo* in the presence of either CARDIAK or kinase-deficient CARDIAK, but not in  
20 their absence. Taken together with the *in vitro* phosphorylation results above, these results indicate that CARDIAK is indirectly involved in CARD2X phosphorylation.

The 30-35 residues at the carboxy terminus of  
25 CARD2X have homology to human Alu family sequences and RhoGAP. Thus, this region can have activity similar to that observed in human Alu family sequences and RhoGAP.

10.0 *Cloning and characterization of CLAN.* CLAN  
encoding cDNA was obtained by polymerase chain reaction  
30 (PCR) using primers CXF1:TACTTACTTTGTCCTTCA (SEQ ID NO:74) and CXR2:TATTTGTCCCCATCTCGTC (SEQ ID NO:75) to amplify cDNA from a human genomic library. Thirty

cycles of PCR were carried out using Turbo *Pfu* DNA polymerase (Stratagene) at annealing temperature 47°C and extension temperature 72°C. The PCR product was then purified by agarose gel electrophoresis and the  
5 purified product subcloned into pGEM-T vector (Promega).

The HTSG database of human genomic DNA sequence data was searched for regions capable of encoding CARDS using the CARD amino-acid sequence of  
10 cIAP-1 as a query with the TBLASTn method. This search revealed strong homology with a human genomic clone (Accession number: AQ889169) that mapped to human chromosome 2p21-22. This locus was not recognized in the human genomic database and was not previously  
15 annotated. In initial studies, two genes encoding CARD domain containing polypeptides, designated CARD4X and CARD5X, were identified. Upon further characterization, it was determined that CARD4X (also known as NAC-X or NAC-4) and CARD5X were actually  
20 encoded by the same gene, which is therefore referenced as CARD4/5X. CARD4/5X was subsequently designated CLAN, which stands for "CARD, LRR and NACHT-containing protein," because at least one of the proteins encoded by it contains CARD, Leucine Rich Repeat (LRR) and  
25 NACHT (NB-ARC) domains, as described below.

The CLAN gene locus lies in close proximity to the gene encoding Spastin (on chromosome 2p21-22), a AAA protein which is frequently mutated in autosomal dominant hereditary spastic paraplegia (AD-HSP). The  
30 CLAN locus is found on the strand opposite the *SPG4* (*SPAST*) locus but with no overlapping regions. This result suggests that mutations in the CLAN gene

potentially occur in patients with this neurodegenerative disorder.

Using GENESCAN for exon prediction, additional regions potentially encoding a NACHT (NB-  
5 ARC) domain and regions corresponding to Leucine-Rich Repeat (LRR) domains were also recognized 3' to the potential CARD-encoding sequences, suggesting the presence of a CED4-like gene.

*10.1 Cloning of CLAN cDNAs.* CLAN-specific primers  
10 corresponding to sequences within the putative CARD and NACHT (NB-ARC) regions (as determined from genomic DNA sequence data) were used in conjunction with 2 universal primers to isolate CLAN cDNAs from first-strand liver and lung cDNA by nested PCR according to  
15 the manufacturer's protocol (SMART RACE, Clontech). Primers used for amplification are 5' RACE primers (5'-CATGTGAATGATCCCTCTAGCAG-3' (SEQ ID NO:153); nested 5'-GGGCTCGGCTATCGTGCTCTA-3' (SEQ ID NO:154)) and 3' RACE primers (5'-ACGATAGCCGAGCCCTTATTC-3' (SEQ ID NO:155);  
20 nested 5'-GTATGGAATGTTCTGAATCGC-3' (SEQ ID NO:156)). Amplification products were purified from agarose gels, ligated into the TA cloning vector (Promega), and sequenced. Four open reading frames were deduced and multiple clones of each isoform were sequenced to  
25 ensure fidelity of PCR products.

The longest transcript, termed CLAN-A, was 3.370 kilobasepairs (kbp) in length (SEQ ID NO:96) with an open reading frame (ORF) coding for a 1024 amino-acid protein (SEQ ID NO:97) containing a CARD, NACHT  
30 (NB-ARC), and LRR-domains, as well as a predicted SAM domain. A second transcript, termed CLAN-B, was 1.374 kbp in length (SEQ ID NO:98), with an ORF coding for a

359 amino-acid protein (SEQ ID NO:99) containing an identical CARD directly spliced to the LRRs. CLAN-C, the third transcript isolated, was 0.768 kbp in length (SEQ ID NO:102) and encoded a 156 amino acid protein (SEQ ID NO:103) containing the CARD and an additional region lacking homology to recognizable domains. Finally, the shortest transcript found, CLAN-D, was 0.578 kbp in length (SEQ ID NO:100) and contained an ORF encoding a 92 amino-acid protein (SEQ ID NO:101) encompassing only the CARD followed by 9 amino acids.

Comparisons of these cDNA sequence data with the genomic DNA sequence data found in the HTSG database suggested that the *CLAN* gene consists of 12 exons, spanning 41.3 kbp on chromosome 2p21-22 (Figure 1A). Six differences were found between the sequence of the *CLAN* cDNA and the sequence within the public database. Additionally, nucleotide regions 1-12 and 3372-3396 do not have equivalent fragments in the public database.

Southern blot analysis was also performed. For Southern blot analysis, 10 µg of restriction endonuclease (EcoRI or PstI) digested genomic DNA was loaded per lane and hybridized with the CARD domain of CLAN as a probe. The probe was derived from the CLAN A-isoform (see Figures 1 and 2), nucleotides 276 to 507 plus an additional 20 upstream nucleotides, which are not present in the cDNA but are present in the genomic DNA. CLAN was found to be a single copy gene.

Two different transcriptional start sites are utilized (corresponding to the beginning of either exon 1 or 2); however both are spliced to exon 3 at the beginning of the CARD. Exons 6 and 7 contain additional internal splice donor sites which are

utilized to generate CLAN-G. Figure 1B shows the pattern of mRNA splicing events predicted to give rise to the CLAN-A, CLAN-B, CLAN-C, and CLAN-D transcripts and encoded proteins. All the exon/intron splice  
5 junctions follow the conserved GT/AG consensus rule.

As predicted by SMART (EMBL, Heidelberg, Germany), CLAN contains a CARD (amino acids 1-87 of SEQ ID NO:97). A  $\psi$ -BLAST search of the non-redundant database using the CLAN CARD as query identified  
10 several homologous CARDS including those from cIAP1 and 2 (58%), caspase-1 and ICEBERG (50%), Nod1, Nod2, and Card8 (~38%) and caspase-13, Ced3, caspase-9, Bcl10 (CIPER) and CARKIAK/RIP2 (~30%).

Following the CARD, a domain containing  
15 consensus sequences for Walker A and B boxes is present (Walker et al., EMBO J. 8:945-951 (1982)) as well as additional characteristics of the family of NTPases termed the NACHT family (Koonin et al., Trends. Biochem. Sci. 25:2230224 (2000)). By  $\psi$ -BLAST search  
20 the NACHT domain of CLAN ("NB" in Figure 1, amino acids 161-457 of SEQ ID NO:97) shows highest similarity to the NACHT domain of NAIP (60%), followed by Nod1 (49%) and Nod2 (47%).

Leucine Rich Repeat (LRR) domains are also  
25 found near the C-terminus of the A and B isoforms of the protein. The C-terminal end consists of four repeated LRRs, each containing a predicted  $\beta$  sheet and  $\alpha$  helical structure, which is in agreement with the prototypical horseshoe-shaped structure of LRRs (Kobe et al., Curr. Opin. Struct. Biol. 5:409-416 (1999)).  
30 LRR 1 (amino acids 760-791 of SEQ ID NO:97) represents a non-Kobe and Deisenhofer (non-K/D) LRR, whereas LRRs

2, 3, and 4 (amino acids 817-848; 845-876; and 934-965 of SEQ ID NO:97, respectively) are in accordance with Kobe and Deisenhofer (K/D) LRR. LRR 2 also shares sequence homology to a prototypical Ribonuclease Inhibitor type A (RI type A). By  $\psi$ -BLAST searches the LRRs show 49% sequence identity to the placental ribonuclease/angiogenin inhibitor (RAI).

Sequences located between the NACHT (NB-ARC) and LRR domains show some similarity to the sterile alpha motif (SAM) (amino acids 642-696 of SEQ ID NO:97), a domain built of five alpha helices originally found in proteins involved in numerous developmental processes. The SAM domain has been shown to function as a protein-protein interaction domain, with ability to homo-as well as hetero-oligomerize with other SAMs (Stapleton et al., Nat. Struct. Biol. 6:44-49 (1999)).

10.2 *In vivo expression of CLAN.* In order to determine which of the various splice variants of CLAN are expressed in adult human tissues, Northern blot analysis was performed. Hybridization probes corresponding to the common CARD domain of all 4 CLAN isoforms or the NACHT and LRR regions were radiolabeled by random priming with hexanucleotides (Roche) and  $\alpha$ -<sup>32</sup>P-dCTP, or Digoxigenin-labeled with a commercially available kit (Roche), incubated with blots containing human poly(A)<sup>+</sup> RNA derived from various human tissues (Origene), washed at high stringency, and exposed to X-ray film. Positive signals were detected by autoradiography or by immunoblotting with HRP-conjugated anti-DIG antibody and an enhanced chemiluminescence method (ECL) (Amersham).

Northern blot analysis with CARD of CLAN revealed expression of an approximately 1.5 kbp transcript corresponding to CLAN-B in nearly all tissues examined, with highest expression in lung and spleen. Northern blot analysis using the NACHT and LRR of CLAN-A as a probe revealed expression of an approximately 3.5 kbp mRNA corresponding to CLAN-A primarily in the lung.

To further explore the tissue-specific patterns of expression of CLAN splicing variants, RT-PCR assays were devised specific for the A, B, C, and D isoforms. A panel of cDNA specimens derived from various human tissues was utilized (Clontech), as well as blood cells, prepared as followed. Peripheral blood leukocytes were obtained from heparinized venous blood by Ficoll-Paque (Amersham) density-gradient centrifugation. Red blood cells were removed from granulocytes by short incubation in hypotonic lysis buffer. Monocytes were separated from lymphocytes by adherence to plastic dishes. Total RNA was isolated from cells using TRIZOL reagent (BRL) and 2 µg was used to generate cDNA in a reverse transcription reaction with Superscript II (BRL).

PCR was carried out on the cDNA samples in an Eppendorf thermal cycler using Taq polymerase (BRL) and the following isoform-specific primer pairs: CLAN-A 5'-GGTGGAGCAGGATGCTGCTAGAGG-3' (SEQ ID NO:159), 5'-CACAGTGGTCCAGGCTCCGAATGAAGTCA-3' (SEQ ID NO:160); CLAN-B 5'-CATCATTTGCTGCGAGAAGGTGGAG-3' (SEQ ID NO:161), 5'-TTAACTTGGATAACACTTGGCTAAG-3' (SEQ ID NO:162); CLAN-C 5'-GTAAACATCATTTGCTGCGAGAA-3' (SEQ ID NO:163), 5'-CCCGGGCAGGTAGAAGATGCTAT-3' (SEQ ID NO:164); CLAN-D

5'AATTCATAAAGGACAATAGCCGAG-3' (SEQ ID NO:165), 5'-  
TGTCTACTGTACTTTCTAAGCTGTT-3' (SEQ ID NO:166).

RT-PCR analysis showed that CLAN-B was  
5 present throughout human tissues (brain, heart, kidney,  
liver, lung, pancreas, placenta, skeletal muscle,  
colon, ovary, leukocytes, prostate, small intestine,  
spleen, testis, thymus), consistent with the Northern  
blot analysis. In contrast, CLAN-A was restricted to  
10 lung, colon, brain, prostate, spleen and leukocytes,  
but not other tissues. Further analysis of leukocyte  
sub-populations revealed expression of the CLAN-A  
isoform predominantly in the monocyte cell fraction,  
with lower expression found in granulocytes and no  
15 expression in lymphocytes. Expression of CLAN-C was  
absent in all normal tissues tested, however,  
expression was evident in the cell line HEK293T,  
suggesting this transcript can be produced under some  
circumstances. CLAN-D transcripts were detected only in  
20 brain by RT-PCR.

RT-PCR was also performed on cell lines.  
RT-PCR was performed using the same CLAN primers as  
used for RT-PCR in normal tissues, as described above.  
RT-PCR was performed in various tumor derived cell  
25 lines: M2, OVCAR3, HEY, HaCaT, 293T, SKOV-3, Jurkat,  
BG-1, 697, HL-60, PC3, DU145, MDA-MB-231, MCF-7, MDA-  
MB-4, HS578T, BT-549, and T-47D. Beta-actin primers  
were used as a control. In contrast to normal tissue,  
the transcript for CLAN was mostly absent in the cell  
30 lines tested. Weak expression was found in the cell  
lines 697, MDA-MB-231, MCF-7, MDA-MB-4, HS578T, and T-  
47D.

10.3 CLAN protein interactions. Interactions between the CARD of CLAN and known CARD domains were tested *in vitro* and *in vivo*.

To test CLAN interactions with other  
5 molecules, an *in vitro* binding assay was performed. CLAN was *in vitro* translated in the absence of label (i.e., cold). Other cellular proteins were labeled *in vitro* with <sup>35</sup>S-Met: CLAN, caspase1, caspase2, caspase8, caspase9, caspase10, Apaf1, Apaf1-CARD, NACa, NAC-CARD,  
10 Bcl10, ASC, cIAP1, cIAP2, XIAP, Nod1, Ced4, RAIDD, and CARDIAK. The *in vitro* translated proteins were mixed separately with unlabeled CLAN and co-immunoprecipitated using an antibody against an epitope tag fused to CARD5X, either myc or hemagglutinin  
15 (HA). CLAN associated proteins were eluted by boiling in Laemmli denaturing buffer and separated by 12% SDS-PAGE. The radioactive bands were visualized by fluorography.

Weak binding to CLAN was observed with  
20 caspase2 and cIAP1, with stronger binding to Nod1 and Cardiak. The strongest binding was observed with Ced4. Caspase8 binding is possibly due to its stickiness. There was no association detected between CLAN and itself.

25 To prepare appropriate expression vectors for *in vivo* interaction studies, a cDNA encoding the CLAN CARD domain was amplified using PFU polymerase and specific primers (5'-CCCGGATCCATGAATTCATAAAGGACAATAGC-3' (SEQ ID NO:153); 5'-CCCTTCGAACAAGTCCTGAAATAGAGGATA-  
30 3' (SEQ ID NO:154)) containing BamHI and HindIII sites. The resulting PCR product was ligated into pcDNA3.1

(-)/Myc-His<sub>6</sub> A (Invitrogen) which places the myc-His<sub>6</sub> tag at the C-terminus of expressed proteins. pcDNA3/HA-CLAN (CARD) was created using a similar strategy. Authenticity of all vectors was confirmed by  
5 DNA sequencing.

The CARD of CLAN was expressed as an epitope-tagged protein in HEK293T cells in co-transfections with a variety of other epitope-tagged CARD-containing proteins, and lysates derived from these cells were  
10 used for co-immunoprecipitation assays. Briefly, HEK293T cells were seeded onto six-well plates (35mm wells) and transfected with 0.2-2 mg plasmid DNA using Superfect (Qiagen) 24 hr later. After culturing for a day, cells were collected and lysed in isotonic lysis  
15 buffer (142.4 mM KCl, 5 mM MgCl<sub>2</sub>, 10 mM HEPES (pH 7.4), 0.5 mM EGTA, 0.2% NP-40, 12.5 mM b-glycerophosphate, 2 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM PMSF, and 1X protease inhibitor mix (Roche)). Lysates were clarified by centrifugation and subjected to immunoprecipitation  
20 using agarose-conjugated anti-c-myc antibodies (Santa Cruz), or non-specific control antibodies and Protein G-agarose for 2-24hr at 4°C. Immune-complexes were washed four times with lysis buffer, boiled in Laemmli buffer, and separated by 12-15% PAGE. Immune-complexes  
25 were then transferred to PVDF membranes and immunoblotted with anti-c-myc (Santa Cruz), anti-HA (Roche), or anti-flag (Sigma) antibodies. Membranes were washed, incubated with HRP-conjugated secondary antibodies, and reactive proteins were detected using  
30 ECL.

Co-immunoprecipitation analysis indicated that the CARD of CLAN bound readily to full-length procaspase-1 but did not significantly bind another CARD-

containing caspase, caspase-9. Among the other CED-4 family members which contain a CARD in conjunction with a nucleotide-binding domain, CLAN interacted with the CARDS of Nod2 and NAC, but not with Apaf-1 or Nod-1.

5 Finally, the CLAN CARD was found to associate with Bcl-10, but not with another adapter protein, RAIDD.

11.0        *Cloning and characterization of CARD3X* Based on an analysis of the overlapping genomic contigs GI 8575872 and GI 5001450, a cDNA sequence for CARD3X was

10 predicted (SEQ ID NO:82), that encoded amino acid sequences designated SEQ ID NOS:83 and 107.

For identification of novel domains in CARD3X, the sequence of the CARD domain of polypeptide CARD3X was used as a query for a tblastn search in the

15 HTGS database, and two overlapping genomic contigs were found (GI numbers 5001450 and 8575872). This contig was analyzed using the GenScan server (<http://ccr-081.mit.edu/GENSCAN.html>) for the presence of exons. (Burge and Karlin, J. Mol. Biol. 268:78-94

20 (1997)). The predicted protein sequences coded by the exons were analyzed by comparison with the NCBI nr protein sequence database using PSI-BLAST. The predicted protein sequences coded by the exons were analyzed also by comparison with a database of proteins

25 with known three-dimensional structures and apoptosis related domains using the profile-profile comparison server at [http://bioinformatics.burnham-inst.org/FFAS\\_apoptosis](http://bioinformatics.burnham-inst.org/FFAS_apoptosis) (Rychlewski, et al., Protein Science 9:232-241 (2000)).

30 CARD3X contains two CARD domains, a CARD-A and CARD-B domain (see Figure 3). An NB-ARC domain was also observed (see Figure 3). The NB-ARC is similar to

both the CLAN and APAF-1 NB-ARC domains and to NB-ARC domains from several plant disease resistance proteins (Aravind et al., Trends Biochem. Sci. 24:47-53 (1999); Young, Curr. Opin. Plant Biol. 4:285-289 (2000)).

5           An angio-R domain was also identified at amino acids 457-839 of SEQ ID NO:107. An "angio-R" is a new domain that can be defined as a region of a polypeptide chain that bears substantial similarity (e.g. 25, 30, 40% sequence identity) to the 514-residue  
10 long protein "angiotensin II/vasopressin receptor" (described in Ruiz-Opazo et al., Nature Med. 1:1074-1081 (1995)). The "angio-R" domain has not been previously described in any protein.

To confirm the predicted sequences, cDNAs  
15 were cloned and sequenced. The CARD3X cDNA was cloned using a Rapid-Screen™ Arrayed Placenta cDNA Library Panel from Origene Technologies, Inc. The library cDNAs had been pre-selected for long clones, unidirectionally cloned into the vector pCMV6-XL4, and  
20 arrayed in a 96-well format. An initial Master Plate containing 500,000 cDNA clones was screened by PCR, using the forward primer 5'-GAAATGTGCTCGCAGGAGG- 3' (SEQ ID NO:185) and the reverse primer 5'-GATGAGCTTCTGACAGGCCC- 3' (SEQ ID NO:186). A set of  
25 5000 clones that were initially positive by PCR were screened again with the same set of primers. Positive clones were plated on LB/Amp plates, and a further round of single colony PCRs was performed in order to obtain the desired clone.

30           Three independent clones were sequenced, each of which corresponded to the nucleotide sequence SEQ ID NO:187. The cDNA sequence differed at both the N- and

C-terminal ends from the CARD3X sequence predicted from analysis of genomic exons. SEQ ID NO:187 encodes a polypeptide of 795 amino acids (SEQ ID NO:188), followed by a stop codon. A second open reading frame  
5 begins after the stop codon, and in the same reading frame, and encodes a polypeptide of 180 amino acids (SEQ ID NO:189). SEQ ID NO:189 contains several leucine rich repeats.

Subsequent to the identification of the two  
10 polypeptides encoded by SEQ ID NO:187, a publication reported the cloning of a gene designated Nod2 cloned (Ogura et al., J. Biol. Chem. 276:4812-4818 (2001)). The published Nod2 sequence has additional N-terminal amino acids relative to SEQ ID NO:188 and, instead of  
15 the stop codon between the residues that encode SEQ ID NO:188 and SEQ ID NO:189, additional coding sequence is present, which encodes several additional leucine rich repeats. The published Nod2 sequence is 1040 amino acids.

20 It is proposed that SEQ ID NO:188 is a splice variant form of CARD3X/Nod2 that does not contain an LRR domain. The LRR of Nod2 has been shown to interfere with the ability of the protein to activate NFkB (Ogura et al., supra (2001)). Therefore, SEQ ID  
25 NO:188 is likely expressed under physiological conditions in which activation of NFkB is required.

Human CARD3X cDNA sequences were used as a query for BLAST searches of several mouse databases. A  
30 genomic sequence, SEQ ID NO:190, was identified. Nucleotides 191-614 of SEQ ID NO:190 are homologous to the ANGIO-R coding region of human CARD3X. Nucleotides 193-612 of SEQ ID NO:191 were predicted to encode SEQ

ID NO:191, which is highly homologous to amino acids 214-341 of the ANGIO-R domain of human CARD3X (SEQ ID NO:176).

PCR was then performed on mouse genomic DNA  
5 obtained from C57B6 and NIH3T3 cell lines, using the following primers: Forward primer:  
5'-CTGCAGAAGGCTGAGCCACACAACCT-3' (SEQ ID NO:194),  
Reverse primer: 5'-ACAGAGTTGTAATCCAGCTGTAGGGCCACA-3' (SEQ ID NO:195). The PCR product so obtained was  
10 sequenced (SEQ ID NO:192), and shown to have several nucleotide differences as compared to the corresponding region of SEQ ID NO:190. The predicted amino acid sequence encoded by SEQ ID NO:192 (designated SEQ ID NO:193) had a single amino acid difference in  
15 comparison with SEQ ID NO:191.

Both the CARD-A and CARD-B domains are independently cloned into pcDNA3 with epitope tags such as myc or HA, as described above, and binding of the CARD domains is tested with co-immunoprecipitation to  
20 test binding of CARD3X CARD domains with other known CARD domains, as described above.

The NB-ARC domain is cloned into a yeast two-hybrid vector and into pcDNA3 with two alternative epitope tags (e.g., myc and Flag) to determine whether  
25 the NB-ARC domain self-associates in an ATP-dependent manner/P-loop mutation. The P-loop, which binds the gamma phosphate of ATP in the NB-ARC domain, is mutated to remove a conserved Lys in the consensus P-loop sequence G-S/T-K, where Lys is generally mutated to  
30 Met. The NB-ARC domain is also tested for binding to the NB-domains of other CED-4 like proteins (e.g., apaf1, nod1, nac).

12.0      *Characterization of COP-1.* Using the amino-acid sequence of the caspase-1 prodomain as a query for BLASTn searches of the public databases, a human EST clone (GenBank accession number AA070591) was identified containing an ORF encoding a 97 amino-acid protein (SEQ ID NO:86) predicted to share 92% sequence identity with the CARD of pro-caspase-1 (SEQ ID NO:87). The predicted protein contains a CARD (residues 1-91), which is followed by 6 amino-acids and then a stop-codon. The CARD region of COP-1 showed 97% identity to the CARD of pro-caspase-1.

To confirm the predicted sequences, cDNAs were amplified from various adult human tissues and sequenced. The sequenced COP-1 cDNA (SEQ ID NO:85) had the same nucleotide sequence as the original EST.

The start codon initiating the ORF in the COP-1 cDNA clones resides in a favorable context for translation, and is preceded by an in-frame stop codon. The 3'- untranslated region contains TAAA and TATA motifs, typical of short-lived mRNAs which are subject to post-transcriptional regulation, and a candidate polyadenylation signal sequence (AATAAA). Thus, this protein contains essentially only a CARD, prompting the moniker CARD Only Protein (COP-1).

To determine the genomic organization of the COP-1 gene, the COP-1 cDNA nucleotide sequence was employed for searches of the High Throughput Genomic Sequence (HTGS) database, resulting in identification of three genomic clones containing the COP-1 gene (GenBank accessions numbers AC027011, AP001153 and AP002787). Comparison of the COP-1 cDNA and genomic

DNA sequences suggests a three exon structure, in which only the first two amino-acids are encoded in exon 1 and only the last 5 residues are encoded in exon 3, such that most of the coding regions (including the entire CARD) are derived from exon 2. The introns separating exons 1, 2, and 3 are 631 and 844 bp in length, respectively, containing consensus dinucleotide splice donor (GT) and splice acceptor (AG) motifs.

The COP-1 genomic clones identified in the HTSG database have been mapped to human chromosome 11q22, which is the same chromosomal region where the pro-caspase-1 gene resides, as well as pro-caspase-4, pro-caspase-5, and ICEBERG. To address the genomic localization of COP, pro-caspase-4, pro-caspase-5, and ICEBERG genes in chromosome 11, the public database of Human Genome Project Working Draft ([www.genome.cse.ucsc.edu](http://www.genome.cse.ucsc.edu)) was searched, and the order of these genes from centromere to telomere was determined to be pro-caspase-4, pro-caspase-5, pro-caspase-1, COP, and ICEBERG. This result suggests that COP-1 is a separate gene, presumably arising from duplication of other homologous genes in this locus.

**14.1 COP-1 expression.** To study the expression of COP-1, Northern blot analysis was performed using RNA derived from several adult human tissues and a <sup>32</sup>P-labeled COP-1 cDNA probe. Blots containing polyA-selected mRNA from various adult tissues (Clontech, Palo Alto, CA) were hybridized using a <sup>32</sup>P-labeled COP-1 cDNA probe. The probe represented a 570 bp length cDNA containing portions of the 5'-untranslated region, the complete ORF, and portions of the 3'-untranslated region of COP. The COP-1 probe (from the EST clone corresponding to AA070591 obtained

from the I.M.A.G.E. Consortium (Washington University School of Medicine, St. Louis, MO)) was excised from the plasmid by restriction digestion with EcoRI and XhoI, gel-purified, and radiolabeled by the random  
5 priming method using [ $\alpha$ - $^{32}$ P] dCTP and a kit from Ambion (Austin, TX). After hybridization, heat-denatured probe was annealed for 1 hr at 68°C with QuickHyb Hybridization Solution (Stratagene, La Jolla, CA) and then blots were washed with solutions containing 2x  
10 SSC, 0.1% (w/v) SDS (twice each for 15 min at 25°C) followed by 0.1x SSC, 0.1% (w/v) SDS (twice for 10 min at 40°C). Bands were visualized by autoradiography.

Hybridizing bands of approximately 0.6 kbp, 1.5 kbp and 2.6 kbp were identified, with the 0.6 kbp  
15 band representing the most abundant of these transcripts and presumably corresponding to the fully-spliced COP-1 mRNA. The less abundant larger 1.5 kbp and 2.6 kbp transcripts could represent unspliced precursors. Alternatively, the 2.6 kbp mRNA could  
20 represent pro-caspase-1 mRNA, resulting from probe cross-hybridization. The 0.6 kbp COP-1 mRNA was most abundant in spleen, followed by liver, placenta, and peripheral blood leukocytes (PBL). However, most tissues (including heart, muscle, colon, kidney,  
25 intestine and lung) were shown to contain at least some detectable 0.6 kbp COP-1 mRNA.

To corroborate the Northern blot analysis, COP-1 mRNA expression in adult human tissues was also examined using RT-PCR and COP-specific primers. cDNA  
30 samples derived from multiple human adult tissues (Clontech, Palo Alto, CA) were amplified using a set of COP-specific primers (a forward primer 5'-GAAGACAGTTACCTGGCAGA-3' (SEQ ID NO:147) and a

reverse primer 5'-TTGTATTCTGAACATGGCACC-3' (SEQ ID NO:148)). The resulting PCR products were size-fractionated by electrophoresis in 1.5% agarose gels, then stained with ethidium bromide for UV-  
5 photography. In some cases, bands were excised from gels, purified, and sequenced, thus verifying amplification of the correct product by the RT-PCR assay.

RT-PCR analysis showed that COP-1 mRNA was  
10 expressed in all tissues analyzed (brain, heart, muscle, colon, spleen, kidney, liver, intestine, placenta, lung and PBL), except thymus. Parallel RT-PCR analysis of  $\beta$ -actin mRNA served as a control. In general, the relative levels of COP-1 mRNA detected  
15 by RT-PCR were in agreement with the Northern blot data.

14.2 *COP-1 interactions.* The prodomain of pro-caspase-1 is required for dimerization and activation of this zymogen. Since the prodomain of  
20 COP-1 shares a high-degree of amino-acid sequence identity with the prodomain of caspase-1, the possibility that COP-1 interacts with pro-caspase-1 in co-immunoprecipitation assays was tested. Interactions with several other CARD-containing proteins were also  
25 tested, including COP-1 itself, RIP2, Bcl-10, cIAP1, cIAP2 and pro-caspase-9.

For these experiments, the entire open reading frame (ORF) of COP-1 was amplified by PCR using the primers (5'-CCAGAATTCATGGCCGACAAGGTCCTGAAG-3' (SEQ  
30 ID NO:145) (forward) and 5'-CCACTCGAGCTAATTTCCAGGTATCGGACC-3' (SEQ ID NO:146) (reverse). The COP-1 PCR product was digested with

EcoRI/XhoI and ligated into mammalian expression vectors pcDNA3-Myc, pcDNA3-HA and pcDNA3-Flag at the EcoRI/XhoI cloning sites. Plasmids encoding wild-type pro-caspase-1, RIP2, and pro-IL-1 $\beta$  were as described in  
5 Thome et al., Curr. Biol. 8:885-888 (1998); Nett-Fiordalisi et al., J. Leukoc. Biol. 58:717-724 (1995); and Wang et al., J. Biol. Chem. 271:20580-20587 (1996).

A pro-caspase-1 Cys 285 Ala mutant was made  
10 from wild-type caspase-1 plasmid by site- directed mutagenesis, using a commercially available kit (Stratagene, La Jolla, CA) and the primers 5'-GATCATCATCCAGGCCGCCCCGTGGTGACAGCCCTGG-3' (SEQ ID NO:149) and 5'-CCAGGGCTGTCACCACGGGCGGCCTGGATGATGATC-3' (SEQ ID NO:150). A truncation mutant of pro-caspase-1  
15 in which a stop codon was introduced downstream of the CARD was created by PCR using primers 5'-CGGAATTCATGGCCGACAAGGTCCTG-3' (SEQ ID NO:151) and CGCTCGAGTTAGTCTTGCATATTAAAGGTAATTCCAGA-3' (SEQ ID  
20 NO:152).

Human embryonic kidney 293T cells were cultured at 37°C in 5% CO<sub>2</sub> in Dulbecco's Modified Eagle's Medium (DMEM) with 10% heat-inactivated fetal bovine serum (FBS). Cells in log phase were  
25 transfected in 60 mm diameter dishes with expression plasmids (5  $\mu$ g total DNA) using Superfect Transfection Reagent (Qiagen, Valencia, CA) according to the manufacturer's recommendations. Cells were harvested 2 days later and lysed in ice-cold NP- 40 lysis buffer  
30 (10 mM HEPES [pH 7.4], 142.5 mM KCl, 0.2% NP-40, 5 mM EGTA), supplemented with 1 mM DTT, 12.5 mM  $\beta$ -glycerophosphate, 1  $\mu$ M Na<sub>3</sub>VO<sub>4</sub>, 1mM PMSF, and 1X protease inhibitor mix (Roche, Indianapolis, IN). Cell

lysates (0.5 ml) were clarified by centrifugation at 16,000xg for 5 minutes, and subjected to immunoprecipitation using specific antibodies, including anti-Myc antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-Flag antibodies (Sigma, St. Louis, MO), in combination with 15 µl Protein A- or G-Sepharose (Zymed, South San Francisco, CA).

Immune-complexes were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to nitrocellulose membranes. The resulting blots were incubated with various antibodies, including anti-HA antibodies (1:1000 v/v; Roche, Indianapolis, IN), anti-Myc antibodies (1:100 v/v; Santa Cruz Biotechnology, Santa Cruz, CA) and anti-Flag antibodies (1: 1000 v/v; Sigma, St. Louis, MO), followed by horseradish peroxidase-conjugated secondary antibodies, and detection by an enhanced chemiluminescence (ECL) method (Amersham-Pharmacia, Piscataway, NJ). Alternatively, lysates were analyzed directly by immunoblotting after normalization for total protein content.

The co-immunoprecipitation results showed that HA-COP-1 co-immunoprecipitated with Myc-COP, indicating that this protein can self-associate. In addition, HA-COP-1 co-immunoprecipitated with Myc-tagged pro-caspase-1 (C285A mutant) as well as with a fragment of pro-caspase-1 containing only its CARD-carrying prodomain. Thus, COP-1 binds pro-caspase-1 through its CARD domain. For these co-immunoprecipitation experiments, the active site cysteine of pro-caspase-1 was mutated to avoid induction of apoptosis, which can occur when

over-expressing this protease. Additionally, Myc-COP-1 co-immunoprecipitated with Flag-RIP2. In contrast, COP-1 did not co-immunoprecipitate with the CARD-containing proteins Bcl-10, cIAP1, cIAP2, or pro-caspase-9, thus demonstrating the specificity of these results.

RIP2 has been shown to bind and activate caspase-1 through the interaction of their CARDS, resulting in oligomerization of pro-caspase-1 and its activation via the "induced proximity" mechanism. The data demonstrating that COP-1 binds to both pro-caspase-1 and RIP2 therefore suggested that COP-1 might function as a modulator of RIP2-induced pro-caspase-1 oligomerization.

To test this hypothesis, experiments were performed in which 293T cells were transiently transfected with expression plasmids encoding Myc-tagged pro-caspase-1 (C285A mutant) and HA-tagged pro-caspase-1 (C285A mutant), with or without Flag-tagged RIP2 and COP, after which Myc-pro-caspase-1 and HA-pro-caspase-1 association was monitored by co-immunoprecipitation assays.

As determined by this co-immunoprecipitation assay, pro-caspase-1 self-associated and this was enhanced by co-expression of RIP2. However, when COP-1 was also co-expressed, this RIP2-mediated effect on pro-caspase-1 self-association was negated. These findings suggested the possibility of a competitive mechanism, in which COP-1 competes with RIP2 for binding to pro-caspase-1. To test this hypothesis, therefore, transfection experiments were performed in which Flag-RIP2 and Myc-tagged pro-caspase-1 (C285A

mutant) were expressed in 293T cells in the presence of increasing amounts of HA-tagged COP-1. The effects of COP-1 on association of RIP2 with pro-caspase-1 were then evaluated by co-immunoprecipitation assays in which immunoprecipitations were performed using anti-Flag antibody to recover Flag-RIP2 protein and the resulting immune-complexes were analyzed by SDS-PAGE/immunoblotting using anti-Myc antibody to detect associated Myc-pro-caspase-1.

The results from these experiments indicated that COP-1 inhibited association of pro-caspase-1 with RIP2 in a dose-dependent manner. Immunoblot analysis of lysates from these same cells demonstrated that COP-1 did not affect the total levels of pro-caspase-1 or RIP2, but rather just their association. These results therefore confirm that COP-1 can interfere with binding of pro-caspase-1 to RIP2.

*14.3 COP-1 inhibition of caspase-1-mediated activation of pro-IL-1 $\beta$ .* Active caspase-1 cleaves pro-IL-1 $\beta$ , resulting in the generation of bioactive IL-1 $\beta$  which is secreted from cells. It was hypothesized that COP-1 could suppress caspase-1-induced pro-IL-1 $\beta$  processing and thus reduce secretion of IL-1 $\beta$ .

To test this hypothesis, COS-7, 293T, or 293HEK cells were co-transfected in 12 well (22 mm in diameter) plates using Lipofectamine Plus Reagent (GIBCO BRL, Grand Island, NY) with plasmids encoding mouse pro-IL-1 $\beta$ , human caspase-1, RIP2, or COP-1, in various amounts (total DNA = 2.0  $\mu$ g). At 1 day after transfection, supernatants were collected and stored at -80°C or used immediately to quantify secretion of

mature murine IL-1 $\beta$  into the culture medium by an ELISA assay, according to the manufacturer's protocol (R&D systems, Minneapolis, MN).

Co-expression of pro-caspase-1 and pro-IL-1 $\beta$  in COS-7 cells resulted in secretion of mature IL-1 $\beta$  ranging from 80 pg/ml to 250 pg/ml, which was proportional to the amount of pro-caspase-1 plasmid used (Figure 17). This IL-1 $\beta$  secretion was enhanced by co-expression of RIP2 plasmid. In contrast, expression of COP-1 together with pro-caspase-1, pro-IL-1 $\beta$ , and RIP2 resulted in a dose-dependent decrease in the amount of mature IL-1 $\beta$  secretion, proportional to the amount of COP-1-encoding plasmid used (Figure 6). Similar results were obtained using 293T or 293HEK cells. These results indicate that COP-1 is capable of suppressing the caspase-1-mediated secretion of IL-1 $\beta$ .

15.0 *Identification of COP-2.* A human CARD-containing proteins, designated COP-2, for CARD-only protein 2, was identified and the gene and cDNA cloned. The predicted protein of COP-2 has high sequence similarity to the CARD-domain of human caspase-1. For COP-2, two primers based on the caspase-15 genomic sequence were designed, one in the middle of the CARD domain (5'-aagaagagacggctgcttatcaat-3'; SEQ ID NO:104) and the other in the catalytic domain (5'-ccacagcaggcctcgaagatgac-3'; SEQ ID NO:105). RT-RTR was performed, and a single band was observed, although the band size was smaller than expected for caspase-15. The PCR product was sequenced, and it was found that two exons were deleted and the catalytic domain was directly connected to the CARD domain. However, due to a frameshift, a stop codon occurs just after the CARD domain, resulting in truncated protein and no translation of the catalytic domain.

To clone the N-terminal region, a primer (5'-atgatacctcctgaagaagag-3'; SEQ ID NO:106) was designed with the genomic sequence in the most N-terminal portion of the CARD domain including ATG. RT-PCR was performed, and the PCR product was sequenced and found to be the same as in the genomic DNA. A merged construct containing both the N-terminal fragment and the CARD domain sequence was made by PCR.

The COP-2 cDNA sequence identified contained 321 nucleotides (SEQ ID NO:89), and the deduced amino acid sequence (SEQ ID NO:90) had a high level of identity with caspase-1. An alignment of COP-2 (SEQ ID NO:90) and caspase-1 (SEQ ID NO:87) is shown in Figure 5, with the consensus sequence (SEQ ID NO:91) shown above the aligned sequences. The amino acids shaded in black are identical. The stippled shading represents a match within 3 distance units. COP-2 is encoded by the caspase-15 gene (Figure 3), but COP-2 is a CARD only protein that lacks the caspase catalytic domain.

COP-2 cDNA encodes a polypeptide with downstream termination codons, which result in shorter proteins containing a CARD domain without associated catalytic protease domains. COP-2 is therefore expected to function as trans-dominant inhibitor that likely prevents caspase activation by binding to the CARD-domains (pro-domains) in pro-enzymes such as pro-caspase-1.

COP-2 polypeptide is expected to function as A regulator of caspase-1 activation by enhancing or suppressing the activation of caspase-1. COP-2 binding activity is tested, for example, by making epitope tagged fusions with COP-2 and caspase-1 and

co-immunoprecipitating to determine binding interactions with caspase-1. Antibodies specific for COP-2 are also made.

The effect of COP-2 on caspase-1 proteolytic activity is also tested. Methods for measuring caspase activity are well known (see, for example, Thornberry, Nature 356:768-774 (1992); Thornberry and Molineaux, Protein Science 4:3-12 (1995); Rano et al., Chem. Biol. 4:149-155 (1997); Fletcher et al., J. Interferon Cytokine Res. 15:243-248 (1995)), and are also described above.

All journal article, reference and patent citations provided above, in parentheses or otherwise, whether previously stated or not, are incorporated herein by reference in their entirety.

Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention.

We claim:

1. An isolated nucleic acid molecule  
encoding a CARD-containing polypeptide, or a CARD, NB-  
ARC, ANGIO-R, LRR or SAM domain therefrom, selected  
5 from:

(a) DNA encoding a polypeptide  
comprising the amino acid sequence set forth  
in SEQ ID NOS: 12, 168, 188, 170, 172, 174,  
176, 97, 99, 101, 103, 178, 180, 182, 184, 86  
10 and 90; and

(b) DNA that hybridizes to the DNA of  
(a) under moderately stringent conditions,  
wherein said DNA encodes a biologically  
active polypeptide.

15 2. The nucleic acid molecule of claim 1,  
wherein the nucleotide sequence of said nucleic acid  
molecule comprises any of SEQ ID NOS:11, 167, 187, 169,  
171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85  
and 89.

20 3. The nucleic acid molecule of claim 1,  
wherein said nucleic acid molecule is cDNA.

4. A vector containing the nucleic acid  
molecule of claim 1.

5. Recombinant cells containing the nucleic  
25 acid molecule of claim 1.

6. An isolated oligonucleotide comprising  
at least 15 contiguous nucleotides of the nucleic acid  
molecule of claim 2.

7. An oligonucleotide according to claim 6, wherein said oligonucleotide is labeled with a detectable marker.

8. A kit for detecting the presence of  
5 CARD-encoding nucleic acid molecule comprising at least one oligonucleotide according to claim 6.

9. An isolated CARD-containing polypeptide, or a CARD, NB-ARC, ANGIO-R, LRR or SAM domain therefrom, comprising an amino acid sequence at least  
10 70% identical to the amino acid sequence set forth in any of SEQ ID NOS:12, 168, 188, 170, 172, 174, 176, 97, 99, 101, 103, 178, 180, 182, 184, 86 and 90.

10. The CARD-containing polypeptide of claim  
15 9, wherein said polypeptide is encoded by a nucleotide sequence set forth as any of SEQ ID NOS:11, 167, 187, 169, 171, 173, 175, 96, 98, 100, 102, 177, 179, 181, 183, 85 and 89.

11. A peptide, comprising at least 10  
20 contiguous amino acids of the polypeptide of claim 9.

12. A method of producing a CARD-containing polypeptide comprising expressing the cDNA of claim 3 *in vitro* or in a cell under conditions suitable for expression of said polypeptide, wherein said cells are  
25 selected from the group consisting of bacteria cells, yeast cells, plant cells, animal cells, mammalian cells and insect cells.

13. An isolated anti-CARD antibody having specific reactivity with the CARD-containing  
30 polypeptide of claim 9.

14. The antibody of claim 13, wherein said antibody is a monoclonal antibody.

15. A cell line producing the monoclonal antibody of claim 14.

5 16. The antibody of claim 13, wherein said antibody is a polyclonal antibody.

17. A method for identifying a nucleic acid molecule encoding a CARD-containing polypeptide, said method comprising:

10 contacting a sample containing nucleic acids with an oligonucleotide according to claim 6, wherein said contacting is effected under high stringency hybridization conditions, and identifying a nucleic acid molecule which hybridizes thereto.

15 18. A method for detecting the presence of a CARD-containing polypeptide in a sample, said method comprising contacting a test sample with an antibody according to claim 13, detecting the presence of an antibody:CARD complex, and thereby detecting the  
20 presence of a human CARD-containing polypeptide in said test sample.

19. A method of identifying a CARD-associated polypeptide (CAP) comprising the steps of:

(a) contacting the CARD-containing  
25 polypeptide of claim 9 with a candidate CAP;  
(b) detecting association of said CARD-containing polypeptide with said CAP.

20. A method of identifying an effective agent that alters the association of a CARD-containing polypeptide with a CARD-associated polypeptide (CAP), comprising the steps of:

- 5 (a) contacting the CARD-containing polypeptide of claim 9 and said CAP under conditions that allow said CARD-containing polypeptide and said CAP to associate with an agent suspected of being able to alter the  
10 association of said CARD-containing polypeptide and said CAP; and
- (b) detecting the altered association of said CARD-containing polypeptide and said CAP, wherein said altered association  
15 identifies an effective agent.

21. A method of identifying an effective agent that alters the association of a CARD-containing polypeptide with a CARD-associated polypeptide (CAP), comprising the steps of:

- 20 (a) contacting the CARD-containing polypeptide of claim 9 and said CAP under conditions that allow said CARD-containing polypeptide and said CAP to associate with an agent suspected of being able to alter the  
25 association of said CARD-containing polypeptide and said CAP; and
- (b) detecting the altered association of said CARD-containing polypeptide and said CAP, wherein said altered association  
30 identifies an effective agent, wherein said CAP is a CARD-containing polypeptide according to claim 9.

22. A method of altering the level of a biochemical process modulated by a CARD-containing polypeptide, comprising the steps of:

- 5 (a) introducing the nucleic acid molecule of claim 1 into a cell; and
- (b) expressing said nucleic acid molecule in said cell, whereby the expression of said nucleic acid alters the level of a biochemical process modulated by a CARD-  
10 containing polypeptide.

23. The method of claim 22, wherein said biochemical process modulated by a CARD-containing polypeptide is selected from the group consisting of apoptosis, NF-kB induction, cytokine processing, cJun  
15 N-terminal kinase induction, caspase-mediated proteolysis, transcription, inflammation and cell adhesion.

24. A method of altering the level of a biochemical process modulated by a CARD-containing  
20 polypeptide, comprising introducing an antisense nucleotide sequence into a cell, wherein said antisense nucleotide sequence specifically hybridizes to a nucleic acid molecule encoding the CARD-containing polypeptide of claim 11, whereby hybridization reduces  
25 or inhibits the expression of said CARD-containing polypeptide in said cell.

25. A method of altering the level of a biochemical process modulated by a CARD-containing polypeptide, comprising contacting a sample with an  
30 agent that effectively alters the association of the CARD-containing polypeptide of claim 9 with a CARD-associated polypeptide, whereby the level of a

biochemical process modulated by a CARD-containing polypeptide is altered.

26. A method of diagnosing or predicting clinical prognosis of a pathology characterized by an increased or decreased level of a CARD-containing polypeptide in a subject, comprising the steps of:

(a) obtaining a test sample from the subject;

(b) contacting said test sample with an agent that can bind the CARD-containing polypeptide of claim 9 under suitable conditions, which allow specific binding of said agent to said CARD-containing polypeptide; and

(c) comparing the amount of said specific binding in said test sample with the amount of specific binding in a reference sample, wherein an increased or decreased amount of said specific binding in said test sample as compared to said reference sample is diagnostic or predictive of clinical prognosis of a pathology.

27. A composition comprising a compound selected from the group consisting of a CARD-containing polypeptide, a functional fragment therefrom, and an anti-CARD antibody; and a pharmaceutically acceptable carrier.

28. A method of treating a pathology characterized by abnormal cell proliferation, abnormal cell death, or inflammation, said method comprising administering to an individual an effective amount of the composition of claim 27.

29. A chimeric polypeptide comprising a domain selected from the group consisting of SEQ ID NOS:168, 170, 172, 174, 176, 178, 180, 182 and 184.

30. A method of identifying an effective agent that modulates an activity of a NB-ARC domain of a CARD-containing polypeptide, comprising the steps of:

(a) contacting a polypeptide comprising an NB-ARC domain set forth as either of SEQ ID NOS:174 or 180 with an agent known or suspected of modulating an activity of an NB-ARC domain; and

(b) measuring the activity of the NB-ARC domain, whereby an increase or decrease of said activity identifies said agent as an agent that modulates the activity of the NB-ARC domain of said CARD-containing polypeptide;

wherein the activity of the NB-ARC domain of said CARD-containing polypeptide is selected from homo-oligomerization, hetero-oligomerization, nucleotide hydrolysis, and nucleotide binding.




Figure 1A




Figure 1B




Figure 1C

2/5

CLANA	WNTFKDUSRALIQRMGHTVIKQITDDLFVHVVLRREEVNIICCEKVEQDAARGIITHMILKKCSSES
CLANB	WNTFKDUSRALIQRMGHTVIKQITDDLFVHVVLRREEVNIICCEKVEQDAARGIITHMILKKCSSES
CLANG	WNTFKDUSRALIQRMGHTVIKQITDDLFVHVVLRREEVNIICCEKVEQDAARGIITHMILKKCSSES
CLAND	WNTFKDUSRALIQRMGHTVIKQITDDLFVHVVLRREEVNIICCEKVEQDAARGIITHMILKKCSSES
CLANA	CNLFPLKSLKEWNTPLFQDLNGOSLEHQTSECDLDDLAQDLKDYHTPSTLWNTPLCEDIDITPL
CLANB	CNLFPLKSLKEWNTPLFQDLNGO-----
CLANG	CNLFPLKSLKEWNTPLFQDLNGOSLEHQTSECDLDDLAQDLKDYHTPSTLWNTPLCEDIDITPL
CLAND	CNLFPLKSLKEWNTPLFQDLNGOSLEHTA
CLANA	KSTFTEDPLWAKDQHHHRVEQLTEENGLLQALQSPCIEGESGKCKSTLLQRIANLWGSCKKALT
CLANB	-----
CLANG	KSTFTEDPLWAKDQHHHRVEQLTEVL
CLANA	KFKFVFFLRLSRAQGGLFETLCDQLLDIPGTIRKQTFNAMLLKLQRVLFLLDGYNEFKPPQNCPE
CLANB	-----
CLANA	IRALIKENHRFKNMVIVTTTTTECLRHIRQFGALTAEVGDMTEDSAQALIREVLIKELAEGLLLQI
CLANB	-----
CLANA	QKSRCCLRNLMTPLFVVITCAIQMGSEFHSHTQTTLFHTPYDLLIQNKHKHKGVAASDFIRSL
CLANB	-----
CLANA	DHRGDLALEGVFSHKFDPELQDVSSVNEVDLLTTGLLCKYTAQRFPKPKYKFFHKSPQEVYTAGRRL
CLANB	-----
CLANA	SSLLTSHEPEEVTKNGCYLQKMVSISDITSTYSSLLRYTCGSSVEATRAVMKHLAAVYQHGCCLLG
CLANB	-----
CLANA	LSIAKRPLWRQESLQSVKNTTEQEILKAININSFVECGINLYQESTSKSALSQEPFAFFQGSLEY
CLANB	-----
CLANA	INSGNIPDYLFDPFEPHLPNCASALDFIKLDPYGGANASWEXAAEDTCGINMEEAPRTYIPSRAYS
CLANB	-----
CLANA	LFPNWKQEFRTLEVTLRDFSKLNKQDIRYLGKIFSSATSLRLQIKRCAGVAGSLSLVLSTCKNIY
CLANB	-----
CLANA	SLMVEASPLTIEDERHITSVTNLKTLSDHDLQNRLP
CLANB	-----
CLANA	TKLAEGLKLNKKMKLEHLLTHLSDIGEGMDYIVKSLSSSEPCDEEYQLVSSGCLSANAVKILAQNLEH
CLANB	TKLAEGLKLNKKMKLEHLLTHLSDIGEGMDYIVKSLSSSEPCDEEYQLVSSGCLSANAVKILAQNLEH
CLANA	WLVKLSILDLSSENYLEKDCNEALHETIDRMNVLEQLTALMLPWCEDVQCSLSSSLKHLBEVPQLV
CLANB	WLVKLSILDLSSENYLEKDCNEALHETIDRMNVLEQLTALMLPWCEDVQCSLSSSLKHLBEVPQLV
CLANA	KLGKLNWRLTDTEIRILCAFFTEKNPLKNFTQQLNLACNRVSSDGNLAFHGVFENLKQLVFFEDFSTK
CLANB	KLGKLNWRLTDTEIRILCAFFTEKNPLKNFTQQLNLACNRVSSDGNLAFHGVFENLKQLVFFEDFSTK
CLANA	EFLPDPAIVRKLSQVLSKLTFLQEARLVCHQEDDDDLSSVITCAFKLVTA
CLANB	EFLPDPAIVRKLSQVLSKLTFLQEARLVCHQEDDDDLSSVITCAFKLVTA

Fig. 2

3/5




Figure 3

4/5

COP    **MADKVLKEKRKLFHSMGECTINGLLDELL** 30  
 caspase-1 **MADKVLKEKRKLFIRSMGECTINGLLDELL** 30  
  
**QTRVLNQEEMEKVKRENATVMDKTRALIDS** 60  
**QTRVLNK EEMEKVKRENATVMDKTRALIDS** 60  
  
**VIPKGAQACQICITYICEEDSYLAETLGLS** 90  
**VIPKGAQACQICITYICEEDSYLAGTLGLS** 90  
  
**AGPIRGN** 97  
**ADQTS GN** 97

Figure 4

MADKVLLEKRKLLINSLGEGTINGLLDELLEETNVLSQEDM Majority  
 10 20 30 40  
 1 **MADKVLKEKRKLFIRSMGECTINGLLDELLQTRVLNKEEM** cas-1  
 1 **M- - ILLKKRRLINSLGEGTINGLLDELLEETNVLSQEDT** cop-2  
  
 EIVKRENATVIDKARALLDSVIRKGAGACEICITYICEED Majority  
 50 60 70 80  
 41 **EKVKRENATVMDKTRALIDSVIPKGAQACQICITYICEED** cas-1  
 38 **EIVKCEENVTVIDKARDLLDSVIRKGAGACEICITYICEED** cop-2  
  
 SYLAGTLGLSAGNAVQAGGACSTSSGQDL Majority  
 90 100  
 81 **SYLAGTLGLSAPQAVQDNPA MPTSSG** cas-1  
 78 **RYLAGTLGLSAGNDYRAGGICSP PRAQDL** cop-2

Figure 5

5/5




Figure 6

## SEQUENCE LISTING

<110> The Burnham Institute  
    Reed, John C.  
    Pio, Frederick F.  
    Godzik, Adam  
    Stehlik, Christian  
    Damiano, Jason S.  
    Lee, Sug-Hyung  
    Oliveira, Vasco A.  
    Hayashi, Hideki  
    Pawlowski, Krzysztof

<120> Novel Card Domain Containing  
    Polypeptides, Encoding Nucleic Acids, and Methods of Use

<130> FP-LJ 4665

<150> US 09/579,240  
<151> 2000-05-24

<150> US 09/686,347  
<151> 2000-10-10

<150> US 60/275,980  
<151> 2001-03-14

<160> 195

<170> FastSEQ for Windows Version 4.0

<210> 1

<400> 1  
    000

<210> 2

<400> 2  
    000

<210> 3

<400> 3  
    000

<210> 4

<400> 4  
    000

<210> 5

<400> 5  
000

<210> 6

<400> 6  
000

<210> 7

<400> 7  
000

<210> 8

<400> 8  
000

<210> 9

<400> 9  
000

<210> 10

<400> 10  
000

<210> 11

<211> 1038

<212> DNA

<213> Homo sapien

<220>

<221> CDS

<222> (1)...(930)

<400> 11

atg gct acc gag agt act ccc tca gag atc ata gaa aga gaa aga aaa	48
Met Ala Thr Glu Ser Thr Pro Ser Glu Ile Ile Glu Arg Glu Arg Lys	
1 5 10 15	

aag ttg ctt gaa atc ctt caa cat gat cct gat tct atc tta gac acg	96
Lys Leu Leu Glu Ile Leu Gln His Asp Pro Asp Ser Ile Leu Asp Thr	
20 25 30	

tta act tct cgg agg ctg att tct gag gaa gag tat gag act ctg gag	144
Leu Thr Ser Arg Arg Leu Ile Ser Glu Glu Glu Tyr Glu Thr Leu Glu	
35 40 45	

aat gtt aca gat ctc ctg aag aaa agt cgg aag ctg tta att ttg gta	192
Asn Val Thr Asp Leu Leu Lys Lys Ser Arg Lys Leu Leu Ile Leu Val	
50 55 60	

cag aaa aag gga gag gcg acc tgt cag cat ttt ctc aag tgt tta ttt	240
---	-----

Gln	Lys	Lys	Gly	Glu	Ala	Thr	Cys	Gln	His	Phe	Leu	Lys	Cys	Leu	Phe	
65					70					75					80	
agt	act	ttt	cca	cag	tca	gct	gcc	att	tgc	ggc	tta	agg	cat	gaa	gtt	288
Ser	Thr	Phe	Pro	Gln	Ser	Ala	Ala	Ile	Cys	Gly	Leu	Arg	His	Glu	Val	
			85					90						95		
tta	aaa	cat	gag	aat	aca	gta	cct	cct	caa	tct	atg	ggg	gca	agc	agt	336
Leu	Lys	His	Glu	Asn	Thr	Val	Pro	Pro	Gln	Ser	Met	Gly	Ala	Ser	Ser	
			100					105					110			
aat	tca	gaa	gat	gct	ttt	tct	cct	gga	ata	aaa	cag	cct	gaa	gcc	cct	384
Asn	Ser	Glu	Asp	Ala	Phe	Ser	Pro	Gly	Ile	Lys	Gln	Pro	Glu	Ala	Pro	
		115					120					125				
gag	atc	aca	gtg	ttc	ttc	agt	gag	aag	gaa	cac	ttg	gat	ttg	gaa	acc	432
Glu	Ile	Thr	Val	Phe	Phe	Ser	Glu	Lys	Glu	His	Leu	Asp	Leu	Glu	Thr	
	130					135					140					
tct	gag	ttt	ttc	agg	gac	aag	aaa	act	agt	tat	agg	gaa	aca	gct	ttg	480
Ser	Glu	Phe	Phe	Arg	Asp	Lys	Lys	Thr	Ser	Tyr	Arg	Glu	Thr	Ala	Leu	
145					150					155					160	
tct	gcc	agg	aag	aat	gag	aag	gaa	tat	gac	aca	cca	gaa	gtc	aca	tta	528
Ser	Ala	Arg	Lys	Asn	Glu	Lys	Glu	Tyr	Asp	Thr	Pro	Glu	Val	Thr	Leu	
			165					170						175		
tca	tat	tca	gtt	gag	aaa	gtt	gga	tgt	gaa	gtt	cca	gca	act	att	aca	576
Ser	Tyr	Ser	Val	Glu	Lys	Val	Gly	Cys	Glu	Val	Pro	Ala	Thr	Ile	Thr	
			180					185					190			
tat	ata	aaa	gat	gga	cag	aga	tat	gag	gag	cta	gat	gat	tct	tta	tac	624
Tyr	Ile	Lys	Asp	Gly	Gln	Arg	Tyr	Glu	Glu	Leu	Asp	Asp	Ser	Leu	Tyr	
		195					200					205				
tta	gga	aaa	gag	gaa	tat	cta	gga	tct	gtt	gac	acc	cct	gaa	gat	gca	672
Leu	Gly	Lys	Glu	Glu	Tyr	Leu	Gly	Ser	Val	Asp	Thr	Pro	Glu	Asp	Ala	
	210					215					220					
gaa	gcc	act	gtg	gaa	gag	gag	gtt	tat	gat	gac	cca	gag	cac	gtt	gga	720
Glu	Ala	Thr	Val	Glu	Glu	Glu	Val	Tyr	Asp	Asp	Pro	Glu	His	Val	Gly	
225					230					235				240		
tat	gat	ggt	gaa	gag	gac	ttc	gag	aat	tca	gaa	acc	aca	gag	ttc	tct	768
Tyr	Asp	Gly	Glu	Glu	Asp	Phe	Glu	Asn	Ser	Glu	Thr	Thr	Glu	Phe	Ser	
			245					250						255		
ggt	gaa	gaa	cca	agt	tat	gag	gga	tca	gaa	acc	agc	ctt	tca	ttg	gag	816
Gly	Glu	Glu	Pro	Ser	Tyr	Glu	Gly	Ser	Glu	Thr	Ser	Leu	Ser	Leu	Glu	
			260					265					270			
gag	gaa	cag	gag	aaa	agt	ata	gaa	ggc	tgg	tct	cga	act	cat	ggg	ctt	864
Glu	Glu	Gln	Glu	Lys	Ser	Ile	Glu	Gly	Trp	Ser	Arg	Thr	His	Gly	Leu	
		275					280					285				

aag cga tcc tcc cac gtt ggc ctc cca aag tgc tgg gat tac agg cgt 912  
 Lys Arg Ser Ser His Val Gly Leu Pro Lys Cys Trp Asp Tyr Arg Arg  
 290 295 300

gag cca ccc tgc ctg gcc tgaaaattct gcctcaaaca tctcaaacat 960  
 Glu Pro Pro Cys Leu Ala  
 305 310

ccatttatat tttgtacaag aaagtaaata aaatttttct ttttaacatt aaaaaaaaaa 1020  
 aaaaaaaaaa aatctaga 1038

<210> 12

<211> 310

<212> PRT

<213> Homo sapien

<400> 12

Met Ala Thr Glu Ser Thr Pro Ser Glu Ile Ile Glu Arg Glu Arg Lys  
 1 5 10 15  
 Lys Leu Leu Glu Ile Leu Gln His Asp Pro Asp Ser Ile Leu Asp Thr  
 20 25 30  
 Leu Thr Ser Arg Arg Leu Ile Ser Glu Glu Glu Tyr Glu Thr Leu Glu  
 35 40 45  
 Asn Val Thr Asp Leu Leu Lys Lys Ser Arg Lys Leu Leu Ile Leu Val  
 50 55 60  
 Gln Lys Lys Gly Glu Ala Thr Cys Gln His Phe Leu Lys Cys Leu Phe  
 65 70 75 80  
 Ser Thr Phe Pro Gln Ser Ala Ala Ile Cys Gly Leu Arg His Glu Val  
 85 90 95  
 Leu Lys His Glu Asn Thr Val Pro Pro Gln Ser Met Gly Ala Ser Ser  
 100 105 110  
 Asn Ser Glu Asp Ala Phe Ser Pro Gly Ile Lys Gln Pro Glu Ala Pro  
 115 120 125  
 Glu Ile Thr Val Phe Phe Ser Glu Lys Glu His Leu Asp Leu Glu Thr  
 130 135 140  
 Ser Glu Phe Phe Arg Asp Lys Lys Thr Ser Tyr Arg Glu Thr Ala Leu  
 145 150 155 160  
 Ser Ala Arg Lys Asn Glu Lys Glu Tyr Asp Thr Pro Glu Val Thr Leu  
 165 170 175  
 Ser Tyr Ser Val Glu Lys Val Gly Cys Glu Val Pro Ala Thr Ile Thr  
 180 185 190  
 Tyr Ile Lys Asp Gly Gln Arg Tyr Glu Glu Leu Asp Asp Ser Leu Tyr  
 195 200 205  
 Leu Gly Lys Glu Glu Tyr Leu Gly Ser Val Asp Thr Pro Glu Asp Ala  
 210 215 220  
 Glu Ala Thr Val Glu Glu Glu Val Tyr Asp Asp Pro Glu His Val Gly  
 225 230 235 240  
 Tyr Asp Gly Glu Glu Asp Phe Glu Asn Ser Glu Thr Thr Glu Phe Ser  
 245 250 255  
 Gly Glu Glu Pro Ser Tyr Glu Gly Ser Glu Thr Ser Leu Ser Leu Glu  
 260 265 270  
 Glu Glu Gln Glu Lys Ser Ile Glu Gly Trp Ser Arg Thr His Gly Leu  
 275 280 285  
 Lys Arg Ser Ser His Val Gly Leu Pro Lys Cys Trp Asp Tyr Arg Arg  
 290 295 300

Glu Pro Pro Cys Leu Ala  
305 310

<210> 13

<400> 13  
000

<210> 14

<400> 14  
000

<210> 15

<400> 15  
000

<210> 16

<400> 16  
000

<210> 17

<400> 17  
000

<210> 18

<400> 18  
000

<210> 19

<400> 19  
000

<210> 20

<400> 20  
000

<210> 21

<400> 21  
000

<210> 22

<400> 22  
000

<210> 23

<400> 23  
000

<210> 24

<400> 24  
000

<210> 25

<400> 25  
000

<210> 26

<400> 26  
000

<210> 27

<400> 27  
000

<210> 28

<400> 28  
000

<210> 29

<400> 29  
000

<210> 30

<400> 30  
000

<210> 31

<400> 31  
000

<210> 32

<400> 32  
000

<210> 33

<400> 33  
000

<210> 34

<400> 34  
000

<210> 35

<400> 35  
000

<210> 36

<400> 36  
000

<210> 37

<400> 37  
000

<210> 38

<400> 38  
000

<210> 39

<400> 39  
000

<210> 40

<400> 40  
000

<210> 41

<400> 41  
000

<210> 42

<400> 42  
000

<210> 43

<400> 43  
000

<210> 44

<400> 44  
000

<210> 45

<400> 45  
000

<210> 46

<400> 46  
000

<210> 47

<400> 47  
000

<210> 48

<400> 48  
000

<210> 49

<400> 49  
000

<210> 50

<400> 50  
000

<210> 51

<400> 51  
000

<210> 52

<400> 52  
000

<210> 53

<400> 53  
000

<210> 54

<400> 54  
000

<210> 55

<400> 55  
000

<210> 56

<400> 56  
000

<210> 57

<400> 57  
000

<210> 58

<400> 58  
000

<210> 59

<400> 59  
000

<210> 60

<400> 60  
000

<210> 61

<400> 61  
000

<210> 62

<400> 62  
000

<210> 63

<400> 63  
000

<210> 64

<400> 64  
000

<210> 65

<400> 65  
000

<210> 66

<400> 66  
000

<210> 67

<400> 67  
000

<210> 68

<400> 68  
000

<210> 69

<400> 69  
000

<210> 70

<400> 70  
000

<210> 71

<400> 71  
000

<210> 72

<400> 72  
000

<210> 73

<400> 73  
000

<210> 74

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 74

tacttacttt gtcccttca

19

<210> 75

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 75

tatttgctccc catctcgtc

19

<210> 76  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 76  
cggaattcat ggctaccgag agtactcc

28

<210> 77  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 77  
gtaaaacgac ggccagt

17

<210> 78  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 78  
gcagaagcca ctgtggaaga ggagggt

27

<210> 79  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 79  
atacgactca ctatagggcg aattggcc

28

<210> 80

<220>  
<223> Primer

<400> 80  
000

<210> 81

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 81

000

&lt;210&gt; 82

&lt;211&gt; 3030

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(1680)

&lt;400&gt; 82

tgt gaa atg tgc tgc cag gag gct ttt cag gca cag agg agc cag ctg	48
Cys Glu Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu	
1 5 10 15	
gtc gag ctg ctg gtc tca ggg tcc ctg gaa ggc ttc gag agt gtc ctg	96
Val Glu Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu	
20 25 30	
gac tgg ctg ctg tcc tgg gag gtc ctc tcc tgg gag gac tac gag ggc	144
Asp Trp Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly	
35 40 45	
ttc cac ctc ctg ggc cag cct ctc tcc cac ttg gcc agg cgc ctt ctg	192
Phe His Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu	
50 55 60	
gac acc gtc tgg aat aag ggt act tgg gcc tgt cag aag ctc atc gcg	240
Asp Thr Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala	
65 70 75 80	
gct gcc caa gaa gcc cag gcc gac agc cag tcc ccc aag ctg cat ggc	288
Ala Ala Gln Glu Ala Gln Ala Asp Ser Gln Ser Pro Lys Leu His Gly	
85 90 95	
tgc tgg gac ccc cac tgc ctc cac cca gcc cga gac ctg cag agt cac	336
Cys Trp Asp Pro His Ser Leu His Pro Ala Arg Asp Leu Gln Ser His	
100 105 110	
cgg cca gcc att gtc agg agg ctc cac agc cat gtg gag aac atg ctg	384
Arg Pro Ala Ile Val Arg Arg Leu His Ser His Val Glu Asn Met Leu	
115 120 125	
gac ctg gca tgg gag cgg ggt ttc gtc agc cag tat gaa tgt gat gaa	432
Asp Leu Ala Trp Glu Arg Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu	
130 135 140	
atc agg ttg ccg atc ttc aca ccg tcc cag agg gca aga agg ctg ctt	480
Ile Arg Leu Pro Ile Phe Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu	
145 150 155 160	

gat ctt gcc acg gtg aaa gcg aat gga ttg gct gcc ttc ctt cta caa	528
Asp Leu Ala Thr Val Lys Ala Asn Gly Leu Ala Ala Phe Leu Leu Gln	
165 170 175	
cat gtt cag gaa tta cca gtc cca ttg gcc ctg cct ttg gaa gct gcc	576
His Val Gln Glu Leu Pro Val Pro Leu Ala Leu Pro Leu Glu Ala Ala	
180 185 190	
aca tgc aag aag tat atg gcc aag ctg agg acc acg gtg tct gct cag	624
Thr Cys Lys Lys Tyr Met Ala Lys Leu Arg Thr Thr Val Ser Ala Gln	
195 200 205	
tct cgc ttc ctc agt acc tat gat gga gca gag acg ctc tgc ctg gag	672
Ser Arg Phe Leu Ser Thr Tyr Asp Gly Ala Glu Thr Leu Cys Leu Glu	
210 215 220	
gac ata tac aca gag aat gtc ctg gag gtc tgg gca gat gtg ggc atg	720
Asp Ile Tyr Thr Glu Asn Val Leu Glu Val Trp Ala Asp Val Gly Met	
225 230 235 240	
gct gga ccc ccg cag aag agc cca gcc acc ctg ggc ctg gag gag ctc	768
Ala Gly Pro Pro Gln Lys Ser Pro Ala Thr Leu Gly Leu Glu Glu Leu	
245 250 255	
ttc agc acc cct ggc cac ctc aat gac gat gcg gac act gtg ctg gtg	816
Phe Ser Thr Pro Gly His Leu Asn Asp Asp Ala Asp Thr Val Leu Val	
260 265 270	
gtg ggt gag gcg ggc agt ggc aag agc acg ctc ctg cag cgg ctg cac	864
Val Gly Glu Ala Gly Ser Gly Lys Ser Thr Leu Leu Gln Arg Leu His	
275 280 285	
ttg ctg tgg gct gca ggg caa gac ttc cag gaa ttt ctc ttt gtc ttc	912
Leu Leu Trp Ala Ala Gly Gln Asp Phe Gln Glu Phe Leu Phe Val Phe	
290 295 300	
cca ttc agc tgc cgg cag ctg cag tgc atg gcc aaa cca ctc tct gtg	960
Pro Phe Ser Cys Arg Gln Leu Gln Cys Met Ala Lys Pro Leu Ser Val	
305 310 315 320	
cgg act cta ctc ttt gag cac tgc tgt tgg cct gat gtt ggt caa gaa	1008
Arg Thr Leu Leu Phe Glu His Cys Cys Trp Pro Asp Val Gly Gln Glu	
325 330 335	
gac atc ttc cag tta ctc ctt gac cac cct gac cgt gtc ctg tta acc	1056
Asp Ile Phe Gln Leu Leu Leu Asp His Pro Asp Arg Val Leu Leu Thr	
340 345 350	
ttt gat ggc ttt gac gag ttc aag ttc agg ttc acg gat cgt gaa cgc	1104
Phe Asp Gly Phe Asp Glu Phe Lys Phe Arg Phe Thr Asp Arg Glu Arg	
355 360 365	
cac tgc tcc ccg acc gac ccc acc tct gtc cag acc ctg ctc ttc aac	1152
His Cys Ser Pro Thr Asp Pro Thr Ser Val Gln Thr Leu Leu Phe Asn	

370	375	380	
ctt ctg cag ggc aac ctg ctg aag aat gcc cgc aag gtg gtg acc agc			1200
Leu Leu Gln Gly Asn Leu Leu Lys Asn Ala Arg Lys Val Val Thr Ser			
385	390	395	400
cgt ccg gcc gct gtg tcg gcg ttc ctc agg aag tac atc cgc acc gag			1248
Arg Pro Ala Ala Val Ser Ala Phe Leu Arg Lys Tyr Ile Arg Thr Glu			
	405	410	415
ttc aac ctc aag ggc ttc tct gaa cag ggc atc gag ctg tac ctg agg			1296
Phe Asn Leu Lys Gly Phe Ser Glu Gln Gly Ile Glu Leu Tyr Leu Arg			
	420	425	430
aag cgc cat cat gag ccc ggg gtg gcg gac cgc ctc atc cgc ctg ctc			1344
Lys Arg His His Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu			
	435	440	445
caa gag acc tca gcc ctg cac ggt ttg tgc cac ctg cct gtc ttc tca			1392
Gln Glu Thr Ser Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser			
	450	455	460
tgg atg gtg tcc aaa tgc cac cag gaa ctg ttg ctg cag gag ggg ggg			1440
Trp Met Val Ser Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly			
465	470	475	480
tcc cca aag acc act aca gat atg tac ctg ctg att ctg cag cat ttt			1488
Ser Pro Lys Thr Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe			
	485	490	495
ctg ctg cat gcc acc ccc cca gac tca gct tcc caa ggt ctg gga ccc			1536
Leu Leu His Ala Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro			
	500	505	510
agt ctt ctt cgg ggc cgc ctc ccc acc ctc ctg cac ctg ggc aga ctg			1584
Ser Leu Leu Arg Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu			
	515	520	525
gct ctg tgg ggc ctg ggc atg tgc tgc tac gtg ttc tca gcc cag cag			1632
Ala Leu Trp Gly Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln			
	530	535	540
ctc cag gca gca cag gtc agc cct gat gac att tct ctt ggc ttc ctg			1680
Leu Gln Ala Ala Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu			
545	550	555	560
gtgcgtgccca aaggtgtcgt gccagggagt acggcgcccc tggaattcct tcacatcact			1740
ttccagtgtct tctttgccgc gttctacctg gcactcagt ctgatgtgcc accagctttg			1800
ctcagacacc tcttcaattg tggcaggcca ggcaactcac caatggccag gctcctgccc			1860
acgatgtgca tccaggcctc ggagggaaaag gacagcagcg tggcagcttt gctgcagaag			1920
gccgagccgc acaaccttca gatcacagca gccttctctg cagggctgtt gtcccgaggag			1980
cactggggcc tgctggctga gtgccagaca tctgagaagg ccctgctccg gcgccaggcc			2040
tgtgcccgtg ggtgtctggc ccgcagcctc cgcaagcact tccactccat cccgccagct			2100
gcaccgggtg aggccaagag cgtgcatgcc atgcccgggt tcatctggct catccggagc			2160
ctgtacgaga tgcaggagga gcggctggct cggaaggctg cacgtggcct gaatgttggg			2220

```

cacctcaagt tgacatthttg cagtgtgggc cccactgagt gtgctgccct ggcctttgtg 2280
ctgcagcacc tccggcggcc cgtggccctg cagctggact acaactctgt ggggtgacatt 2340
ggcgtggagc agctgctgcc ttgccttggg gtctgcaagg ctctgtattt gcgcgataac 2400
aatatctcag accgagggcat ctgcaagctc attgaatgtg ctcttactg cgagcaattg 2460
cagaagttag cgctggggaa taactacatc actgccgcgg gagcccaagt gctggccgag 2520
gggctccgag gcaacacctc cttgcagttc ctgggattct ggggcaacag agtgggtgac 2580
gagggggccc agggcctggc tgaagccttg ggtgatcacc agagcttgag gtggctcagc 2640
ctgggtggga acaacatttg cagtgtgggt gcccaagcct tggcactgat gctggcaaag 2700
aacgtcatgc tagaagaact ctgcctggag gagaaccatc tccaggatga aggtgtatgt 2760
tctctcgcag aaggactgaa gaaaaattca agtttgaaaa tcctgaacat aaaaattcat 2820
gcttcgggat tcaacaaact cttggaaagc attttctgca tcctcctggg tgtggaagca 2880
tttttctgc agaaagttgt caagattctt gaagaaatgg tagtcagttg gctagaggtc 2940
aggttgcca ataactgcac cacctaccta ggggcagaag ccctcctgca ggcccttgaa 3000
aggaatgaca ccacctgga agtctggtaa 3030

```

&lt;210&gt; 83

&lt;211&gt; 560

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 83

```

Cys Glu Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu
 1           5           10          15
Val Glu Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu
          20          25          30
Asp Trp Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly
          35          40          45
Phe His Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu
          50          55          60
Asp Thr Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala
          65          70          75          80
Ala Ala Gln Glu Ala Gln Ala Asp Ser Gln Ser Pro Lys Leu His Gly
          85          90          95
Cys Trp Asp Pro His Ser Leu His Pro Ala Arg Asp Leu Gln Ser His
          100         105         110
Arg Pro Ala Ile Val Arg Arg Leu His Ser His Val Glu Asn Met Leu
          115         120         125
Asp Leu Ala Trp Glu Arg Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu
          130         135         140
Ile Arg Leu Pro Ile Phe Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu
          145         150         155         160
Asp Leu Ala Thr Val Lys Ala Asn Gly Leu Ala Ala Phe Leu Leu Gln
          165         170         175
His Val Gln Glu Leu Pro Val Pro Leu Ala Leu Pro Leu Glu Ala Ala
          180         185         190
Thr Cys Lys Lys Tyr Met Ala Lys Leu Arg Thr Thr Val Ser Ala Gln
          195         200         205
Ser Arg Phe Leu Ser Thr Tyr Asp Gly Ala Glu Thr Leu Cys Leu Glu
          210         215         220
Asp Ile Tyr Thr Glu Asn Val Leu Glu Val Trp Ala Asp Val Gly Met
          225         230         235         240
Ala Gly Pro Pro Gln Lys Ser Pro Ala Thr Leu Gly Leu Glu Glu Leu
          245         250         255
Phe Ser Thr Pro Gly His Leu Asn Asp Asp Ala Asp Thr Val Leu Val
          260         265         270

```

Val Gly Glu Ala Gly Ser Gly Lys Ser Thr Leu Leu Gln Arg Leu His  
           275                                  280                                  285  
 Leu Leu Trp Ala Ala Gly Gln Asp Phe Gln Glu Phe Leu Phe Val Phe  
           290                                  295                                  300  
 Pro Phe Ser Cys Arg Gln Leu Gln Cys Met Ala Lys Pro Leu Ser Val  
 305                                  310                                  315                                  320  
 Arg Thr Leu Leu Phe Glu His Cys Cys Trp Pro Asp Val Gly Gln Glu  
                                   325                                  330                                  335  
 Asp Ile Phe Gln Leu Leu Leu Asp His Pro Asp Arg Val Leu Leu Thr  
                                   340                                  345                                  350  
 Phe Asp Gly Phe Asp Glu Phe Lys Phe Arg Phe Thr Asp Arg Glu Arg  
                                   355                                  360                                  365  
 His Cys Ser Pro Thr Asp Pro Thr Ser Val Gln Thr Leu Leu Phe Asn  
 370                                  375                                  380  
 Leu Leu Gln Gly Asn Leu Leu Lys Asn Ala Arg Lys Val Val Thr Ser  
 385                                  390                                  395                                  400  
 Arg Pro Ala Ala Val Ser Ala Phe Leu Arg Lys Tyr Ile Arg Thr Glu  
                                   405                                  410                                  415  
 Phe Asn Leu Lys Gly Phe Ser Glu Gln Gly Ile Glu Leu Tyr Leu Arg  
                                   420                                  425                                  430  
 Lys Arg His His Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu  
                                   435                                  440                                  445  
 Gln Glu Thr Ser Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser  
                                   450                                  455                                  460  
 Trp Met Val Ser Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly  
 465                                  470                                  475                                  480  
 Ser Pro Lys Thr Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe  
                                   485                                  490                                  495  
 Leu Leu His Ala Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro  
                                   500                                  505                                  510  
 Ser Leu Leu Arg Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu  
                                   515                                  520                                  525  
 Ala Leu Trp Gly Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln  
                                   530                                  535                                  540  
 Leu Gln Ala Ala Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu  
 545                                  550                                  555                                  560

&lt;210&gt; 84

&lt;211&gt; 1107

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 84

attctttttt taactttttac ttattcatta ggatgatttc ataatatatt tcctggttta 60  
 gaggaacag gaacaatggc taccgagagt actccctcag agatcataga aagagaaaga 120  
 aaaaagtgtc ttgaaatcct tcaacatgat cctgattcta tcttagacac gttaacttct 180  
 cggaggctga tttctgagga agagtatgag actctggaga atgttacaga tctcctgaag 240  
 aaaagtcgga agctgttaat tttggtacag aaaaagggag aggcgacctg tcagcatttt 300  
 ctcaagtgtt tatatttagtac ttttccacag tcagctgccca tttgcggctt aaggcatgaa 360  
 gttttaaaac atgagaatac agtacctcct caatctatgg gggcaagcag taattcagaa 420  
 gatgcttttt ctctggaat aaaacagcct gaagcccctg agatcacagt gttcttcagt 480  
 gagaaggaac acttggaatt ggaaacctct gagtttttca gggacaagaa aactagttat 540  
 agggaaacag ctttgtctgc caggaagaat gagaaggaat atgacacacc agaagtcaca 600  
 ttatcatatt cagttgagaa agttggatgt gaagttccag caactattac atatataaaa 660

```

gatggacaga gatatgagga gctagatgat tctttatact taggaaaaga ggaatatcta 720
ggatctgttg acaccctga agatgcagaa gccactgttg aagaggaggt ttatgatgac 780
ccagagcacg ttggatatga tgggtgaagag gacttcgaga attcagaaac cacagagttc 840
tctggtgaag aaccaagtta tgagggatca gaaaccagcc tttcattgga ggaggaacag 900
gagaaaagta tagaaggctg gtctcgaact catgggctta agcgatcctc ccacgttggc 960
ctcccaaagt gctgggatta caggcgtgag ccaccctgcc tggcctgaaa attctgcctc 1020
aaacatctca aacatccatt tatattttgt acaagaaagt aaataaaaatt tttcttttta 1080
acattaaaaa aaaaaaaaaa aaaaaaa 1107

```

&lt;210&gt; 85

&lt;211&gt; 510

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (15) ... (305)

&lt;400&gt; 85

```

aggagagaaa agcc atg gcc gac aag gtc ctg aag gag aag aga aag ctg 50
                Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu
                1                5                10

ttt atc cat tcc atg ggt gaa ggt aca ata aat ggc tta ctg gat gaa 98
Phe Ile His Ser Met Gly Glu Gly Thr Ile Asn Gly Leu Leu Asp Glu
    15                20                25

tta tta cag aca agg gtg ctg aac cag gaa gag atg gag aaa gta aaa 146
Leu Leu Gln Thr Arg Val Leu Asn Gln Glu Glu Met Glu Lys Val Lys
    30                35                40

cgt gaa aat gct aca gtt atg gat aag acc cga gct ttg att gac tcc 194
Arg Glu Asn Ala Thr Val Met Asp Lys Thr Arg Ala Leu Ile Asp Ser
    45                50                55                60

gtt att ccg aaa ggg gca cag gca tgc caa att tgc atc aca tac att 242
Val Ile Pro Lys Gly Ala Gln Ala Cys Gln Ile Cys Ile Thr Tyr Ile
    65                70                75

tgt gaa gaa gac agt tac ctg gca gag acg ctg gga ctc tca gca ggt 290
Cys Glu Glu Asp Ser Tyr Leu Ala Glu Thr Leu Gly Leu Ser Ala Gly
    80                85                90

ccg ata cct gga aat tagcttagct tagtacacaa gactcccaat tactatatttc 345
Pro Ile Pro Gly Asn
    95

ttccttccca gctcttcagg cagtgcagga caaccagct atgccacat gctcaagccc 405
agaaggcaga atcaagcttt gctttctaga agacgctcaa aggatatgga aacaaaagtt 465
gcagagggtgc catgttcaga atacaataat aaagtggagt aaaga 510

```

&lt;210&gt; 86

&lt;211&gt; 97

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 86

```

Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe Ile His Ser
 1          5          10          15
Met Gly Glu Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Gln Thr
          20          25          30
Arg Val Leu Asn Gln Glu Glu Met Glu Lys Val Lys Arg Glu Asn Ala
          35          40          45
Thr Val Met Asp Lys Thr Arg Ala Leu Ile Asp Ser Val Ile Pro Lys
          50          55          60
Gly Ala Gln Ala Cys Gln Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp
65          70          75          80
Ser Tyr Leu Ala Glu Thr Leu Gly Leu Ser Ala Gly Pro Ile Pro Gly
          85          90          95
Asn

```

&lt;210&gt; 87

&lt;211&gt; 97

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 87

```

Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe Ile Arg Ser
 1          5          10          15
Met Gly Glu Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Gln Thr
          20          25          30
Arg Val Leu Asn Lys Glu Glu Met Glu Lys Val Lys Arg Glu Asn Ala
          35          40          45
Thr Val Met Asp Lys Thr Arg Ala Leu Ile Asp Ser Val Ile Pro Lys
          50          55          60
Gly Ala Gln Ala Cys Gln Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp
65          70          75          80
Ser Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Asp Gln Thr Ser Gly
          85          90          95
Asn

```

&lt;210&gt; 88

&lt;400&gt; 88

000

&lt;210&gt; 89

&lt;211&gt; 321

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1) ... (318)

&lt;400&gt; 89

```

atg atc ctc ctg aag aag aga cgg ctg ctt atc aat tca ttg ggt gaa 48
Met Ile Leu Leu Lys Lys Arg Arg Leu Leu Ile Asn Ser Leu Gly Glu
  1             5             10             15

ggg aca ata aat ggc tta ctg gat gaa tta ttg gag aca aat gtg ctg 96
Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Glu Thr Asn Val Leu
          20             25             30

agc cag gaa gac aca gag ata gta aaa tgt gaa aat gtt aca gtt atc 144
Ser Gln Glu Asp Thr Glu Ile Val Lys Cys Glu Asn Val Thr Val Ile
          35             40             45

gat aag gcc cga gat ttg ctt gac tct gtt att cgg aaa ggg gca ggg 192
Asp Lys Ala Arg Asp Leu Leu Asp Ser Val Ile Arg Lys Gly Ala Gly
          50             55             60

gca tgt gaa att tgc atc aca tac att tgt gaa gaa gac agg tac ctg 240
Ala Cys Glu Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp Arg Tyr Leu
          65             70             75             80

gca ggg acg ctg gga ctc tca gca gga aat gac tac aga gct gga ggc 288
Ala Gly Thr Leu Gly Leu Ser Ala Gly Asn Asp Tyr Arg Ala Gly Gly
          85             90             95

att tgc tca ccg ccc aga gca caa gac ctc tga 321
Ile Cys Ser Pro Pro Arg Ala Gln Asp Leu
          100             105

```

<210> 90  
 <211> 106  
 <212> PRT  
 <213> Homo sapien

```

<400> 90
Met Ile Leu Leu Lys Lys Arg Arg Leu Leu Ile Asn Ser Leu Gly Glu
  1             5             10             15
Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Glu Thr Asn Val Leu
          20             25             30
Ser Gln Glu Asp Thr Glu Ile Val Lys Cys Glu Asn Val Thr Val Ile
          35             40             45
Asp Lys Ala Arg Asp Leu Leu Asp Ser Val Ile Arg Lys Gly Ala Gly
          50             55             60
Ala Cys Glu Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp Arg Tyr Leu
          65             70             75             80
Ala Gly Thr Leu Gly Leu Ser Ala Gly Asn Asp Tyr Arg Ala Gly Gly
          85             90             95
Ile Cys Ser Pro Pro Arg Ala Gln Asp Leu
          100             105

```

<210> 91  
 <211> 108  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 91

```

Met Ala Asp Lys Val Leu Leu Glu Lys Arg Lys Leu Leu Ile Asn Ser
 1           5           10           15
Leu Gly Glu Gly Thr Ile Asn Gly Leu Leu Asp Glu Leu Leu Glu Thr
           20           25           30
Asn Val Leu Ser Gln Glu Asp Glu Ile Val Lys Arg Glu Asn Ala Thr
           35           40           45
Val Ile Asp Lys Ala Arg Ala Leu Leu Asp Ser Val Ile Arg Lys Gly
           50           55           60
Ala Gly Ala Cys Glu Ile Cys Ile Thr Tyr Ile Cys Glu Glu Asp Ser
65           70           75           80
Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Gly Asn Ala Val Gln Ala
           85           90           95
Gly Gly Ala Cys Ser Thr Ser Ser Gly Gln Asp Leu
           100          105

```

&lt;210&gt; 92

&lt;400&gt; 92

000

&lt;210&gt; 93

&lt;400&gt; 93

000

&lt;210&gt; 94

&lt;400&gt; 94

000

&lt;210&gt; 95

&lt;400&gt; 95

000

&lt;210&gt; 96

&lt;211&gt; 3396

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (277)... (3348)

&lt;400&gt; 96

```

cgccccgggca ggtgtttata ctccggaggg tgtccccgtg cgtcatcggt ggagtggacc 60
aaaacttggtg atctgtttgc cctgtgtgac cttgcccgaga accctgctga ctgagagaac 120
acatctgctg gaagtcctct gggattcaag gtacagggaa tgaagagtag ttttacagaa 180
aaaagaggac aatattggga tcaccttga cctttccatt tggaaataat attttctatt 240
gtgttataga aaggtgggaa gctttcatcc agaaca atg aat ttc ata aag gac 294
                               Met Asn Phe Ile Lys Asp
                               1           5

```

aat agc cga gcc ctt att caa aga atg gga atg act gtt ata aag caa	342
Asn Ser Arg Ala Leu Ile Gln Arg Met Gly Met Thr Val Ile Lys Gln	
10 15 20	
atc aca gat gac cta ttt gta tgg aat gtt ctg aat cgc gaa gaa gta	390
Ile Thr Asp Asp Leu Phe Val Trp Asn Val Leu Asn Arg Glu Glu Val	
25 30 35	
aac atc att tgc tgc gag aag gtg gag cag gat gct gct aga ggg atc	438
Asn Ile Ile Cys Cys Glu Lys Val Glu Gln Asp Ala Ala Arg Gly Ile	
40 45 50	
att cac atg att ttg aaa aag ggt tca gag tcc tgt aac ctc ttt ctt	486
Ile His Met Ile Leu Lys Lys Gly Ser Glu Ser Cys Asn Leu Phe Leu	
55 60 65 70	
aaa tcc ctt aag gag tgg aac tat cct cta ttt cag gac ttg aat gga	534
Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu Phe Gln Asp Leu Asn Gly	
75 80 85	
caa agt ctt ttt cat cag aca tca gaa gga gac ttg gac gat ttg gct	582
Gln Ser Leu Phe His Gln Thr Ser Glu Gly Asp Leu Asp Asp Leu Ala	
90 95 100	
cag gat tta aag gac ttg tac cat acc cca tct ttt ctg aac ttt tat	630
Gln Asp Leu Lys Asp Leu Tyr His Thr Pro Ser Phe Leu Asn Phe Tyr	
105 110 115	
ccc ctt ggt gaa gat att gac att att ttt aac ttg aaa agc acc ttc	678
Pro Leu Gly Glu Asp Ile Asp Ile Ile Phe Asn Leu Lys Ser Thr Phe	
120 125 130	
aca gaa cct atc ctg tgg agg aag gac caa cac cat cac cgc gtg gag	726
Thr Glu Pro Ile Leu Trp Arg Lys Asp Gln His His His Arg Val Glu	
135 140 145 150	
cag ctg acc ctg aat ggc ctc ctg cag gct ctt cag agc ccc tgc atc	774
Gln Leu Thr Leu Asn Gly Leu Leu Gln Ala Leu Gln Ser Pro Cys Ile	
155 160 165	
att gaa ggg gaa tct ggc aaa ggc aag tcc act ctg ctg cag cgc att	822
Ile Glu Gly Glu Ser Gly Lys Gly Lys Ser Thr Leu Leu Gln Arg Ile	
170 175 180	
gcc atg ctc tgg ggc tcc gga aag tgc aag gct ctg acc aag ttc aaa	870
Ala Met Leu Trp Gly Ser Gly Lys Cys Lys Ala Leu Thr Lys Phe Lys	
185 190 195	
ttc gtc ttc ttc ctc cgt ctc agc agg gcc cag ggt gga ctt ttt gaa	918
Phe Val Phe Phe Leu Arg Leu Ser Arg Ala Gln Gly Gly Leu Phe Glu	
200 205 210	
acc ctc tgt gat caa ctc ctg gat ata cct ggc aca atc agg aag cag	966
Thr Leu Cys Asp Gln Leu Leu Asp Ile Pro Gly Thr Ile Arg Lys Gln	

215	220	225	230	
aca ttc atg gcc atg ctg ctg aag ctg cgg cag agg gtt ctt ttc ctt				1014
Thr Phe Met Ala Met Leu Leu Lys Leu Arg Gln Arg Val Leu Phe Leu				
	235	240	245	
ctt gat ggc tac aat gaa ttc aag ccc cag aac tgc cca gaa atc gaa				1062
Leu Asp Gly Tyr Asn Glu Phe Lys Pro Gln Asn Cys Pro Glu Ile Glu				
	250	255	260	
gcc ctg ata aag gaa aac cac cgc ttc aag aac atg gtc atc gtc acc				1110
Ala Leu Ile Lys Glu Asn His Arg Phe Lys Asn Met Val Ile Val Thr				
	265	270	275	
act acc act gag tgc ctg agg cac ata cgg cag ttt ggt gcc ctg act				1158
Thr Thr Thr Glu Cys Leu Arg His Ile Arg Gln Phe Gly Ala Leu Thr				
	280	285	290	
gct gag gtg ggg gat atg aca gaa gac agc gcc cag gct ctc atc cga				1206
Ala Glu Val Gly Asp Met Thr Glu Asp Ser Ala Gln Ala Leu Ile Arg				
	295	300	305	310
gaa gtg ctg atc aag gag ctt gct gaa ggc ttg ttg ctc caa att cag				1254
Glu Val Leu Ile Lys Glu Leu Ala Glu Gly Leu Leu Leu Gln Ile Gln				
	315	320	325	
aaa tcc agg tgc ttg agg aat ctc atg aag acc cct ctc ttt gtg gtc				1302
Lys Ser Arg Cys Leu Arg Asn Leu Met Lys Thr Pro Leu Phe Val Val				
	330	335	340	
atc act tgt gca atc cag atg ggt gaa agt gag ttc cac tct cac aca				1350
Ile Thr Cys Ala Ile Gln Met Gly Glu Ser Glu Phe His Ser His Thr				
	345	350	355	
caa aca acg ctg ttc cat acc ttc tat gat ctg ttg ata cag aaa aac				1398
Gln Thr Thr Leu Phe His Thr Phe Tyr Asp Leu Leu Ile Gln Lys Asn				
	360	365	370	
aaa cac aaa cat aaa ggt gtg gct gca agt gac ttc att cgg agc ctg				1446
Lys His Lys His Lys Gly Val Ala Ala Ser Asp Phe Ile Arg Ser Leu				
	375	380	385	390
gac cac cgt gga gac cta gct ctg gag ggt gtg ttc tcc cac aag ttt				1494
Asp His Arg Gly Asp Leu Ala Leu Glu Gly Val Phe Ser His Lys Phe				
	395	400	405	
gat ttc gaa ctg cag gat gtg tcc agc gtg aat gag gat gtc ctg ctg				1542
Asp Phe Glu Leu Gln Asp Val Ser Ser Val Asn Glu Asp Val Leu Leu				
	410	415	420	
aca act ggg ctc ctc tgt aaa tat aca gct caa agg ttc aag cca aag				1590
Thr Thr Gly Leu Leu Cys Lys Tyr Thr Ala Gln Arg Phe Lys Pro Lys				
	425	430	435	
tat aaa ttc ttt cac aag tca ttc cag gag tac aca gca gga cga aga				1638

Tyr	Lys	Phe	Phe	His	Lys	Ser	Phe	Gln	Glu	Tyr	Thr	Ala	Gly	Arg	Arg		
440						445					450						
ctc	agc	agt	tta	ttg	acg	tct	cat	gag	cca	gag	gag	gtg	acc	aag	ggg	1686	
Leu	Ser	Ser	Leu	Leu	Thr	Ser	His	Glu	Pro	Glu	Glu	Val	Thr	Lys	Gly		
455					460					465					470		
aat	ggt	tac	ttg	cag	aaa	atg	gtt	tcc	att	tcg	gac	att	aca	tcc	act	1734	
Asn	Gly	Tyr	Leu	Gln	Lys	Met	Val	Ser	Ile	Ser	Asp	Ile	Thr	Ser	Thr		
				475					480					485			
tat	agc	agc	ctg	ctc	cgg	tac	acc	tgt	ggg	tca	tct	gtg	gaa	gcc	acc	1782	
Tyr	Ser	Ser	Leu	Leu	Arg	Tyr	Thr	Cys	Gly	Ser	Ser	Val	Glu	Ala	Thr		
			490					495					500				
agg	gct	gtt	atg	aag	cac	ctc	gca	gca	gtg	tat	caa	cac	ggc	tgc	ctt	1830	
Arg	Ala	Val	Met	Lys	His	Leu	Ala	Ala	Val	Tyr	Gln	His	Gly	Cys	Leu		
		505					510					515					
ctc	gga	ctt	tcc	atc	gcc	aag	agg	cct	ctc	tgg	aga	cag	gaa	tct	ttg	1878	
Leu	Gly	Leu	Ser	Ile	Ala	Lys	Arg	Pro	Leu	Trp	Arg	Gln	Glu	Ser	Leu		
	520					525					530						
caa	agt	gtg	aaa	aac	acc	act	gag	caa	gaa	att	ctg	aaa	gcc	ata	aac	1926	
Gln	Ser	Val	Lys	Asn	Thr	Thr	Glu	Gln	Glu	Ile	Leu	Lys	Ala	Ile	Asn		
535					540					545					550		
atc	aat	tcc	ttt	gta	gag	tgt	ggc	atc	cat	tta	tat	caa	gag	agt	aca	1974	
Ile	Asn	Ser	Phe	Val	Glu	Cys	Gly	Ile	His	Leu	Tyr	Gln	Glu	Ser	Thr		
				555					560					565			
tcc	aaa	tca	gcc	ctg	agc	caa	gaa	ttt	gaa	gct	ttc	ttt	caa	ggt	aaa	2022	
Ser	Lys	Ser	Ala	Leu	Ser	Gln	Glu	Phe	Glu	Ala	Phe	Phe	Gln	Gly	Lys		
			570					575					580				
agc	tta	tat	atc	aac	tca	ggg	aac	atc	ccc	gat	tac	tta	ttt	gac	ttc	2070	
Ser	Leu	Tyr	Ile	Asn	Ser	Gly	Asn	Ile	Pro	Asp	Tyr	Leu	Phe	Asp	Phe		
		585					590					595					
ttt	gaa	cat	ttg	ccc	aat	tgt	gca	agt	gcc	ctg	gac	ttc	att	aaa	ctg	2118	
Phe	Glu	His	Leu	Pro	Asn	Cys	Ala	Ser	Ala	Leu	Asp	Phe	Ile	Lys	Leu		
	600					605					610						
gac	ttt	tat	ggg	gga	gct	atg	gct	tca	tgg	gaa	aag	gct	gca	gaa	gac	2166	
Asp	Phe	Tyr	Gly	Gly	Ala	Met	Ala	Ser	Trp	Glu	Lys	Ala	Ala	Glu	Asp		
615					620					625					630		
aca	ggt	gga	atc	cac	atg	gaa	gag	gcc	cca	gaa	acc	tac	att	ccc	agc	2214	
Thr	Gly	Gly	Ile	His	Met	Glu	Glu	Ala	Pro	Glu	Thr	Tyr	Ile	Pro	Ser		
				635					640					645			
agg	gct	gta	tct	ttg	ttc	ttc	aac	tgg	aag	cag	gaa	ttc	agg	act	ctg	2262	
Arg	Ala	Val	Ser	Leu	Phe	Phe	Asn	Trp	Lys	Gln	Glu	Phe	Arg	Thr	Leu		
			650					655					660				

gag gtc aca ctc cgg gat ttc agc aag ttg aat aag caa gat atc aga	2310
Glu Val Thr Leu Arg Asp Phe Ser Lys Leu Asn Lys Gln Asp Ile Arg	
665 670 675	
tat ctg ggg aaa ata ttc agc tct gcc aca agc ctc agg ctg caa ata	2358
Tyr Leu Gly Lys Ile Phe Ser Ser Ala Thr Ser Leu Arg Leu Gln Ile	
680 685 690	
aag aga tgt gct ggt gtg gct gga agc ctc agt ttg gtc ctc agc acc	2406
Lys Arg Cys Ala Gly Val Ala Gly Ser Leu Ser Leu Val Leu Ser Thr	
695 700 705 710	
tgt aag aac att tat tct ctc atg gtg gaa gcc agt ccc ctc acc ata	2454
Cys Lys Asn Ile Tyr Ser Leu Met Val Glu Ala Ser Pro Leu Thr Ile	
715 720 725	
gaa gat gag agg cac atc aca tct gta aca aac ctg aaa acc ttg agt	2502
Glu Asp Glu Arg His Ile Thr Ser Val Thr Asn Leu Lys Thr Leu Ser	
730 735 740	
att cat gac cta cag aat caa cgg ctg ccg ggt ggt ctg act gac agc	2550
Ile His Asp Leu Gln Asn Gln Arg Leu Pro Gly Gly Leu Thr Asp Ser	
745 750 755	
ttg ggt aac ttg aag aac ctt aca aag ctc ata atg gat aac ata aag	2598
Leu Gly Asn Leu Lys Asn Leu Thr Lys Leu Ile Met Asp Asn Ile Lys	
760 765 770	
atg aat gaa gaa gat gct ata aaa cta gct gaa ggc ctg aaa aac ctg	2646
Met Asn Glu Glu Asp Ala Ile Lys Leu Ala Glu Gly Leu Lys Asn Leu	
775 780 785 790	
aag aag atg tgt tta ttt cat ttg acc cac ttg tct gac att gga gag	2694
Lys Lys Met Cys Leu Phe His Leu Thr His Leu Ser Asp Ile Gly Glu	
795 800 805	
gga atg gat tac ata gtc aag tct ctg tca agt gaa ccc tgt gac ctt	2742
Gly Met Asp Tyr Ile Val Lys Ser Leu Ser Ser Glu Pro Cys Asp Leu	
810 815 820	
gaa gaa att caa tta gtc tcc tgc tgc ttg tct gca aat gca gtg aaa	2790
Glu Glu Ile Gln Leu Val Ser Cys Cys Leu Ser Ala Asn Ala Val Lys	
825 830 835	
atc cta gct cag aat ctt cac aat ttg gtc aaa ctg agc att ctt gat	2838
Ile Leu Ala Gln Asn Leu His Asn Leu Val Lys Leu Ser Ile Leu Asp	
840 845 850	
tta tca gaa aat tac ctg gaa aaa gat gga aat gaa gct ctt cat gaa	2886
Leu Ser Glu Asn Tyr Leu Glu Lys Asp Gly Asn Glu Ala Leu His Glu	
855 860 865 870	
ctg atc gac agg atg aac gtg cta gaa cag ctc acc gca ctg atg ctg	2934
Leu Ile Asp Arg Met Asn Val Leu Glu Gln Leu Thr Ala Leu Met Leu	
875 880 885	

ccc tgg ggc tgt gac gtg caa ggc agc ctg agc agc ctg ttg aaa cat 2982  
 Pro Trp Gly Cys Asp Val Gln Gly Ser Leu Ser Ser Leu Leu Lys His  
 890 895 900

ttg gag gag gtc cca caa ctc gtc aag ctt ggg ttg aaa aac tgg aga 3030  
 Leu Glu Glu Val Pro Gln Leu Val Lys Leu Gly Leu Lys Asn Trp Arg  
 905 910 915

ctc aca gat aca gag att aga att tta ggt gca ttt ttt gga aag aac 3078  
 Leu Thr Asp Thr Glu Ile Arg Ile Leu Gly Ala Phe Phe Gly Lys Asn  
 920 925 930

cct ctg aaa aac ttc cag cag ttg aat ttg gcg gga aat cgt gtg agc 3126  
 Pro Leu Lys Asn Phe Gln Gln Leu Asn Leu Ala Gly Asn Arg Val Ser  
 935 940 945 950

agt gat gga tgg ctt gcc ttc atg ggt gta ttt gag aat ctt aag caa 3174  
 Ser Asp Gly Trp Leu Ala Phe Met Gly Val Phe Glu Asn Leu Lys Gln  
 955 960 965

tta gtg ttt ttt gac ttt agt act aaa gaa ttt cta cct gat cca gca 3222  
 Leu Val Phe Phe Asp Phe Ser Thr Lys Glu Phe Leu Pro Asp Pro Ala  
 970 975 980

tta gtc aga aaa ctt agc caa gtg tta tcc aag tta act ttt ctg caa 3270  
 Leu Val Arg Lys Leu Ser Gln Val Leu Ser Lys Leu Thr Phe Leu Gln  
 985 990 995

gaa gct agg ctt gtt ggg tgg caa ttt gat gat gat gat ctc agt gtt 3318  
 Glu Ala Arg Leu Val Gly Trp Gln Phe Asp Asp Asp Asp Leu Ser Val  
 1000 1005 1010

att aca ggt gct ttt aaa cta gta act gct taaataaaagt gtactcgaag 3368  
 Ile Thr Gly Ala Phe Lys Leu Val Thr Ala  
 1015 1020

ccaaaaaaaaa aaaaaaaaaa aaaaaaaaa 3396

<210> 97  
 <211> 1024  
 <212> PRT  
 <213> Homo sapien

<400> 97  
 Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly  
 1 5 10 15  
 Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val  
 20 25 30  
 Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln  
 35 40 45  
 Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu  
 50 55 60  
 Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu  
 65 70 75 80

Phe Gln Asp Leu Asn Gly Gln Ser Leu Phe His Gln Thr Ser Glu Gly  
 85 90 95  
 Asp Leu Asp Asp Leu Ala Gln Asp Leu Lys Asp Leu Tyr His Thr Pro  
 100 105 110  
 Ser Phe Leu Asn Phe Tyr Pro Leu Gly Glu Asp Ile Asp Ile Ile Phe  
 115 120 125  
 Asn Leu Lys Ser Thr Phe Thr Glu Pro Ile Leu Trp Arg Lys Asp Gln  
 130 135 140  
 His His His Arg Val Glu Gln Leu Thr Leu Asn Gly Leu Leu Gln Ala  
 145 150 155 160  
 Leu Gln Ser Pro Cys Ile Ile Glu Gly Glu Ser Gly Lys Gly Lys Ser  
 165 170 175  
 Thr Leu Leu Gln Arg Ile Ala Met Leu Trp Gly Ser Gly Lys Cys Lys  
 180 185 190  
 Ala Leu Thr Lys Phe Lys Phe Val Phe Phe Leu Arg Leu Ser Arg Ala  
 195 200 205  
 Gln Gly Gly Leu Phe Glu Thr Leu Cys Asp Gln Leu Leu Asp Ile Pro  
 210 215 220  
 Gly Thr Ile Arg Lys Gln Thr Phe Met Ala Met Leu Leu Lys Leu Arg  
 225 230 235 240  
 Gln Arg Val Leu Phe Leu Leu Asp Gly Tyr Asn Glu Phe Lys Pro Gln  
 245 250 255  
 Asn Cys Pro Glu Ile Glu Ala Leu Ile Lys Glu Asn His Arg Phe Lys  
 260 265 270  
 Asn Met Val Ile Val Thr Thr Thr Thr Glu Cys Leu Arg His Ile Arg  
 275 280 285  
 Gln Phe Gly Ala Leu Thr Ala Glu Val Gly Asp Met Thr Glu Asp Ser  
 290 295 300  
 Ala Gln Ala Leu Ile Arg Glu Val Leu Ile Lys Glu Leu Ala Glu Gly  
 305 310 315 320  
 Leu Leu Leu Gln Ile Gln Lys Ser Arg Cys Leu Arg Asn Leu Met Lys  
 325 330 335  
 Thr Pro Leu Phe Val Val Ile Thr Cys Ala Ile Gln Met Gly Glu Ser  
 340 345 350  
 Glu Phe His Ser His Thr Gln Thr Thr Leu Phe His Thr Phe Tyr Asp  
 355 360 365  
 Leu Leu Ile Gln Lys Asn Lys His Lys His Lys Gly Val Ala Ala Ser  
 370 375 380  
 Asp Phe Ile Arg Ser Leu Asp His Arg Gly Asp Leu Ala Leu Glu Gly  
 385 390 395 400  
 Val Phe Ser His Lys Phe Asp Phe Glu Leu Gln Asp Val Ser Ser Val  
 405 410 415  
 Asn Glu Asp Val Leu Leu Thr Thr Gly Leu Leu Cys Lys Tyr Thr Ala  
 420 425 430  
 Gln Arg Phe Lys Pro Lys Tyr Lys Phe Phe His Lys Ser Phe Gln Glu  
 435 440 445  
 Tyr Thr Ala Gly Arg Arg Leu Ser Ser Leu Leu Thr Ser His Glu Pro  
 450 455 460  
 Glu Glu Val Thr Lys Gly Asn Gly Tyr Leu Gln Lys Met Val Ser Ile  
 465 470 475 480  
 Ser Asp Ile Thr Ser Thr Tyr Ser Ser Leu Leu Arg Tyr Thr Cys Gly  
 485 490 495  
 Ser Ser Val Glu Ala Thr Arg Ala Val Met Lys His Leu Ala Ala Val  
 500 505 510  
 Tyr Gln His Gly Cys Leu Leu Gly Leu Ser Ile Ala Lys Arg Pro Leu

515	520	525
Trp Arg Gln Glu Ser Leu	Gln Ser Val Lys Asn Thr	Thr Glu Gln Glu
530	535	540
Ile Leu Lys Ala Ile Asn	Ile Asn Ser Phe Val	Glu Cys Gly Ile His
545	550	555
Leu Tyr Gln Glu Ser Thr	Ser Lys Ser Ala Leu	Ser Gln Glu Phe Glu
565	570	575
Ala Phe Phe Gln Gly Lys	Ser Leu Tyr Ile Asn	Ser Gly Asn Ile Pro
580	585	590
Asp Tyr Leu Phe Asp Phe	Phe Glu His Leu Pro	Asn Cys Ala Ser Ala
595	600	605
Leu Asp Phe Ile Lys Leu	Asp Phe Tyr Gly Gly	Ala Met Ala Ser Trp
610	615	620
Glu Lys Ala Ala Glu Asp	Thr Gly Gly Ile His	Met Glu Glu Ala Pro
625	630	635
Glu Thr Tyr Ile Pro Ser	Arg Ala Val Ser Leu	Phe Phe Asn Trp Lys
645	650	655
Gln Glu Phe Arg Thr Leu	Glu Val Thr Leu Arg	Asp Phe Ser Lys Leu
660	665	670
Asn Lys Gln Asp Ile Arg	Tyr Leu Gly Lys Ile	Phe Ser Ser Ala Thr
675	680	685
Ser Leu Arg Leu Gln Ile	Lys Arg Cys Ala Gly	Val Ala Gly Ser Leu
690	695	700
Ser Leu Val Leu Ser Thr	Cys Lys Asn Ile Tyr	Ser Leu Met Val Glu
705	710	715
Ala Ser Pro Leu Thr Ile	Glu Asp Glu Arg His	Ile Thr Ser Val Thr
725	730	735
Asn Leu Lys Thr Leu Ser	Ile His Asp Leu Gln	Asn Gln Arg Leu Pro
740	745	750
Gly Gly Leu Thr Asp Ser	Leu Gly Asn Leu Lys	Asn Leu Thr Lys Leu
755	760	765
Ile Met Asp Asn Ile Lys	Met Asn Glu Glu Asp	Ala Ile Lys Leu Ala
770	775	780
Glu Gly Leu Lys Asn Leu	Lys Lys Met Cys Leu	Phe His Leu Thr His
785	790	795
Leu Ser Asp Ile Gly Glu	Gly Met Asp Tyr Ile	Val Lys Ser Leu Ser
805	810	815
Ser Glu Pro Cys Asp Leu	Glu Glu Ile Gln Leu	Val Ser Cys Cys Leu
820	825	830
Ser Ala Asn Ala Val Lys	Ile Leu Ala Gln Asn	Leu His Asn Leu Val
835	840	845
Lys Leu Ser Ile Leu Asp	Leu Ser Glu Asn Tyr	Leu Glu Lys Asp Gly
850	855	860
Asn Glu Ala Leu His Glu	Leu Ile Asp Arg Met	Asn Val Leu Glu Gln
865	870	875
Leu Thr Ala Leu Met Leu	Pro Trp Gly Cys Asp	Val Gln Gly Ser Leu
885	890	895
Ser Ser Leu Leu Lys His	Leu Glu Glu Val Pro	Gln Leu Val Lys Leu
900	905	910
Gly Leu Lys Asn Trp Arg	Leu Thr Asp Thr Glu	Ile Arg Ile Leu Gly
915	920	925
Ala Phe Phe Gly Lys Asn	Pro Leu Lys Asn Phe	Gln Gln Leu Asn Leu
930	935	940
Ala Gly Asn Arg Val Ser	Ser Asp Gly Trp Leu	Ala Phe Met Gly Val
945	950	955
		960

```
<210> 98
<211> 1395
<212> DNA
<213> Homo sapien

<220>
<221> CDS
<222> (277)...(1353)
```

<400> 98															
cgcccgggca	ggtgtttata	ctccggaggg	tgtccccgtg	cgtcatcggg	ggagtggaac	60									
aaaactggtg	atctgtttgc	cctgtgtgac	cttgcccaga	accctgctga	ctgagagAAC	120									
acatctgctg	gaagtcctct	gggattcaag	gtacagggaa	tgaagagtag	ttttacagaa	180									
aaaagaggac	aatattggga	tcacctttga	cctttccatt	tggaaataat	attttctatt	240									
gtgttataga	aagggtggaa	gctttcatcc	agaaca atg	aat ttc ata	aag gac	294									
			Met	Asn Phe Ile	Lys Asp										
			1		5										
aat agc cga gcc ctt att caa aga atg gga atg act gtt ata aag caa	342														
Asn Ser Arg Ala Leu Ile Gln Arg Met Gly Met Thr Val Ile Lys Gln															
	10		15		20										
atc aca gat gac cta ttt gta tgg aat gtt ctg aat cgc gaa gaa gta	390														
Ile Thr Asp Asp Leu Phe Val Trp Asn Val Leu Asn Arg Glu Glu Val															
	25		30		35										
aac atc att tgc tgc gag aag gtg gag cag gat gct gct aga ggg atc	438														
Asn Ile Ile Cys Cys Glu Lys Val Glu Gln Asp Ala Ala Arg Gly Ile															
	40		45		50										
att cac atg att ttg aaa aag ggt tca gag tcc tgt aac ctc ttt ctt	486														
Ile His Met Ile Leu Lys Lys Gly Ser Glu Ser Cys Asn Leu Phe Leu															
	55		60		65		70								
aaa tcc ctt aag gag tgg aac tat cct cta ttt cag gac ttg aat gga	534														
Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu Phe Gln Asp Leu Asn Gly															
		75		80		85									
caa agt ggt ctg act gac agc ttg ggt aac ttg aag aac ctt aca aag	582														
Gln Ser Gly Leu Thr Asp Ser Leu Gly Asn Leu Lys Asn Leu Thr Lys															
	90		95		100										
ctc ata atg gat aac ata aag atg aat gaa gaa gat gct ata aaa cta	630														
Leu Ile Met Asp Asn Ile Lys Met Asn Glu Glu Asp Ala Ile Lys Leu															
	105		110		115										

gct gaa ggc ctg aaa aac ctg aag aag atg tgt tta ttt cat ttg acc	678
Ala Glu Gly Leu Lys Asn Leu Lys Lys Met Cys Leu Phe His Leu Thr	
120 125 130	
cac ttg tct gac att gga gag gga atg gat tac ata gtc aag tct ctg	726
His Leu Ser Asp Ile Gly Glu Gly Met Asp Tyr Ile Val Lys Ser Leu	
135 140 145 150	
tca agt gaa ccc tgt gac ctt gaa gaa att caa tta gtc tcc tgc tgc	774
Ser Ser Glu Pro Cys Asp Leu Glu Glu Ile Gln Leu Val Ser Cys Cys	
155 160 165	
ttg tct gca aat gca gtg aaa atc cta gct cag aat ctt cac aat ttg	822
Leu Ser Ala Asn Ala Val Lys Ile Leu Ala Gln Asn Leu His Asn Leu	
170 175 180	
gtc aaa ctg agc att ctt gat tta tca gaa aat tac ctg gaa aaa gat	870
Val Lys Leu Ser Ile Leu Asp Leu Ser Glu Asn Tyr Leu Glu Lys Asp	
185 190 195	
gga aat gaa gct ctt cat gaa ctg atc gac agg atg aac gtg cta gaa	918
Gly Asn Glu Ala Leu His Glu Leu Ile Asp Arg Met Asn Val Leu Glu	
200 205 210	
cag ctc acc gca ctg atg ctg ccc tgg ggc tgt gac gtg caa ggc agc	966
Gln Leu Thr Ala Leu Met Leu Pro Trp Gly Cys Asp Val Gln Gly Ser	
215 220 225 230	
ctg agc agc ctg ttg aaa cat ttg gag gag gtc cca caa ctc gtc aag	1014
Leu Ser Ser Leu Leu Lys His Leu Glu Glu Val Pro Gln Leu Val Lys	
235 240 245	
ctt ggg ttg aaa aac tgg aga ctc aca gat aca gag att aga att tta	1062
Leu Gly Leu Lys Asn Trp Arg Leu Thr Asp Thr Glu Ile Arg Ile Leu	
250 255 260	
ggg gca ttt ttt gga aag aac cct ctg aaa aac ttc cag cag ttg aat	1110
Gly Ala Phe Phe Gly Lys Asn Pro Leu Lys Asn Phe Gln Gln Leu Asn	
265 270 275	
ttg gcg gga aat cgt gtg agc agt gat gga tgg ctt gcc ttc atg ggt	1158
Leu Ala Gly Asn Arg Val Ser Ser Asp Gly Trp Leu Ala Phe Met Gly	
280 285 290	
gta ttt gag aat ctt aag caa tta gtg ttt ttt gac ttt agt act aaa	1206
Val Phe Glu Asn Leu Lys Gln Leu Val Phe Phe Asp Phe Ser Thr Lys	
295 300 305 310	
gaa ttt cta cct gat cca gca tta gtc aga aaa ctt agc caa gtg tta	1254
Glu Phe Leu Pro Asp Pro Ala Leu Val Arg Lys Leu Ser Gln Val Leu	
315 320 325	
tcc aag tta act ttt ctg caa gaa gct agg ctt gtt ggg tgg caa ttt	1302
Ser Lys Leu Thr Phe Leu Gln Glu Ala Arg Leu Val Gly Trp Gln Phe	

```

          330              335              340
gat gat gat gat ctc agt gtt att aca ggt gct ttt aaa cta gta act 1350
Asp Asp Asp Asp Leu Ser Val Ile Thr Gly Ala Phe Lys Leu Val Thr
          345              350              355

gct taaataaaagt gtactcgaag caaaaaaaaaa aaaaaaaaaa aa 1395
Ala

```

```

<210> 99
<211> 359
<212> PRT
<213> Homo sapien

```

```

<400> 99
Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly
 1              5              10              15
Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val
          20              25              30
Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln
          35              40              45
Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu
          50              55              60
Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu
          65              70              75              80
Phe Gln Asp Leu Asn Gly Gln Ser Gly Leu Thr Asp Ser Leu Gly Asn
          85              90              95
Leu Lys Asn Leu Thr Lys Leu Ile Met Asp Asn Ile Lys Met Asn Glu
          100             105             110
Glu Asp Ala Ile Lys Leu Ala Glu Gly Leu Lys Asn Leu Lys Lys Met
          115             120             125
Cys Leu Phe His Leu Thr His Leu Ser Asp Ile Gly Glu Gly Met Asp
          130             135             140
Tyr Ile Val Lys Ser Leu Ser Ser Glu Pro Cys Asp Leu Glu Glu Ile
          145             150             155             160
Gln Leu Val Ser Cys Cys Leu Ser Ala Asn Ala Val Lys Ile Leu Ala
          165             170             175
Gln Asn Leu His Asn Leu Val Lys Leu Ser Ile Leu Asp Leu Ser Glu
          180             185             190
Asn Tyr Leu Glu Lys Asp Gly Asn Glu Ala Leu His Glu Leu Ile Asp
          195             200             205
Arg Met Asn Val Leu Glu Gln Leu Thr Ala Leu Met Leu Pro Trp Gly
          210             215             220
Cys Asp Val Gln Gly Ser Leu Ser Ser Leu Leu Lys His Leu Glu Glu
          225             230             235             240
Val Pro Gln Leu Val Lys Leu Gly Leu Lys Asn Trp Arg Leu Thr Asp
          245             250             255
Thr Glu Ile Arg Ile Leu Gly Ala Phe Phe Gly Lys Asn Pro Leu Lys
          260             265             270
Asn Phe Gln Gln Leu Asn Leu Ala Gly Asn Arg Val Ser Ser Asp Gly
          275             280             285
Trp Leu Ala Phe Met Gly Val Phe Glu Asn Leu Lys Gln Leu Val Phe
          290             295             300

```

Phe Asp Phe Ser Thr Lys Glu Phe Leu Pro Asp Pro Ala Leu Val Arg  
 305 310 315 320  
 Lys Leu Ser Gln Val Leu Ser Lys Leu Thr Phe Leu Gln Glu Ala Arg  
 325 330 335  
 Leu Val Gly Trp Gln Phe Asp Asp Asp Leu Ser Val Ile Thr Gly  
 340 345 350  
 Ala Phe Lys Leu Val Thr Ala  
 355

<210> 100

<211> 578

<212> DNA

<213> Homo sapien

<220>

<221> CDS

<222> (277)...(552)

<400> 100

cgccccgggca ggtgtttata ctccggaggg tgtccccgtg cgtcatcggg ggagtggacc 60  
 aaaactggtg atctgtttgc cctgtgtgac cttgcccaga accctgctga ctgagagaac 120  
 acatctgctg gaagtcctct gggattcaag gtacagggaa tgaagagtag ttttacagaa 180  
 aaaagaggac aatattggga tcacctttga cctttccatt tggaaataat attttctatt 240  
 gtgttataga aaggtgggaa gctttcatcc agaaca atg aat ttc ata aag gac 294  
 Met Asn Phe Ile Lys Asp  
 1 5  
 aat agc cga gcc ctt att caa aga atg gga atg act gtt ata aag caa 342  
 Asn Ser Arg Ala Leu Ile Gln Arg Met Gly Met Thr Val Ile Lys Gln  
 10 15 20  
 atc aca gat gac cta ttt gta tgg aat gtt ctg aat cgc gaa gaa gta 390  
 Ile Thr Asp Asp Leu Phe Val Trp Asn Val Leu Asn Arg Glu Glu Val  
 25 30 35  
 aac atc att tgc tgc gag aag gtg gag cag gat gct gct aga ggg atc 438  
 Asn Ile Ile Cys Cys Glu Lys Val Glu Gln Asp Ala Ala Arg Gly Ile  
 40 45 50  
 att cac atg att ttg aaa aag ggt tca gag tcc tgt aac ctc ttt ctt 486  
 Ile His Met Ile Leu Lys Lys Gly Ser Glu Ser Cys Asn Leu Phe Leu  
 55 60 65 70  
 aaa tcc ctt aag gag tgg aac tat cct cta ttt cag gac ttg aat gga 534  
 Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu Phe Gln Asp Leu Asn Gly  
 75 80 85  
 caa agt ctt tta aca gct tagaaagtac agtagacata ctggggg 578  
 Gln Ser Leu Leu Thr Ala  
 90

<210> 101

<211> 92

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 101

```

Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly
 1           5           10           15
Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val
          20           25           30
Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln
          35           40           45
Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu
          50           55           60
Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu
65           70           75           80
Phe Gln Asp Leu Asn Gly Gln Ser Leu Leu Thr Ala
          85           90

```

&lt;210&gt; 102

&lt;211&gt; 768

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (277)...(744)

&lt;400&gt; 102

```

cgccccgggca ggtgtttata ctccggagggt tgtccccgtg cgtcatcggt ggagtggacc 60
aaaactgggtg atctgtttgc cctgtgtgac cttgcccaga accctgctga ctgagagaac 120
acatctgctg gaagtcctct gggattcaag gtacagggaa tgaagagtag ttttacagaa 180
aaaagaggac aatattggga tcacctttga cctttccatt tggaaataat attttctatt 240
gtgttataga aagggtgggaa gctttcatcc agaaca atg aat ttc ata aag gac 294
                               Met Asn Phe Ile Lys Asp
                               1           5

aat agc cga gcc ctt att caa aga atg gga atg act gtt ata aag caa 342
Asn Ser Arg Ala Leu Ile Gln Arg Met Gly Met Thr Val Ile Lys Gln
          10           15           20

atc aca gat gac cta ttt gta tgg aat gtt ctg aat cgc gaa gaa gta 390
Ile Thr Asp Asp Leu Phe Val Trp Asn Val Leu Asn Arg Glu Glu Val
          25           30           35

aac atc att tgc tgc gag aag gtg gag cag gat gct gct aga ggg atc 438
Asn Ile Ile Cys Cys Glu Lys Val Glu Gln Asp Ala Ala Arg Gly Ile
          40           45           50

att cac atg att ttg aaa aag ggt tca gag tcc tgt aac ctc ttt ctt 486
Ile His Met Ile Leu Lys Lys Gly Ser Glu Ser Cys Asn Leu Phe Leu
          55           60           65           70

aaa tcc ctt aag gag tgg aac tat cct cta ttt cag gac ttg aat gga 534
Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu Phe Gln Asp Leu Asn Gly
          75           80           85

```

caa agt ctt ttt cat cag aca tca gaa gga gac ttg gac gat ttg gct 582  
 Gln Ser Leu Phe His Gln Thr Ser Glu Gly Asp Leu Asp Asp Leu Ala  
                   90                                  95                                  100

cag gat tta aag gac ttg tac cat acc cca tct ttt ctg aac ttt tat 630  
 Gln Asp Leu Lys Asp Leu Tyr His Thr Pro Ser Phe Leu Asn Phe Tyr  
                   105                                  110                                  115

ccc ctt ggt gaa gat att gac att att ttt aac ttg aaa agc acc ttc 678  
 Pro Leu Gly Glu Asp Ile Asp Ile Ile Phe Asn Leu Lys Ser Thr Phe  
                   120                                  125                                  130

aca gaa cct gtc ctg tgg agg aag gac caa cac cat cac cgc gtg gag 726  
 Thr Glu Pro Val Leu Trp Arg Lys Asp Gln His His His Arg Val Glu  
                   135                                  140                                  145                                  150

cag ctg acc cta gtt tta tagcatcttc tacctgcccg ggcg 768  
 Gln Leu Thr Leu Val Leu  
                                   155

<210> 103

<211> 156

<212> PRT

<213> Homo sapien

<400> 103

Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly  
   1                                  5                                  10                                  15  
 Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val  
                   20                                  25                                  30  
 Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln  
                   35                                  40                                  45  
 Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu  
                   50                                  55                                  60  
 Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu  
   65                                  70                                  75                                  80  
 Phe Gln Asp Leu Asn Gly Gln Ser Leu Phe His Gln Thr Ser Glu Gly  
                                   85                                  90                                  95  
 Asp Leu Asp Asp Leu Ala Gln Asp Leu Lys Asp Leu Tyr His Thr Pro  
                   100                                  105                                  110  
 Ser Phe Leu Asn Phe Tyr Pro Leu Gly Glu Asp Ile Asp Ile Ile Phe  
                   115                                  120                                  125  
 Asn Leu Lys Ser Thr Phe Thr Glu Pro Val Leu Trp Arg Lys Asp Gln  
                   130                                  135                                  140  
 His His His Arg Val Glu Gln Leu Thr Leu Val Leu  
   145                                  150                                  155

<210> 104

<211> 24

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 104

aagaagagac ggctgcttat caat

24

&lt;210&gt; 105

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 105

ccacagcagg cctcgaagat gatc

24

&lt;210&gt; 106

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 106

atgatcctcc tgaagaagag

20

&lt;210&gt; 107

&lt;211&gt; 1009

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 107

Cys	Glu	Met	Cys	Ser	Gln	Glu	Ala	Phe	Gln	Ala	Gln	Arg	Ser	Gln	Leu
1			5						10					15	
Val	Glu	Leu	Leu	Val	Ser	Gly	Ser	Leu	Glu	Gly	Phe	Glu	Ser	Val	Leu
		20						25				30			
Asp	Trp	Leu	Leu	Ser	Trp	Glu	Val	Leu	Ser	Trp	Glu	Asp	Tyr	Glu	Gly
	35					40					45				
Phe	His	Leu	Leu	Gly	Gln	Pro	Leu	Ser	His	Leu	Ala	Arg	Arg	Leu	Leu
	50				55					60					
Asp	Thr	Val	Trp	Asn	Lys	Gly	Thr	Trp	Ala	Cys	Gln	Lys	Leu	Ile	Ala
65				70					75					80	
Ala	Ala	Gln	Glu	Ala	Gln	Ala	Asp	Ser	Gln	Ser	Pro	Lys	Leu	His	Gly
			85					90					95		
Cys	Trp	Asp	Pro	His	Ser	Leu	His	Pro	Ala	Arg	Asp	Leu	Gln	Ser	His
			100					105				110			
Arg	Pro	Ala	Ile	Val	Arg	Arg	Leu	His	Ser	His	Val	Glu	Asn	Met	Leu
		115				120					125				
Asp	Leu	Ala	Trp	Glu	Arg	Gly	Phe	Val	Ser	Gln	Tyr	Glu	Cys	Asp	Glu
	130					135					140				
Ile	Arg	Leu	Pro	Ile	Phe	Thr	Pro	Ser	Gln	Arg	Ala	Arg	Arg	Leu	Leu
145				150					155					160	
Asp	Leu	Ala	Thr	Val	Lys	Ala	Asn	Gly	Leu	Ala	Ala	Phe	Leu	Leu	Gln

- 35 -

Arg Pro Gly Asn Ser Pro Met Ala Arg Leu Leu Pro Thr Met Cys Ile  
 610 615 620  
 Gln Ala Ser Glu Gly Lys Asp Ser Ser Val Ala Ala Leu Leu Gln Lys  
 625 630 635 640  
 Ala Glu Pro His Asn Leu Gln Ile Thr Ala Ala Phe Leu Ala Gly Leu  
 645 650 655  
 Leu Ser Arg Glu His Trp Gly Leu Leu Ala Glu Cys Gln Thr Ser Glu  
 660 665 670  
 Lys Ala Leu Leu Arg Arg Gln Ala Cys Ala Arg Trp Cys Leu Ala Arg  
 675 680 685  
 Ser Leu Arg Lys His Phe His Ser Ile Pro Pro Ala Ala Pro Gly Glu  
 690 695 700  
 Ala Lys Ser Val His Ala Met Pro Gly Phe Ile Trp Leu Ile Arg Ser  
 705 710 715 720  
 Leu Tyr Glu Met Gln Glu Glu Arg Leu Ala Arg Lys Ala Ala Arg Gly  
 725 730 735  
 Leu Asn Val Gly His Leu Lys Leu Thr Phe Cys Ser Val Gly Pro Thr  
 740 745 750  
 Glu Cys Ala Ala Leu Ala Phe Val Leu Gln His Leu Arg Arg Pro Val  
 755 760 765  
 Ala Leu Gln Leu Asp Tyr Asn Ser Val Gly Asp Ile Gly Val Glu Gln  
 770 775 780  
 Leu Leu Pro Cys Leu Gly Val Cys Lys Ala Leu Tyr Leu Arg Asp Asn  
 785 790 795 800  
 Asn Ile Ser Asp Arg Gly Ile Cys Lys Leu Ile Glu Cys Ala Leu His  
 805 810 815  
 Cys Glu Gln Leu Gln Lys Leu Ala Leu Gly Asn Asn Tyr Ile Thr Ala  
 820 825 830  
 Ala Gly Ala Gln Val Leu Ala Glu Gly Leu Arg Gly Asn Thr Ser Leu  
 835 840 845  
 Gln Phe Leu Gly Phe Trp Gly Asn Arg Val Gly Asp Glu Gly Ala Gln  
 850 855 860  
 Ala Leu Ala Glu Ala Leu Gly Asp His Gln Ser Leu Arg Trp Leu Ser  
 865 870 875 880  
 Leu Val Gly Asn Asn Ile Gly Ser Val Gly Ala Gln Ala Leu Ala Leu  
 885 890 895  
 Met Leu Ala Lys Asn Val Met Leu Glu Glu Leu Cys Leu Glu Glu Asn  
 900 905 910  
 His Leu Gln Asp Glu Gly Val Cys Ser Leu Ala Glu Gly Leu Lys Lys  
 915 920 925  
 Asn Ser Ser Leu Lys Ile Leu Asn Ile Lys Ile His Ala Ser Gly Phe  
 930 935 940  
 Asn Lys Leu Leu Glu Ser Ile Phe Cys Ile Leu Leu Val Val Glu Ala  
 945 950 955 960  
 Phe Phe Leu Gln Lys Val Val Lys Ile Leu Glu Glu Met Val Val Ser  
 965 970 975  
 Trp Leu Glu Val Arg Leu Ser Asn Asn Cys Ile Thr Tyr Leu Gly Ala  
 980 985 990  
 Glu Ala Leu Leu Gln Ala Leu Glu Arg Asn Asp Thr Ile Leu Glu Val  
 995 1000 1005  
 Trp

&lt;210&gt; 108

<400> 108  
000

<210> 109

<400> 109  
000

<210> 110

<400> 110  
000

<210> 111

<400> 111  
000

<210> 112

<220>

<221> VARIANT

<222> (1)... (87)

<223> Xaa = Any Amino Acid

<400> 112  
000

<210> 113

<400> 113  
000

<210> 114

<400> 114  
000

<210> 115

<400> 115  
000

<210> 116

<400> 116  
000

<210> 117

<400> 117  
000

<210> 118

<400> 118  
000

<210> 119

<400> 119  
000

<210> 120

<400> 120  
000

<210> 121

<400> 121  
000

<210> 122

<400> 122  
000

<210> 123

<400> 123  
000

<210> 124

<400> 124  
000

<210> 125

<400> 125  
000

<210> 126

<400> 126  
000

<210> 127

<400> 127  
000

<210> 128

<400> 128  
000

<210> 129

<400> 129  
000

<210> 130

<400> 130  
000

<210> 131

<400> 131  
000

<210> 132

<400> 132  
000

<210> 133

<400> 133  
000

<210> 134

<400> 134  
000

<210> 135

<400> 135  
000

<210> 136

<400> 136  
000

<210> 137

<400> 137  
000

<210> 138

<400> 138  
000

<210> 139

<400> 139  
000

<210> 140

<400> 140  
000

<210> 141

<400> 141  
000

<210> 142

<400> 142  
000

<210> 143

<400> 143  
000

<210> 144

<400> 144  
000

<210> 145

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 145

ccagaattca tggccgacaa ggtcctgaag

30

<210> 146

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 146

ccactcgagc taatttcag gtatcggacc

30

<210> 147

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 147

gaagacagtt acctggcaga

20

<210> 148

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 148

ttgtattctg aacatggcac c

21

<210> 149

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 149

gatcatcatc caggccgccc gtggtgacag ccctgg

36

<210> 150

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 150

ccagggtgt caccacgggc ggctggatg atgac

36

<210> 151

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 151

cggaattcat ggccgacaag gtcctg

26

<210> 152

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 152

cgctcgagtt agtcttgcat attaaggtaa tttccaga 38

<210> 153  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 153  
catgtgaatg atccctctag cag 23

<210> 154  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 154  
gggctcggct atcgtgctct a 21

<210> 155  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 155  
acgatagccg agcccttatt c 21

<210> 156  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 156  
gtatggaatg ttctgaatcg c 21

<210> 157  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 157

cccgatcca tgaatttcat aaaggacaat agc 33

<210> 158  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 158  
cccttcgaac aagtcctgaa atagaggata 30

<210> 159  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 159  
ggtggagcag gatgctgcta gagg 24

<210> 160  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 160  
cacagtggtc caggctccga atgaagtca 29

<210> 161  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 161  
catcatttgc tgcgagaagg tggag 25

<210> 162  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 162

ttaacttgga taacacttgg ctaag 25

<210> 163  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 163  
gtaaacatca ttgctgga gaa 23

<210> 164  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 164  
ccgggcagg tagaatgc tat 23

<210> 165  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 165  
aatttcataa aggacaatag ccgag 25

<210> 166  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> primer

<400> 166  
tgtctactgt actttctaag ctgtt 25

<210> 167  
<211> 225  
<212> DNA  
<213> Homo sapiens

<220>  
<221> CDS  
<222> (1) ... (225)

&lt;400&gt; 167

gag agt act ccc tca gag atc ata gaa aga gaa aga aaa aag ttg ctt 48  
 Glu Ser Thr Pro Ser Glu Ile Ile Glu Arg Glu Arg Lys Lys Leu Leu  
 1 5 10 15

gaa atc ctt caa cat gat cct gat tct atc tta gac acg tta act tct 96  
 Glu Ile Leu Gln His Asp Pro Asp Ser Ile Leu Asp Thr Leu Thr Ser  
 20 25 30

cgg agg ctg att tct gag gaa gag tat gag act ctg gag aat gtt aca 144  
 Arg Arg Leu Ile Ser Glu Glu Glu Tyr Glu Thr Leu Glu Asn Val Thr  
 35 40 45

gat ctc ctg aag aaa agt cgg aag ctg tta att ttg gta cag aaa aag 192  
 Asp Leu Leu Lys Lys Ser Arg Lys Leu Leu Ile Leu Val Gln Lys Lys  
 50 55 60

gga gag gcg acc tgt cag cat ttt ctc aag tgt 225  
 Gly Glu Ala Thr Cys Gln His Phe Leu Lys Cys  
 65 70 75

&lt;210&gt; 168

&lt;211&gt; 75

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 168

Glu Ser Thr Pro Ser Glu Ile Ile Glu Arg Glu Arg Lys Lys Leu Leu  
 1 5 10 15  
 Glu Ile Leu Gln His Asp Pro Asp Ser Ile Leu Asp Thr Leu Thr Ser  
 20 25 30  
 Arg Arg Leu Ile Ser Glu Glu Glu Tyr Glu Thr Leu Glu Asn Val Thr  
 35 40 45  
 Asp Leu Leu Lys Lys Ser Arg Lys Leu Leu Ile Leu Val Gln Lys Lys  
 50 55 60  
 Gly Glu Ala Thr Cys Gln His Phe Leu Lys Cys  
 65 70 75

&lt;210&gt; 169

&lt;211&gt; 228

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(228)

&lt;400&gt; 169

atg tgc tcg cag gag gct ttt cag gca cag agg agc cag ctg gtc gag 48  
 Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu  
 1 5 10 15

ctg ctg gtc tca ggg tcc ctg gaa ggc ttc gag agt gtc ctg gac tgg 96

```

Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp
      20              25              30

ctg ctg tcc tgg gag gtc ctc tcc tgg gag gac tac gag ggc ttc cac 144
Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His
      35              40              45

ctc ctg ggc cag cct ctc tcc cac ttg gcc agg cgc ctt ctg gac acc 192
Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr
      50              55              60

gtc tgg aat aag ggt act tgg gcc tgt cag aag ctc 228
Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu
      65              70              75

```

<210> 170  
 <211> 76  
 <212> PRT  
 <213> Homo sapiens

```

<400> 170
Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu Val Glu
 1              5              10              15
Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu Asp Trp
      20              25              30
Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly Phe His
      35              40              45
Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu Asp Thr
      50              55              60
Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu
      65              70              75

```

<210> 171  
 <211> 243  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (1)...(243)

```

<400> 171
cca gcc cga gac ctg cag agt cac cgg cca gcc att gtc agg agg ctc 48
Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg Leu
 1              5              10              15

cac agc cat gtg gag aac atg ctg gac ctg gca tgg gag cgg ggt ttc 96
His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly Phe
      20              25              30

gtc agc cag tat gaa tgt gat gaa atc agg ttg ccg atc ttc aca ccg 144
Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr Pro
      35              40              45

```

```

tcc cag agg gca aga agg ctg ctt gat ctt gcc acg gtg aaa gcg aat 192
Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala Asn
    50                55                60

gga ttg gct gcc ttc ctt cta caa cat gtt cag gaa tta cca gtc cca 240
Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val Pro
    65                70                75                80

ttg 243
Leu

```

<210> 172  
 <211> 81  
 <212> PRT  
 <213> Homo sapiens

```

<400> 172
Pro Ala Arg Asp Leu Gln Ser His Arg Pro Ala Ile Val Arg Arg Leu
 1          5          10          15
His Ser His Val Glu Asn Met Leu Asp Leu Ala Trp Glu Arg Gly Phe
    20          25          30
Val Ser Gln Tyr Glu Cys Asp Glu Ile Arg Leu Pro Ile Phe Thr Pro
    35          40          45
Ser Gln Arg Ala Arg Arg Leu Leu Asp Leu Ala Thr Val Lys Ala Asn
    50          55          60
Gly Leu Ala Ala Phe Leu Leu Gln His Val Gln Glu Leu Pro Val Pro
 65          70          75          80
Leu

```

<210> 173  
 <211> 888  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (1) ... (888)

```

<400> 173
gac gat gcg gac act gtg ctg gtg ggt gag gcg ggc agt ggc aag 48
Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly Lys
 1          5          10          15

agc acg ctc ctg cag cgg ctg cac ttg ctg tgg gct gca ggg caa gac 96
Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln Asp
    20          25          30

ttc cag gaa ttt ctc ttt gtc ttc cca ttc agc tgc cgg cag ctg cag 144
Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu Gln
    35          40          45

```

tgc atg gcc aaa cca ctc tct gtg cgg act cta ctc ttt gag cac tgc	192
Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His Cys	
50 55 60	
tgt tgg cct gat gtt ggt caa gaa gac atc ttc cag tta ctc ctt gac	240
Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu Asp	
65 70 75 80	
cac cct gac cgt gtc ctg tta acc ttt gat ggc ttt gac gag ttc aag	288
His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe Lys	
85 90 95	
ttc agg ttc acg gat cgt gaa cgc cac tgc tcc ccg acc gac ccc acc	336
Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro Thr	
100 105 110	
tct gtc cag acc ctg ctc ttc aac ctt ctg cag ggc aac ctg ctg aag	384
Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu Lys	
115 120 125	
aat gcc cgc aag gtg gtg acc agc cgt ccg gcc gct gtg tcg gcg ttc	432
Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala Phe	
130 135 140	
ctc agg aag tac atc cgc acc gag ttc aac ctc aag ggc ttc tct gaa	480
Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser Glu	
145 150 155 160	
cag ggc atc gag ctg tac ctg agg aag cgc cat cat gag ccc ggg gtg	528
Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly Val	
165 170 175	
gcg gac cgc ctc atc cgc ctg ctc caa gag acc tca gcc ctg cac ggt	576
Ala Asp Arg Leu Ile Arg Leu Leu Glu Thr Ser Ala Leu His Gly	
180 185 190	
ttg tgc cac ctg cct gtc ttc tca tgg atg gtg tcc aaa tgc cac cag	624
Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His Gln	
195 200 205	
gaa ctg ttg ctg cag gag ggg ggg tcc cca aag acc act aca gat atg	672
Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp Met	
210 215 220	
tac ctg ctg att ctg cag cat ttt ctg ctg cat gcc acc ccc cca gac	720
Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro Asp	
225 230 235 240	
tca gct tcc caa ggt ctg gga ccc agt ctt ctt cgg ggc cgc ctc ccc	768
Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu Pro	
245 250 255	
acc ctc ctg cac ctg ggc aga ctg gct ctg tgg ggc ctg ggc atg tgc	816
Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met Cys	

260 265 270  
 tgc tac gtg ttc tca gcc cag cag ctc cag gca gca cag gtc agc cct 864  
 Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser Pro  
 275 280 285

gat gac att tct ctt ggc ttc ctg 888  
 Asp Asp Ile Ser Leu Gly Phe Leu  
 290 295

<210> 174

<211> 296

<212> PRT

<213> Homo sapiens

<400> 174

Asp Asp Ala Asp Thr Val Leu Val Val Gly Glu Ala Gly Ser Gly Lys  
 1 5 10 15  
 Ser Thr Leu Leu Gln Arg Leu His Leu Leu Trp Ala Ala Gly Gln Asp  
 20 25 30  
 Phe Gln Glu Phe Leu Phe Val Phe Pro Phe Ser Cys Arg Gln Leu Gln  
 35 40 45  
 Cys Met Ala Lys Pro Leu Ser Val Arg Thr Leu Leu Phe Glu His Cys  
 50 55 60  
 Cys Trp Pro Asp Val Gly Gln Glu Asp Ile Phe Gln Leu Leu Leu Asp  
 65 70 75 80  
 His Pro Asp Arg Val Leu Leu Thr Phe Asp Gly Phe Asp Glu Phe Lys  
 85 90 95  
 Phe Arg Phe Thr Asp Arg Glu Arg His Cys Ser Pro Thr Asp Pro Thr  
 100 105 110  
 Ser Val Gln Thr Leu Leu Phe Asn Leu Leu Gln Gly Asn Leu Leu Lys  
 115 120 125  
 Asn Ala Arg Lys Val Val Thr Ser Arg Pro Ala Ala Val Ser Ala Phe  
 130 135 140  
 Leu Arg Lys Tyr Ile Arg Thr Glu Phe Asn Leu Lys Gly Phe Ser Glu  
 145 150 155 160  
 Gln Gly Ile Glu Leu Tyr Leu Arg Lys Arg His His Glu Pro Gly Val  
 165 170 175  
 Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser Ala Leu His Gly  
 180 185 190  
 Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser Lys Cys His Gln  
 195 200 205  
 Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr Thr Thr Asp Met  
 210 215 220  
 Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala Thr Pro Pro Asp  
 225 230 235 240  
 Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg Gly Arg Leu Pro  
 245 250 255  
 Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly Leu Gly Met Cys  
 260 265 270  
 Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala Gln Val Ser Pro  
 275 280 285  
 Asp Asp Ile Ser Leu Gly Phe Leu  
 290 295

<210> 175  
 <211> 1209  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (1)...(1209)

<400> 175  
 gag ccc ggg gtg gcg gac cgc ctc atc cgc ctg ctc caa gag acc tca 48  
 Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser  
 1 5 10 15  
 gcc ctg cac ggt ttg tgc cac ctg cct gtc ttc tca tgg atg gtg tcc 96  
 Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser  
 20 25 30  
 aaa tgc cac cag gaa ctg ttg ctg cag gag ggg ggg tcc cca aag acc 144  
 Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr  
 35 40 45  
 act aca gat atg tac ctg ctg att ctg cag cat ttt ctg ctg cat gcc 192  
 Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala  
 50 55 60  
 acc ccc cca gac tca gct tcc caa ggt ctg gga ccc agt ctt ctt cgg 240  
 Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg  
 65 70 75 80  
 ggc cgc ctc ccc acc ctc ctg cac ctg ggc aga ctg gct ctg tgg ggc 288  
 Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly  
 85 90 95  
 ctg ggc atg tgc tgc tac gtg ttc tca gcc cag cag ctc cag gca gca 336  
 Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala  
 100 105 110  
 cag gtc agc cct gat gac att tct ctt ggc ttc ctg gtg cgt gcc aaa 384  
 Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys  
 115 120 125  
 ggt gtc gtg cca ggg agt acg gcg ccc ctg gaa ttc ctt cac atc act 432  
 Gly Val Val Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr  
 130 135 140  
 ttc cag tgc ttc ttt gcc gcg ttc tac ctg gca ctc agt gct gat gtg 480  
 Phe Gln Cys Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val  
 145 150 155 160  
 cca cca gct ttg ctc aga cac ctc ttc aat tgt ggc agg cca ggc aac 528  
 Pro Pro Ala Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn  
 165 170 175

tca cca atg gcc agg ctc ctg ccc acg atg tgc atc cag gcc tcg gag	576
Ser Pro Met Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu	
180 185 190	
gga aag gac agc agc gtg gca gct ttg ctg cag aag gcc gag ccg cac	624
Gly Lys Asp Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His	
195 200 205	
aac ctt cag atc aca gca gcc ttc ctg gca ggg ctg ttg tcc cgg gag	672
Asn Leu Gln Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu	
210 215 220	
cac tgg ggc ctg ctg gct gag tgc cag aca tct gag aag gcc ctg ctc	720
His Trp Gly Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu	
225 230 235 240	
cgg cgc cag gcc tgt gcc cgc tgg tgt ctg gcc cgc agc ctc cgc aag	768
Arg Arg Gln Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys	
245 250 255	
cac ttc cac tcc atc ccg cca gct gca ccg ggt gag gcc aag agc gtg	816
His Phe His Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val	
260 265 270	
cat gcc atg ccc ggg ttc atc tgg ctc atc cgg agc ctg tac gag atg	864
His Ala Met Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met	
275 280 285	
cag gag gag cgg ctg gct cgg aag gct gca cgt ggc ctg aat gtt ggg	912
Gln Glu Glu Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly	
290 295 300	
cac ctc aag ttg aca ttt tgc agt gtg ggc ccc act gag tgt gct gcc	960
His Leu Lys Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala	
305 310 315 320	
ctg gcc ttt gtg ctg cag cac ctc cgg cgg ccc gtg gcc ctg cag ctg	1008
Leu Ala Phe Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu	
325 330 335	
gac tac aac tct gtg ggt gac att ggc gtg gag cag ctg ctg cct tgc	1056
Asp Tyr Asn Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys	
340 345 350	
ctt ggt gtc tgc aag gct ctg tat ttg cgc gat aac aat atc tca gac	1104
Leu Gly Val Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp	
355 360 365	
cga ggc atc tgc aag ctc att gaa tgt gct ctt cac tgc gag caa ttg	1152
Arg Gly Ile Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu	
370 375 380	
cag aag tta gcg ctg ggg aat aac tac atc act gcc gcg gga gcc caa	1200
Gln Lys Leu Ala Leu Gly Asn Asn Tyr Ile Thr Ala Ala Gly Ala Gln	

385

390

395

400

gtg ctg gcc  
Val Leu Ala

1209

&lt;210&gt; 176

&lt;211&gt; 403

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 176

Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu Gln Glu Thr Ser  
1 5 10 15  
Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser Trp Met Val Ser  
20 25 30  
Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly Ser Pro Lys Thr  
35 40 45  
Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe Leu Leu His Ala  
50 55 60  
Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro Ser Leu Leu Arg  
65 70 75 80  
Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu Ala Leu Trp Gly  
85 90 95  
Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln Leu Gln Ala Ala  
100 105 110  
Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu Val Arg Ala Lys  
115 120 125  
Gly Val Val Pro Gly Ser Thr Ala Pro Leu Glu Phe Leu His Ile Thr  
130 135 140  
Phe Gln Cys Phe Phe Ala Ala Phe Tyr Leu Ala Leu Ser Ala Asp Val  
145 150 155 160  
Pro Pro Ala Leu Leu Arg His Leu Phe Asn Cys Gly Arg Pro Gly Asn  
165 170 175  
Ser Pro Met Ala Arg Leu Leu Pro Thr Met Cys Ile Gln Ala Ser Glu  
180 185 190  
Gly Lys Asp Ser Ser Val Ala Ala Leu Leu Gln Lys Ala Glu Pro His  
195 200 205  
Asn Leu Gln Ile Thr Ala Ala Phe Leu Ala Gly Leu Leu Ser Arg Glu  
210 215 220  
His Trp Gly Leu Leu Ala Glu Cys Gln Thr Ser Glu Lys Ala Leu Leu  
225 230 235 240  
Arg Arg Gln Ala Cys Ala Arg Trp Cys Leu Ala Arg Ser Leu Arg Lys  
245 250 255  
His Phe His Ser Ile Pro Pro Ala Ala Pro Gly Glu Ala Lys Ser Val  
260 265 270  
His Ala Met Pro Gly Phe Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met  
275 280 285  
Gln Glu Glu Arg Leu Ala Arg Lys Ala Ala Arg Gly Leu Asn Val Gly  
290 295 300  
His Leu Lys Leu Thr Phe Cys Ser Val Gly Pro Thr Glu Cys Ala Ala  
305 310 315 320  
Leu Ala Phe Val Leu Gln His Leu Arg Arg Pro Val Ala Leu Gln Leu  
325 330 335

Asp Tyr Asn Ser Val Gly Asp Ile Gly Val Glu Gln Leu Leu Pro Cys  
                   340                  345                  350  
 Leu Gly Val Cys Lys Ala Leu Tyr Leu Arg Asp Asn Asn Ile Ser Asp  
                   355                  360                  365  
 Arg Gly Ile Cys Lys Leu Ile Glu Cys Ala Leu His Cys Glu Gln Leu  
                   370                  375                  380  
 Gln Lys Leu Ala Leu Gly Asn Asn Tyr Ile Thr Ala Ala Gly Ala Gln  
 385                  390                  395                  400  
 Val Leu Ala

&lt;210&gt; 177

&lt;211&gt; 261

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1) ... (261)

&lt;400&gt; 177

atg aat ttc ata aag gac aat agc cga gcc ctt att caa aga atg gga 48  
 Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly  
   1                  5                  10                  15  
  
 atg act gtt ata aag caa atc aca gat gac cta ttt gta tgg aat gtt 96  
 Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val  
                   20                  25                  30  
  
 ctg aat cgc gaa gaa gta aac atc att tgc tgc gag aag gtg gag cag 144  
 Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln  
                   35                  40                  45  
  
 gat gct gct aga ggg atc att cac atg att ttg aaa aag ggt tca gag 192  
 Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu  
                   50                  55                  60  
  
 tcc tgt aac ctc ttt ctt aaa tcc ctt aag gag tgg aac tat cct cta 240  
 Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu  
                   65                  70                  75                  80  
  
 ttt cag gac ttg aat gga caa 261  
 Phe Gln Asp Leu Asn Gly Gln  
                   85

&lt;210&gt; 178

&lt;211&gt; 87

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 178

Met Asn Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly  
   1                  5                  10                  15

```

Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val
      20                      25                      30
Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln
      35                      40                      45
Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu
      50                      55                      60
Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu
      65                      70                      75                      80
Phe Gln Asp Leu Asn Gly Gln
                        85

```

&lt;210&gt; 179

&lt;211&gt; 891

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1) ... (891)

&lt;400&gt; 179

```

ctt cag agc ccc tgc atc att gaa ggg gaa tct ggc aaa ggc aag tcc 48
Leu Gln Ser Pro Cys Ile Ile Glu Gly Glu Ser Gly Lys Gly Lys Ser
  1                      5                      10                      15

act ctg ctg cag cgc att gcc atg ctc tgg ggc tcc gga aag tgc aag 96
Thr Leu Leu Gln Arg Ile Ala Met Leu Trp Gly Ser Gly Lys Cys Lys
      20                      25                      30

gct ctg acc aag ttc aaa ttc gtc ttc ttc ctc cgt ctc agc agg gcc 144
Ala Leu Thr Lys Phe Lys Phe Val Phe Phe Leu Arg Leu Ser Arg Ala
      35                      40                      45

cag ggt gga ctt ttt gaa acc ctc tgt gat caa ctc ctg gat ata cct 192
Gln Gly Gly Leu Phe Glu Thr Leu Cys Asp Gln Leu Leu Asp Ile Pro
      50                      55                      60

ggc aca atc agg aag cag aca ttc atg gcc atg ctg ctg aag ctg cgg 240
Gly Thr Ile Arg Lys Gln Thr Phe Met Ala Met Leu Leu Lys Leu Arg
      65                      70                      75                      80

cag agg gtt ctt ttc ctt ctt gat ggc tac aat gaa ttc aag ccc cag 288
Gln Arg Val Leu Phe Leu Leu Asp Gly Tyr Asn Glu Phe Lys Pro Gln
      85                      90                      95

aac tgc cca gaa atc gaa gcc ctg ata aag gaa aac cac cgc ttc aag 336
Asn Cys Pro Glu Ile Glu Ala Leu Ile Lys Glu Asn His Arg Phe Lys
      100                      105                      110

aac atg gtc atc gtc acc act acc act gag tgc ctg agg cac ata cgg 384
Asn Met Val Ile Val Thr Thr Thr Thr Glu Cys Leu Arg His Ile Arg
      115                      120                      125

cag ttt ggt gcc ctg act gct gag gtg ggg gat atg aca gaa gac agc 432

```

Gln Phe Gly Ala Leu Thr Ala Glu Val Gly Asp Met Thr Glu Asp Ser  
 130 135 140  
 gcc cag gct ctc atc cga gaa gtg ctg atc aag gag ctt gct gaa ggc 480  
 Ala Gln Ala Leu Ile Arg Glu Val Leu Ile Lys Glu Leu Ala Glu Gly  
 145 150 155 160  
 ttg ttg ctc caa att cag aaa tcc agg tgc ttg agg aat ctc atg aag 528  
 Leu Leu Leu Gln Ile Gln Lys Ser Arg Cys Leu Arg Asn Leu Met Lys  
 165 170 175  
 acc cct ctc ttt gtg gtc atc act tgt gca atc cag atg ggt gaa agt 576  
 Thr Pro Leu Phe Val Val Ile Thr Cys Ala Ile Gln Met Gly Glu Ser  
 180 185 190  
 gag ttc cac tct cac aca caa aca acg ctg ttc cat acc ttc tat gat 624  
 Glu Phe His Ser His Thr Gln Thr Thr Leu Phe His Thr Phe Tyr Asp  
 195 200 205  
 ctg ttg ata cag aaa aac aaa cac aaa cat aaa ggt gtg gct gca agt 672  
 Leu Leu Ile Gln Lys Asn Lys His Lys His Lys Gly Val Ala Ala Ser  
 210 215 220  
 gac ttc att cgg agc ctg gac cac cgt gga gac cta gct ctg gag ggt 720  
 Asp Phe Ile Arg Ser Leu Asp His Arg Gly Asp Leu Ala Leu Glu Gly  
 225 230 235 240  
 gtg ttc tcc cac aag ttt gat ttc gaa ctg cag gat gtg tcc agc gtg 768  
 Val Phe Ser His Lys Phe Asp Phe Glu Leu Gln Asp Val Ser Ser Val  
 245 250 255  
 aat gag gat gtc ctg ctg aca act ggg ctc ctc tgt aaa tat aca gct 816  
 Asn Glu Asp Val Leu Leu Thr Thr Gly Leu Leu Cys Lys Tyr Thr Ala  
 260 265 270  
 caa agg ttc aag cca aag tat aaa ttc ttt cac aag tca ttc cag gag 864  
 Gln Arg Phe Lys Pro Lys Tyr Lys Phe Phe His Lys Ser Phe Gln Glu  
 275 280 285  
 tac aca gca gga cga aga ctc agc agt 891  
 Tyr Thr Ala Gly Arg Arg Leu Ser Ser  
 290 295

&lt;210&gt; 180

&lt;211&gt; 297

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 180

Leu Gln Ser Pro Cys Ile Ile Glu Gly Glu Ser Gly Lys Gly Lys Ser  
 1 5 10 15  
 Thr Leu Leu Gln Arg Ile Ala Met Leu Trp Gly Ser Gly Lys Cys Lys  
 20 25 30  
 Ala Leu Thr Lys Phe Lys Phe Val Phe Phe Leu Arg Leu Ser Arg Ala

		35					40					45						
Gln	Gly	Gly	Leu	Phe	Glu	Thr	Leu	Cys	Asp	Gln	Leu	Leu	Asp	Ile	Pro			
	50					55					60							
Gly	Thr	Ile	Arg	Lys	Gln	Thr	Phe	Met	Ala	Met	Leu	Leu	Lys	Leu	Arg			
65					70					75					80			
Gln	Arg	Val	Leu	Phe	Leu	Leu	Asp	Gly	Tyr	Asn	Glu	Phe	Lys	Pro	Gln			
				85					90					95				
Asn	Cys	Pro	Glu	Ile	Glu	Ala	Leu	Ile	Lys	Glu	Asn	His	Arg	Phe	Lys			
			100						105				110					
Asn	Met	Val	Ile	Val	Thr	Thr	Thr	Thr	Glu	Cys	Leu	Arg	His	Ile	Arg			
		115					120					125						
Gln	Phe	Gly	Ala	Leu	Thr	Ala	Glu	Val	Gly	Asp	Met	Thr	Glu	Asp	Ser			
	130					135				140								
Ala	Gln	Ala	Leu	Ile	Arg	Glu	Val	Leu	Ile	Lys	Glu	Leu	Ala	Glu	Gly			
145					150					155					160			
Leu	Leu	Leu	Gln	Ile	Gln	Lys	Ser	Arg	Cys	Leu	Arg	Asn	Leu	Met	Lys			
				165					170					175				
Thr	Pro	Leu	Phe	Val	Val	Ile	Thr	Cys	Ala	Ile	Gln	Met	Gly	Glu	Ser			
			180					185					190					
Glu	Phe	His	Ser	His	Thr	Gln	Thr	Thr	Leu	Phe	His	Thr	Phe	Tyr	Asp			
		195					200					205						
Leu	Leu	Ile	Gln	Lys	Asn	Lys	His	Lys	His	Lys	Gly	Val	Ala	Ala	Ser			
		210					215				220							
Asp	Phe	Ile	Arg	Ser	Leu	Asp	His	Arg	Gly	Asp	Leu	Ala	Leu	Glu	Gly			
225					230					235					240			
Val	Phe	Ser	His	Lys	Phe	Asp	Phe	Glu	Leu	Gln	Asp	Val	Ser	Ser	Val			
				245					250					255				
Asn	Glu	Asp	Val	Leu	Leu	Thr	Thr	Gly	Leu	Leu	Cys	Lys	Tyr	Thr	Ala			
			260					265					270					
Gln	Arg	Phe	Lys	Pro	Lys	Tyr	Lys	Phe	Phe	His	Lys	Ser	Phe	Gln	Glu			
		275					280					285						
Tyr	Thr	Ala	Gly	Arg	Arg	Leu	Ser	Ser										
	290					295												

```
<210> 181
<211> 618
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> CDS
<222> (1) ... (618)
```

<400> 181																
ggt	aac	ttg	aag	aac	ctt	aca	aag	ctc	ata	atg	gat	aac	ata	aag	atg	48
Gly	Asn	Leu	Lys	Asn	Leu	Thr	Lys	Leu	Ile	Met	Asp	Asn	Ile	Lys	Met	
1				5					10					15		
aat	gaa	gaa	gat	gct	ata	aaa	cta	gct	gaa	ggc	ctg	aaa	aac	ctg	aag	96
Asn	Glu	Glu	Asp	Ala	Ile	Lys	Leu	Ala	Glu	Gly	Leu	Lys	Asn	Leu	Lys	
			20					25					30			
aag	atg	tgt	tta	ttt	cat	ttg	acc	cac	ttg	tct	gac	att	gga	gag	gga	144
Lys	Met	Cys	Leu	Phe	His	Leu	Thr	His	Leu	Ser	Asp	Ile	Gly	Glu	Gly	

35	40	45	
atg gat tac ata gtc aag tct ctg tca agt gaa ccc tgt gac ctt gaa			192
Met Asp Tyr Ile Val Lys Ser Leu Ser Ser Glu Pro Cys Asp Leu Glu			
50	55	60	
gaa att caa tta gtc tcc tgc tgc ttg tct gca aat gca gtg aaa atc			240
Glu Ile Gln Leu Val Ser Cys Cys Leu Ser Ala Asn Ala Val Lys Ile			
65	70	75	80
cta gct cag aat ctt cac aat ttg gtc aaa ctg agc att ctt gat tta			288
Leu Ala Gln Asn Leu His Asn Leu Val Lys Leu Ser Ile Leu Asp Leu			
85	90	95	
tca gaa aat tac ctg gaa aaa gat gga aat gaa gct ctt cat gaa ctg			336
Ser Glu Asn Tyr Leu Glu Lys Asp Gly Asn Glu Ala Leu His Glu Leu			
100	105	110	
atc gac agg atg aac gtg cta gaa cag ctc acc gca ctg atg ctg ccc			384
Ile Asp Arg Met Asn Val Leu Glu Gln Leu Thr Ala Leu Met Leu Pro			
115	120	125	
tgg ggc tgt gac gtg caa ggc agc ctg agc agc ctg ttg aaa cat ttg			432
Trp Gly Cys Asp Val Gln Gly Ser Leu Ser Ser Leu Leu Lys His Leu			
130	135	140	
gag gag gtc cca caa ctc gtc aag ctt ggg ttg aaa aac tgg aga ctc			480
Glu Glu Val Pro Gln Leu Val Lys Leu Gly Leu Lys Asn Trp Arg Leu			
145	150	155	160
aca gat aca gag att aga att tta ggt gca ttt ttt gga aag aac cct			528
Thr Asp Thr Glu Ile Arg Ile Leu Gly Ala Phe Phe Gly Lys Asn Pro			
165	170	175	
ctg aaa aac ttc cag cag ttg aat ttg gcg gga aat cgt gtg agc agt			576
Leu Lys Asn Phe Gln Gln Leu Asn Leu Ala Gly Asn Arg Val Ser Ser			
180	185	190	
gat gga tgg ctt gcc ttc atg ggt gta ttt gag aat ctt aag			618
Asp Gly Trp Leu Ala Phe Met Gly Val Phe Glu Asn Leu Lys			
195	200	205	

&lt;210&gt; 182

&lt;211&gt; 206

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 182

Gly Asn Leu Lys Asn Leu Thr Lys Leu Ile Met Asp Asn Ile Lys Met	
1	5
Asn Glu Glu Asp Ala Ile Lys Leu Ala Glu Gly Leu Lys Asn Leu Lys	
20	25
Lys Met Cys Leu Phe His Leu Thr His Leu Ser Asp Ile Gly Glu Gly	
30	

```
<210> 184
<211> 55
<212> PRT
<213> Homo sapiens
```

&lt;400&gt; 184

Thr Tyr Ile Pro Ser Arg Ala Val Ser Leu Phe Phe Asn Trp Lys Gln  
 1 5 10 15  
 Glu Phe Arg Thr Leu Glu Val Thr Leu Arg Asp Phe Ser Lys Leu Asn  
 20 25 30  
 Lys Gln Asp Ile Arg Tyr Leu Gly Lys Ile Phe Ser Ser Ala Thr Ser  
 35 40 45  
 Leu Arg Leu Gln Ile Lys Arg  
 50 55

&lt;210&gt; 185

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; primer

&lt;400&gt; 185

gaaatgtgct cgcaggagg

19

&lt;210&gt; 186

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; primer

&lt;400&gt; 186

gatgagcttc tgacaggccc

20

&lt;210&gt; 187

&lt;211&gt; 3063

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(2385)

&lt;221&gt; CDS

&lt;222&gt; (2389)...(2928)

&lt;400&gt; 187

tgt gaa atg tgc tgc cag gag gct ttt cag gca cag agg agc cag ctg 48  
 Cys Glu Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu  
 1 5 10 15

gtc gag ctg ctg gtc tca ggg tcc ctg gaa ggc ttc gag agt gtc ctg 96  
 Val Glu Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu  
 20 25 30

gac tgg ctg ctg tcc tgg gag gtc ctc tcc tgg gag gac tac gag ggc 144

Asp	Trp	Leu	Leu	Ser	Trp	Glu	Val	Leu	Ser	Trp	Glu	Asp	Tyr	Glu	Gly	
		35					40					45				
ttc	cac	ctc	ctg	ggc	cag	cct	ctc	tcc	cac	ttg	gcc	agg	cgc	ctt	ctg	192
Phe	His	Leu	Leu	Gly	Gln	Pro	Leu	Ser	His	Leu	Ala	Arg	Arg	Leu	Leu	
		50				55					60					
gac	acc	gtc	tgg	aat	aag	ggg	act	tgg	gcc	tgt	cag	aag	ctc	atc	gcg	240
Asp	Thr	Val	Trp	Asn	Lys	Gly	Thr	Trp	Ala	Cys	Gln	Lys	Leu	Ile	Ala	
		65			70					75					80	
gct	gcc	caa	gaa	gcc	cag	gcc	gac	agc	cag	tcc	ccc	aag	ctg	cat	ggc	288
Ala	Ala	Gln	Glu	Ala	Gln	Ala	Asp	Ser	Gln	Ser	Pro	Lys	Leu	His	Gly	
				85					90					95		
tgc	tgg	gac	ccc	cac	tcg	ctc	cac	cca	gcc	cga	gac	ctg	cag	agt	cac	336
Cys	Trp	Asp	Pro	His	Ser	Leu	His	Pro	Ala	Arg	Asp	Leu	Gln	Ser	His	
			100					105					110			
cgg	cca	gcc	att	gtc	agg	agg	ctc	cac	agc	cat	gtg	gag	aac	atg	ctg	384
Arg	Pro	Ala	Ile	Val	Arg	Arg	Leu	His	Ser	His	Val	Glu	Asn	Met	Leu	
		115					120					125				
gac	ctg	gca	tgg	gag	cgg	ggg	ttc	gtc	agc	cag	tat	gaa	tgt	gat	gaa	432
Asp	Leu	Ala	Trp	Glu	Arg	Gly	Phe	Val	Ser	Gln	Tyr	Glu	Cys	Asp	Glu	
		130				135					140					
atc	agg	ttg	ccg	atc	ttc	aca	ccg	tcc	cag	agg	gca	aga	agg	ctg	ctt	480
Ile	Arg	Leu	Pro	Ile	Phe	Thr	Pro	Ser	Gln	Arg	Ala	Arg	Arg	Leu	Leu	
		145			150				155					160		
gat	ctt	gcc	acg	gtg	aaa	gcg	aat	gga	ttg	gct	gcc	ttc	ctt	cta	caa	528
Asp	Leu	Ala	Thr	Val	Lys	Ala	Asn	Gly	Leu	Ala	Ala	Phe	Leu	Leu	Gln	
			165					170					175			
cat	gtt	cag	gaa	tta	cca	gtc	cca	ttg	gcc	ctg	cct	ttg	gaa	gct	gcc	576
His	Val	Gln	Glu	Leu	Pro	Val	Pro	Leu	Ala	Leu	Pro	Leu	Glu	Ala	Ala	
			180				185					190				
aca	tgc	aag	aag	tat	atg	gcc	aag	ctg	agg	acc	acg	gtg	tct	gct	cag	624
Thr	Cys	Lys	Lys	Tyr	Met	Ala	Lys	Leu	Arg	Thr	Thr	Val	Ser	Ala	Gln	
		195					200					205				
tct	cgc	ttc	ctc	agt	acc	tat	gat	gga	gca	gag	acg	ctc	tgc	ctg	gag	672
Ser	Arg	Phe	Leu	Ser	Thr	Tyr	Asp	Gly	Ala	Glu	Thr	Leu	Cys	Leu	Glu	
		210				215					220					
gac	ata	tac	aca	gag	aat	gtc	ctg	gag	gtc	tgg	gca	gat	gtg	ggc	atg	720
Asp	Ile	Tyr	Thr	Glu	Asn	Val	Leu	Glu	Val	Trp	Ala	Asp	Val	Gly	Met	
		225			230					235				240		
gct	gga	ccc	ccg	cag	aag	agc	cca	gcc	acc	ctg	ggc	ctg	gag	gag	ctc	768
Ala	Gly	Pro	Pro	Gln	Lys	Ser	Pro	Ala	Thr	Leu	Gly	Leu	Glu	Glu	Leu	
				245				250					255			

ttc agc acc cct ggc cac ctc aat gac gat gcg gac act gtg ctg gtg	816
Phe Ser Thr Pro Gly His Leu Asn Asp Asp Ala Asp Thr Val Leu Val	
260 265 270	
gtg ggt gag gcg ggc agt ggc aag agc acg ctc ctg cag cgg ctg cac	864
Val Gly Glu Ala Gly Ser Gly Lys Ser Thr Leu Leu Gln Arg Leu His	
275 280 285	
ttg ctg tgg gct gca ggg caa gac ttc cag gaa ttt ctc ttt gtc ttc	912
Leu Leu Trp Ala Ala Gly Gln Asp Phe Gln Glu Phe Leu Phe Val Phe	
290 295 300	
cca ttc agc tgc cgg cag ctg cag tgc atg gcc aaa cca ctc tct gtg	960
Pro Phe Ser Cys Arg Gln Leu Gln Cys Met Ala Lys Pro Leu Ser Val	
305 310 315 320	
cgg act cta ctc ttt gag cac tgc tgt tgg cct gat gtt ggt caa gaa	1008
Arg Thr Leu Leu Phe Glu His Cys Cys Trp Pro Asp Val Gly Gln Glu	
325 330 335	
gac atc ttc cag tta ctc ctt gac cac cct gac cgt gtc ctg tta acc	1056
Asp Ile Phe Gln Leu Leu Leu Asp His Pro Asp Arg Val Leu Leu Thr	
340 345 350	
ttt gat ggc ttt gac gag ttc aag ttc agg ttc acg gat cgt gaa cgc	1104
Phe Asp Gly Phe Asp Glu Phe Lys Phe Arg Phe Thr Asp Arg Glu Arg	
355 360 365	
cac tgc tcc ccg acc gac ccc acc tct gtc cag acc ctg ctc ttc aac	1152
His Cys Ser Pro Thr Asp Pro Thr Ser Val Gln Thr Leu Leu Phe Asn	
370 375 380	
ctt ctg cag ggc aac ctg ctg aag aat gcc cgc aag gtg gtg acc agc	1200
Leu Leu Gln Gly Asn Leu Leu Lys Asn Ala Arg Lys Val Val Thr Ser	
385 390 395 400	
cgt ccg gcc gct gtg tcg gcg ttc ctc agg aag tac atc cgc acc gag	1248
Arg Pro Ala Ala Val Ser Ala Phe Leu Arg Lys Tyr Ile Arg Thr Glu	
405 410 415	
ttc aac ctc aag ggc ttc tct gaa cag ggc atc gag ctg tac ctg agg	1296
Phe Asn Leu Lys Gly Phe Ser Glu Gln Gly Ile Glu Leu Tyr Leu Arg	
420 425 430	
aag cgc cat cat gag ccc ggg gtg gcg gac cgc ctc atc cgc ctg ctc	1344
Lys Arg His His Glu Pro Gly Val Ala Asp Arg Leu Ile Arg Leu Leu	
435 440 445	
caa gag acc tca gcc ctg cac ggt ttg tgc cac ctg cct gtc ttc tca	1392
Gln Glu Thr Ser Ala Leu His Gly Leu Cys His Leu Pro Val Phe Ser	
450 455 460	
tgg atg gtg tcc aaa tgc cac cag gaa ctg ttg ctg cag gag ggg ggg	1440
Trp Met Val Ser Lys Cys His Gln Glu Leu Leu Leu Gln Glu Gly Gly	
465 470 475 480	

tcc cca aag acc act aca gat atg tac ctg ctg att ctg cag cat ttt	1488
Ser Pro Lys Thr Thr Thr Asp Met Tyr Leu Leu Ile Leu Gln His Phe	
485 490 495	
ctg ctg cat gcc acc ccc cca gac tca gct tcc caa ggt ctg gga ccc	1536
Leu Leu His Ala Thr Pro Pro Asp Ser Ala Ser Gln Gly Leu Gly Pro	
500 505 510	
agt ctt ctt cgg ggc cgc ctc ccc acc ctc ctg cac ctg ggc aga ctg	1584
Ser Leu Leu Arg Gly Arg Leu Pro Thr Leu Leu His Leu Gly Arg Leu	
515 520 525	
gct ctg tgg ggc ctg ggc atg tgc tgc tac gtg ttc tca gcc cag cag	1632
Ala Leu Trp Gly Leu Gly Met Cys Cys Tyr Val Phe Ser Ala Gln Gln	
530 535 540	
ctc cag gca gca cag gtc agc cct gat gac att tct ctt ggc ttc ctg	1680
Leu Gln Ala Ala Gln Val Ser Pro Asp Asp Ile Ser Leu Gly Phe Leu	
545 550 555 560	
gtg cgt gcc aaa ggt gtc gtg cca ggg agt acg gcg ccc ctg gaa ttc	1728
Val Arg Ala Lys Gly Val Val Pro Gly Ser Thr Ala Pro Leu Glu Phe	
565 570 575	
ctt cac atc act ttc cag tgc ttc ttt gcc gcg ttc tac ctg gca ctc	1776
Leu His Ile Thr Phe Gln Cys Phe Phe Ala Ala Phe Tyr Leu Ala Leu	
580 585 590	
agt gct gat gtg cca cca gct ttg ctc aga cac ctc ttc aat tgt ggc	1824
Ser Ala Asp Val Pro Pro Ala Leu Leu Arg His Leu Phe Asn Cys Gly	
595 600 605	
agg cca ggc aac tca cca atg gcc agg ctc ctg ccc acg atg tgc atc	1872
Arg Pro Gly Asn Ser Pro Met Ala Arg Leu Leu Pro Thr Met Cys Ile	
610 615 620	
cag gcc tcg gag gga aag gac agc agc gtg gca gct ttg ctg cag aag	1920
Gln Ala Ser Glu Gly Lys Asp Ser Ser Val Ala Ala Leu Leu Gln Lys	
625 630 635 640	
gcc gag ccg cac aac ctt cag atc aca gca gcc ttc ctg gca ggc ctg	1968
Ala Glu Pro His Asn Leu Gln Ile Thr Ala Ala Phe Leu Ala Gly Leu	
645 650 655	
ttg tcc cgg gag cac tgg ggc ctg ctg gct gag tgc cag aca tct gag	2016
Leu Ser Arg Glu His Trp Gly Leu Leu Ala Glu Cys Gln Thr Ser Glu	
660 665 670	
aag gcc ctg ctc cgg cgc cag gcc tgt gcc cgc tgg tgt ctg gcc cgc	2064
Lys Ala Leu Leu Arg Arg Gln Ala Cys Ala Arg Trp Cys Leu Ala Arg	
675 680 685	
agc ctc cgc aag cac ttc cac tcc atc ccg cca gct gca ccg ggt gag	2112
Ser Leu Arg Lys His Phe His Ser Ile Pro Pro Ala Ala Pro Gly Glu	

690	695	700	
gcc aag agc gtg cat	gcc atg ccc ggg ttc atc	tgg ctc atc cgg agc	2160
Ala Lys Ser Val His	Ala Met Pro Gly Phe Ile	Trp Leu Ile Arg Ser	
705	710	715 720	
ctg tac gag atg cag gag	gag cgg ctg gct cgg aag	gct gca cgt ggc	2208
Leu Tyr Glu Met Gln	Glu Glu Arg Leu Ala Arg	Lys Ala Ala Arg Gly	
	725	730 735	
ctg aat gtt ggg cac ctc	aag ttg aca ttt tgc agt	gtg ggc ccc act	2256
Leu Asn Val Gly His	Leu Lys Leu Thr Phe Cys	Ser Val Gly Pro Thr	
	740	745 750	
gag tgt gct gcc ctg gcc	ttt gtg ctg cag cac ctc	cgg cgg ccc gtg	2304
Glu Cys Ala Ala Leu	Ala Phe Val Leu Gln His	Leu Arg Arg Pro Val	
	755	760 765	
gcc ctg cag ctg gac tac	aac tct gtg ggt gac att	ggc gtg gag cag	2352
Ala Leu Gln Leu Asp	Tyr Asn Ser Val Gly Asp	Ile Gly Val Glu Gln	
	770	775 780	
ctg ctg cct tgc ctt ggt	gtc tgc aag gct ctg taa	ttc tgg ggc aac	2400
Leu Leu Pro Cys Leu	Gly Val Cys Lys Ala Leu	Phe Trp Gly Asn	
	785	790 795	
aga gtg ggt gac gag ggg	gcc cag gcc ctg gct gaa	gcc ttg ggt gat	2448
Arg Val Gly Asp Glu	Gly Ala Gln Ala Leu	Glu Ala Leu Gly Asp	
	800	805 810 815	
cac cag agc ttg agg tgg	ctc agc ctg gtg ggg aac	aac att ggc agt	2496
His Gln Ser Leu Arg	Trp Leu Ser Leu Val	Gly Asn Asn Ile Gly Ser	
	820	825 830	
gtg ggt gcc caa gcc ttg	gca ctg atg ctg gca aag	aac gtc atg cta	2544
Val Gly Ala Gln Ala	Leu Ala Leu Met Leu	Ala Lys Asn Val Met Leu	
	835	840 845	
gaa gaa ctc tgc ctg gag	gag aac cat ctc cag gat	gaa ggt gta tgt	2592
Glu Glu Leu Cys Leu	Glu Glu Asn His Leu	Gln Asp Glu Gly Val Cys	
	850	855 860	
tct ctc gca gaa gga ctg	aag aaa aat tca agt ttg	aaa atc ctg aac	2640
Ser Leu Ala Glu Gly	Leu Lys Lys Asn Ser	Ser Leu Lys Ile Leu Asn	
	865	870 875	
ata aaa att cat gct tgc	gga ttc aac aaa ctc ttg	gaa agc att ttc	2688
Ile Lys Ile His Ala	Ser Gly Phe Asn Lys	Leu Leu Glu Ser Ile Phe	
	880	885 890 895	
tgc atc ctc ctg gtt gtg	gaa gca ttt ttc ctg cag	aaa gtt gtc aag	2736
Cys Ile Leu Leu Val	Val Glu Ala Phe Phe	Leu Gln Lys Val Val Lys	
	900	905 910	
att ctt gaa gaa atg gta	gtc agt tgg cta gag gtc	agg ttg tcc aat	2784

```

Ile Leu Glu Glu Met Val Val Ser Trp Leu Glu Val Arg Leu Ser Asn
      915                      920                      925

aac tgc atc acc tac cta ggg gca gaa gcc ctc ctg cag gcc ctt gaa 2832
Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu Gln Ala Leu Glu
      930                      935                      940

agg aat gac acc atc ctg gaa gtc tgg ctc cga ggg aac act ttc tct 2880
Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly Asn Thr Phe Ser
      945                      950                      955

cta gag gag gtt gac aag ctc ggc tgc agg gac acc aga ctc ttg ctt 2928
Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr Arg Leu Leu Leu
      960                      965                      970                      975

tgaagtctcc gggaggatgt tcgtctcagt ttgtttgtga gcaggctgtg agtttggggcc 2988
ccagaggctg ggtgacatgt gttggcagcc tcttcaaaat gagccctgtc ctgcctaagg 3048
ctgaacttgt tttct                                     3063

```

&lt;210&gt; 188

&lt;211&gt; 795

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 188

```

Cys Glu Met Cys Ser Gln Glu Ala Phe Gln Ala Gln Arg Ser Gln Leu
  1          5          10          15
Val Glu Leu Leu Val Ser Gly Ser Leu Glu Gly Phe Glu Ser Val Leu
      20          25          30
Asp Trp Leu Leu Ser Trp Glu Val Leu Ser Trp Glu Asp Tyr Glu Gly
      35          40          45
Phe His Leu Leu Gly Gln Pro Leu Ser His Leu Ala Arg Arg Leu Leu
      50          55          60
Asp Thr Val Trp Asn Lys Gly Thr Trp Ala Cys Gln Lys Leu Ile Ala
      65          70          75          80
Ala Ala Gln Glu Ala Gln Ala Asp Ser Gln Ser Pro Lys Leu His Gly
      85          90          95
Cys Trp Asp Pro His Ser Leu His Pro Ala Arg Asp Leu Gln Ser His
      100          105          110
Arg Pro Ala Ile Val Arg Arg Leu His Ser His Val Glu Asn Met Leu
      115          120          125
Asp Leu Ala Trp Glu Arg Gly Phe Val Ser Gln Tyr Glu Cys Asp Glu
      130          135          140
Ile Arg Leu Pro Ile Phe Thr Pro Ser Gln Arg Ala Arg Arg Leu Leu
      145          150          155          160
Asp Leu Ala Thr Val Lys Ala Asn Gly Leu Ala Ala Phe Leu Leu Gln
      165          170          175
His Val Gln Glu Leu Pro Val Pro Leu Ala Leu Pro Leu Glu Ala Ala
      180          185          190
Thr Cys Lys Lys Tyr Met Ala Lys Leu Arg Thr Thr Val Ser Ala Gln
      195          200          205
Ser Arg Phe Leu Ser Thr Tyr Asp Gly Ala Glu Thr Leu Cys Leu Glu
      210          215          220
Asp Ile Tyr Thr Glu Asn Val Leu Glu Val Trp Ala Asp Val Gly Met
      225          230          235          240

```

- 65 -

	675						680				685					
Ser	Leu	Arg	Lys	His	Phe	His	Ser	Ile	Pro	Pro	Ala	Ala	Pro	Gly	Glu	
	690					695				700						
Ala	Lys	Ser	Val	His	Ala	Met	Pro	Gly	Phe	Ile	Trp	Leu	Ile	Arg	Ser	
705						710				715					720	
Leu	Tyr	Glu	Met	Gln	Glu	Glu	Arg	Leu	Ala	Arg	Lys	Ala	Ala	Arg	Gly	
	725									730					735	
Leu	Asn	Val	Gly	His	Leu	Lys	Leu	Thr	Phe	Cys	Ser	Val	Gly	Pro	Thr	
	740					745				750						
Glu	Cys	Ala	Ala	Leu	Ala	Phe	Val	Leu	Gln	His	Leu	Arg	Arg	Pro	Val	
	755					760				765						
Ala	Leu	Gln	Leu	Asp	Tyr	Asn	Ser	Val	Gly	Asp	Ile	Gly	Val	Glu	Gln	
	770					775				780						
Leu	Leu	Pro	Cys	Leu	Gly	Val	Cys	Lys	Ala	Leu						
785	790					795										

```
<210> 189
<211> 180
<212> PRT
<213> Homo sapiens
```

<400>	189
Phe Trp Gly Asn Arg Val Gly Asp Glu Gly Ala Gln Ala Leu Ala Glu	
1                        5                        10                        15	
Ala Leu Gly Asp His Gln Ser Leu Arg Trp Leu Ser Leu Val Gly Asn	
20                        25                        30	
Asn Ile Gly Ser Val Gly Ala Gln Ala Leu Ala Leu Met Leu Ala Lys	
35                        40                        45	
Asn Val Met Leu Glu Glu Leu Cys Leu Glu Glu Asn His Leu Gln Asp	
50                        55                        60	
Glu Gly Val Cys Ser Leu Ala Glu Gly Leu Lys Lys Asn Ser Ser Leu	
65                        70                        75                        80	
Lys Ile Leu Asn Ile Lys Ile His Ala Ser Gly Phe Asn Lys Leu Leu	
85                        90                        95	
Glu Ser Ile Phe Cys Ile Leu Leu Val Val Glu Ala Phe Phe Leu Gln	
100                        105                        110	
Lys Val Val Lys Ile Leu Glu Glu Met Val Val Ser Trp Leu Glu Val	
115                        120                        125	
Arg Leu Ser Asn Asn Cys Ile Thr Tyr Leu Gly Ala Glu Ala Leu Leu	
130                        135                        140	
Gln Ala Leu Glu Arg Asn Asp Thr Ile Leu Glu Val Trp Leu Arg Gly	
145                        150                        155                        160	
Asn Thr Phe Ser Leu Glu Glu Val Asp Lys Leu Gly Cys Arg Asp Thr	
165                        170                        175	
Arg Leu Leu Leu	
180	

```
<210> 190
<211> 721
<212> DNA
<213> Mus musculus
```

**<220>**

&lt;221&gt; CDS

&lt;222&gt; (193)...(612)

&lt;400&gt; 190

```

cctgggggttc ctgcacatta ccttccgtgc ttttttgccg ctttctactt ggctgtcagt 60
gctgacacat cggtggcctc tctcaagcac cttttcagct gtggccggct gggcagctca 120
ctgctgggaa ggctgctgcc caacctgtgt atccagggct ccagagtcaa gaagggcagc 180
gaagcagccc tg ctg cag aag gct gag cca cac aac ctg caa atc aca gca 231
          Leu Gln Lys Ala Glu Pro His Asn Leu Gln Ile Thr Ala
              1             5             10

```

```

gcc ttc cta gca ggt ctg ttg tcc cag cag cat cgg gac ctg ttg gct 279
Ala Phe Leu Ala Gly Leu Leu Ser Gln Gln His Arg Asp Leu Leu Ala
      15             20             25

```

```

gca tgc cag gtc tcc gag agg gta ctg ctc cag cgt cag gca cgt gcc 327
Ala Cys Gln Val Ser Glu Arg Val Leu Leu Gln Arg Gln Ala Arg Ala
      30             35             40             45

```

```

cgc tcg tgt ctg gcc cac agc ctc cgc gag cac ttc cat tcc atc ccg 375
Arg Ser Cys Leu Ala His Ser Leu Arg Glu His Phe His Ser Ile Pro
              50             55             60

```

```

cct gcc gtg ccc ggt gag acc aag agc atg cat gct atg ccg ggc ttc 423
Pro Ala Val Pro Gly Glu Thr Lys Ser Met His Ala Met Pro Gly Phe
              65             70             75

```

```

att tgg ctc atc cgt agc ctg tac gag atg cag gag gag cag ttg gcc 471
Ile Trp Leu Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu Gln Leu Ala
      80             85             90

```

```

cag gag gct gtc cgt cgc ttg gac atc ggg cac ctg aag ttg aca ttt 519
Gln Glu Ala Val Arg Arg Leu Asp Ile Gly His Leu Lys Leu Thr Phe
      95             100             105

```

```

tgc aga gtg ggc cct gca gag tgt gct gca ctg gcc ttt gta ctg caa 567
Cys Arg Val Gly Pro Ala Glu Cys Ala Ala Leu Ala Phe Val Leu Gln
     110             115             120             125

```

```

cat ctc cag cgg cct gtg gcc cta cag ctg gat tac aac tct gtg 612
His Leu Gln Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn Ser Val
              130             135             140

```

```

ggagatgttg ggagtggaa agctgcgacc gtgccttttg ggtctgcaca gctctgtagt 672
gagtgtgaca aggtcttgcc gattgggcct gtggc aaatg ctactgtca 721

```

&lt;210&gt; 191

&lt;211&gt; 140

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 191

```

Leu Gln Lys Ala Glu Pro His Asn Leu Gln Ile Thr Ala Ala Phe Leu
  1             5             10             15
Ala Gly Leu Leu Ser Gln Gln His Arg Asp Leu Leu Ala Ala Cys Gln

```

```

      20      25      30
Val Ser Glu Arg Val Leu Leu Gln Arg Gln Ala Arg Ala Arg Ser Cys
      35      40      45
Leu Ala His Ser Leu Arg Glu His Phe His Ser Ile Pro Pro Ala Val
      50      55      60
Pro Gly Glu Thr Lys Ser Met His Ala Met Pro Gly Phe Ile Trp Leu
      65      70      75      80
Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu Gln Leu Ala Gln Glu Ala
      85      90      95
Val Arg Arg Leu Asp Ile Gly His Leu Lys Leu Thr Phe Cys Arg Val
      100      105      110
Gly Pro Ala Glu Cys Ala Ala Leu Ala Phe Val Leu Gln His Leu Gln
      115      120      125
Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn Ser Val
      130      135      140

```

&lt;210&gt; 192

&lt;211&gt; 419

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1) ... (417)

&lt;400&gt; 192

```

ctg cag aag gct gag cca cac aac ctg cag atc aca gca gcc ttc cta 48
Leu Gln Lys Ala Glu Pro His Asn Leu Gln Ile Thr Ala Ala Phe Leu
  1           5           10           15

```

```

gca ggt ctg ttg tcc cag cag cat cgg gac ctg ttg gct gca tgc cag 96
Ala Gly Leu Leu Ser Gln Gln His Arg Asp Leu Leu Ala Ala Cys Gln
      20      25      30

```

```

atc tcc gag agg gtg ctg ctc cag cgt cag gca cgt gcc cgc tcg tgt 144
Ile Ser Glu Arg Val Leu Leu Gln Arg Gln Ala Arg Ala Arg Ser Cys
      35      40      45

```

```

ctg gcc cac agc ctc cgc gag cac ttc cat tcc atc ccg cct gcc gtg 192
Leu Ala His Ser Leu Arg Glu His Phe His Ser Ile Pro Pro Ala Val
      50      55      60

```

```

ccc ggt gag acc aag agc atg cat gct atg ccg ggc ttt att tgg ctc 240
Pro Gly Glu Thr Lys Ser Met His Ala Met Pro Gly Phe Ile Trp Leu
      65      70      75      80

```

```

atc cgg agc ctg tac gag atg cag gag gag cag ttg gcc cag gag gct 288
Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu Gln Leu Ala Gln Glu Ala
      85      90      95

```

```

gtc cgt cgc ttg gac atc ggg cac ctg aag ttg aca ttt tgc aga gtg 336
Val Arg Arg Leu Asp Ile Gly His Leu Lys Leu Thr Phe Cys Arg Val
      100      105      110

```

ggc cct gca gag tgt gct gcg ctg gcc ttt gta ctg caa cat ctc cag 384  
 Gly Pro Ala Glu Cys Ala Ala Leu Ala Phe Val Leu Gln His Leu Gln  
           115                          120                          125

cgg cct gtg gcc cta cag ctg gat tac aac tct gt 419  
 Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn Ser  
           130                          135

<210> 193

<211> 139

<212> PRT

<213> Mus musculus

<400> 193

Leu Gln Lys Ala Glu Pro His Asn Leu Gln Ile Thr Ala Ala Phe Leu  
   1                          5                          10                          15  
 Ala Gly Leu Leu Ser Gln Gln His Arg Asp Leu Leu Ala Ala Cys Gln  
                           20                          25                          30  
 Ile Ser Glu Arg Val Leu Leu Gln Arg Gln Ala Arg Ala Arg Ser Cys  
           35                          40                          45  
 Leu Ala His Ser Leu Arg Glu His Phe His Ser Ile Pro Pro Ala Val  
           50                          55                          60  
 Pro Gly Glu Thr Lys Ser Met His Ala Met Pro Gly Phe Ile Trp Leu  
   65                          70                          75                          80  
 Ile Arg Ser Leu Tyr Glu Met Gln Glu Glu Gln Leu Ala Gln Glu Ala  
                           85                          90                          95  
 Val Arg Arg Leu Asp Ile Gly His Leu Lys Leu Thr Phe Cys Arg Val  
                           100                          105                          110  
 Gly Pro Ala Glu Cys Ala Ala Leu Ala Phe Val Leu Gln His Leu Gln  
           115                          120                          125  
 Arg Pro Val Ala Leu Gln Leu Asp Tyr Asn Ser  
           130                          135

<210> 194

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 194

ctgcagaagg ctgagccaca caacct

26

<210> 195

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 195

WO 01/90156

P  
PCT/US01/17158

acagagttgt aatccagctg tagggccaca

30